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Abstract 
Pancreatic cancer or pancreatic ductal adenocarcinoma (PDAC), is the deadliest type of cancerous 
malignancy with a survival rate of only 3.7 % after 5 years. The first line current treatment is a drug 
called gemcitabine, which has been shown to display effectiveness in only 23.8 % of patients. Hybrid 
nanoparticles (HNPs) comprised of an iron oxide core and outer gold coat have shown great potential 
for anti-cancer therapies. The magnetic iron oxide cores and the surface plasmon resonance (SPR) 
properties of the gold surface provide the HNPs with the capabilities of diagnostic imaging and drug 
delivery, making them true theranostic agents. 
A novel thiolated thermally labile drug (TTLD) analogue of gemcitabine was successfully synthesized 
and attached to the surface of HNPs forming a novel drug formulation called TTLD+HNP. This TTLD 
compound is comprised of a gemcitabine molecule with a Diels Alder cycloadduct. Gem-Mal, a 
maleimide derivative of gemcitabine is released during retro Diels Alder (rDA). The mode of release 
involves heat-activation of the rDA reaction facilitated by the SPR of the gold shell. TTLD was 
characterised with mass spectrometry, nuclear magnetic spectroscopy and IR spectroscopy.   
Preliminary studies determined that the TTLD compound doesn’t undergo rDA at 20 °C and a 
subsequent 4 week study displayed no rDA occurring at 20 °C. Afterwards in vitro experiments 
including the MTT and trypan blue assay determined that Gem-Mal is 4.6 times less cytotoxic than 
gemcitabine but is taken up by cells 11 fold faster when attached to the HNPs. Upon heat-activation 
at 44 °C, the TTLD+HNP formulations cytotoxicity increased by 56 % outperforming gemcitabine by 26 
%, confirming its temperature driven activity. The TTLD+HNP drug formulation is the first of its kind 
and has displayed superior anti-cancer activity to the current first line drug gemcitabine after heat 
mediated controlled release.  
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1.0. Cancer 
Cancer is one of the biggest causes of death for humans worldwide. It occurs due to 
irregular cell growth and uncontrolled cellular division (Yang et al. 2013; Bouyssou et al. 
2014; Su et al. 2014). Cell growth and division is common in nearly every type of tissue, 
which is why cancer comes in many forms and can be found anywhere in the human body. 
Neoplasia is new tissue caused by the abnormal growth of cells, which exceed the growth 
rate of the cells around it forming a condensed mass of tissue in that region (de Wilde et 
al. 2012). Neoplasia can be caused by mutations in oncogenes, which are genes that have 
the potential to cause cancers as they control cell growth and division via the oncoproteins 
they produce (de Wilde et al. 2012; Aird & Zhang 2015). Other causes of cancer are 
attributed to cells losing the ability to undergo apoptosis, which is programmed cell death 
(Felt et al. 2015). Neoplasia of the pancreas (Pancreatic Intraepithelial Neoplasia or PanIN) 
can progress into malignant cancerous tissue called pancreatic ductal adenocarcinoma 
(PDAC) (Yuqing Zhang et al. 2013a). The smallpox vaccine was the first of its kind and 
responsible for the subsequent eradication of this disease worldwide (Foster et al. 2011; 
Tarantola & Foster 2011). Other diseases such as polio and measles have seen significant 
reductions in the last few decades with fewer cases occurring annually (Doshi et al. 2015; 
Mwenge et al. 2016). These advances are partly due to the fact that the agent responsible 
for each disease is known. The genetic and physical structure have been elucidated and 
treatments can be designed to halt the ability of the disease to infect or augment the body 
in fighting the disease. Unlike infectious diseases, cancer is best described as our own 
bodies working against us. There is no singular cause for cancer and it affects every person 
differently because every persons body is unique and therefore, every cancer is unique. At 
the present time, we have specific vaccines designed to combat specific diseases that are 
effective in the majority of people. However it’s highly unlikely that we will have a single 
treatment that is effective on all cancer types in almost all patients, although research into 
cancer vaccines is already underway (Corocleanu 2008). The causes of cancer are many and 
include; exposure to carcinogens, infections, ionising radiation, lifestyle choices and genetic 
predisposition.  
About 5-10 % of cancers are caused by genetic defects (Nagy et al. 2004). This leaves about 
90-95 % of all cancers being attributed to lifestyle and environmental factors. 25-30 % of 
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cancer related deaths are due to tobacco use and 30-35 % is linked to diet and 
exercise(Anand et al. 2008). Infections are linked to 15-20 % of cancer related 
deaths(Anand et al. 2008). The human papilloma virus for example, is an infectious agent 
that has been linked to over 5 % of all cancer cases worldwide and is responsible for 99.7 
% of all cervical cancer cases (Ault 2006). Viruses infect human cells by inserting their 
genetic code into our DNA. Its code can then be used by the human cell to produce more 
copies of itself and produce proteins (Anand et al. 2008). Some of these genes are 
oncogenes such as the E6 and E7, which prevents apoptosis (Ault 2006). Carcinogen is a 
term used to describe something that causes cancer. These are often chemical compounds, 
but can also include ionising radiation such as gamma rays and radioactive atoms (Barlow 
& Schlatter 2010). Asbestos is responsible for over 100,000 deaths annually, which is over 
half of all occupational cancer deaths, due to exposure from airborne fibres (Turci et al. 
2016). Ionizing radiation such as UV exposure can damage the DNA of healthy cells causing 
mutations (Megha et al. 2015). These often cause the cell to trigger apoptosis. In some 
cases the cell might lose the ability to signal cellular apoptosis due to DNA damage, which 
can lead to the formation of cancerous cells.  
1.0.1. Types of cancers  
Neoplasm is a term used to describe the abnormal growth of localised cells. These cells can 
form a mass called a tumour. The two main types of tumour tissues are benign and 
malignant. Benign tumours lack the ability to metastasize and are therefore not classed as 
malignant cancers (Hanahan & Weinberg 2000). Examples of benign tumours include; 
moles, lipomas and adenomas (Horibe et al. 2016; Schofield 2009; Namiki et al. 2016). 
Moles are abnormal skin growths that can be subdermal (beneath the skin) or on the 
surface. Surface moles are darker due to having a higher concentration of the skin pigment 
melanin (Schofield 2009). Lipomas are benign tumours formed from fat tissues and are 
more commonly found in middle aged and the elderly (Bagherzade & Etemad 2016). 
Adenomas are benign tumours of glandular tissue and/or the epithelial cells that line 
glandular organs (Peters et al. 2016; Jayaram et al. 2015; L. Yang et al. 2016). These can 
grow from many of the body’s glandular tissue, such as the prostate, adrenal, pituitary and 
pancreas. Benign tumours are often harmless to the organism and are sometimes left alone 
without any ill effects. However, some benign tumours, depending on their type and 
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location may be harmful (Hruban & Fukushima 2008; Eyesan et al. 2011; Galea 2016). This 
can be due to their presence causing the compression of neighbouring tissues and blocking 
blood vessels. This can cause poor blood flow in certain areas of the body that can lead to 
nerve, organ damage and necrosis. Others benign tumours, such as some adenomas may 
secret hormones leading to an elevated level of them within the body (Jukes et al. 2016). 
Due to the random chance occurrence of neoplastic growths, they have the potential to 
occur at any age group. The average number of moles is between 1 and 3, for a child of 
European descent under the age of 10. A 20 year old young adult of European descent has 
roughly 21. This number climbs to around 22 for men and 33 for women in their thirties 
(Mackie et al. 1985). Malignant neoplasm of the skin is one of a plethora of possible cancer 
types that can occur.  
Malignant or cancerous cells possess the ability to migrate away from their parent location 
and form satellite tumours in another location or organ in the body. This process is called 
metastasis and it’s what distinguishes them from benign tumours (Chambers et al. 2002). 
These secondary tumours will be comprised of the same cell types as their original tumour. 
For example, metastasised pancreatic cancer cells in the liver will be made up of pancreatic 
cancer cells, not liver cancer cells. In order for a tissue to be described as cancerous it must 
satisfy the “hallmarks of cancer”. There were initially 6 hallmarks which were; avoidance of 
programmed apoptosis, promoting the formation of new blood vessels, heightened rate of 
cell division, continuous growth, unlimited number of cell divisions and the ability to spread 
to new sites (metastasize) (Hanahan & Weinberg 2000). A further 4 hallmarks were added 
which are; genome instability, abnormal metabolic pathways, tumour promoting 
inflammation and the avoidance of immune mediated destruction (Hanahan & Weinberg 
2011). Cancer occurs due to an accumulation of mutations in the DNA over multiple cell 
divisions as shown in Figure 1. Some of these mutations such as a mutation of the k-ras 
gene might cause continuous cell division leading to the formation of tumours  (Reckamp 
et al. 2016; Almoguera et al. 1988). Another mutation might affect the p53 gene for 
example, which is important for tumour suppression (Li et al. 1998). Genes that causes this 
are called oncogenes. Normally these genes help cells grow and divide. If these genes 
become mutated they may become overexpressed or permanently switched on leading to 
rapid and continuous cell division. 
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Figure 1: Diagram depicting how a series of mutations leads to the formation of malignant carcinomas. 
Tumour suppressor genes slow down cell division and detect DNA damage. They can also 
trigger cellular apoptosis especially when mutated genes are present. If these genes are 
inhibited or mutated then the cell can grow without resistance (Li et al. 1998). The 
development of cancer can be described as a miniature example of evolution. Each 
mutation might confer an advantage to the survival of each daughter cell allowing it to 
outlive neighbouring normal cells. 
1.0.2. Pancreatic cancer 
Pancreatic cancer is caused by the formation of neoplasia within the intraepithelial regions 
of the pancreas (Roshani et al. 2014; de Wilde et al. 2012; Zhi et al. 2014). The pancreas is 
located within the abdomen surrounded by several other organs, major blood vessels and 
tissue types. This allows pancreatic cancer to spread quickly to neighbouring areas (Zhi et 
al. 2014). They can spread when a single cancer cell enters the bloodstream. They are 
quickly swept away and usually settle when they reach a capillary (Z’graggen et al. 2001). 
Afterwards they pass through the wall of the blood vessel and attach to other tissues, 
organs or bone forming secondary cancers. The process of cancer cells emigrating to new 
sites is highly unlikely because it is very stressful for the cells which nearly always perish 
before completing the journey. However it only takes one out of the multitude of cancer 
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cells to survive. Pancreatic cancer cells have the advantage of being situated near many 
blood vessels, multiple organ and tissue targets as well as the lymphatic system (Paiella et 
al. 2016). The lymphatic system consists of lymphatic vessels that transport a fluid called 
lymph around the body. Lymph nodes are clusters of lymph tissue that are found along 
these lymphatic vessels. Pancreatic cancer cells can penetrate the lymphatic system and 
collect at lymph nodes forming tumours as well as travel along the lymphatic system 
spreading to other organs via this route (Xiao et al. 2014). This makes transport though the 
lymphatic system, an ideal method of invasion of for cancerous cells. Therefore even with 
successful treatment pancreatic cancer still has the possibility of reoccurring from satellite 
sites (Z’graggen et al. 2001; Prasad & Katiyar 2013). Surgery is the only method capable of 
curing pancreatic cancer and is often accompanied by post-operative chemotherapy to 
reduce the chances of recurrence (Bockhorn et al. 2014). Even after early detection, 
subsequent surgery and post-operation chemotherapy the survival rate only increases to 
21 % (Yuqing Zhang et al. 2013c; Bockhorn et al. 2014). A contributing reason for this is 
because pancreatic cancer rarely causes noticeable symptoms primarily attributed to 
cancer until it is fairly advanced and has spread to surrounding tissues (Ling et al. 2013). 
Once this has occurred, surgery is no longer an option and patient quality of life becomes 
the top priority. Most patients rarely survive beyond one year after a pancreatic cancer 
diagnosis, therefore a balance has to be struck between the patients quality of life and the 
extension of their life (Kristensen et al. 2016). 
1.0.3. Cancer statistics 
Pancreatic cancer has an absolute 5 year survival rate of 3.7 % (Vincent et al. 2011). This 
means that after the disease is first diagnosed the patient has less than 5 % chance of 
surviving after 5 years (Yuqing Zhang et al. 2013b; Liu et al. 2012a; Tran et al. 2013a). This 
particularly deadly type of cancer has the worst prognosis of all cancer types (Yuqing Zhang 
et al. 2013c; Al Shemaili et al. 2014; Malvezzi et al. 2013). Pancreatic cancer is the 5th most 
common cause of cancer death in the UK (Maraveyas et al. 2012) and 4th most common in 
the US (Zhang et al. 2011; Pinho et al. 2014). It occurs in only 2.6 % of all cancer cases as of 
2011, but is responsible for 5.2 % of cancer deaths in the UK which is a significantly 
disproportionate survival statistic owing to its poor prognosis. The 5 year survival rate of 
pancreatic cancer has only increased from 2 % to 3.7 % on average since 1975. These 
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statistics show the deadliness and great importance in improving the survival rates of those 
who are diagnosed with pancreatic cancer.  In contrast to pancreatic cancer’s prognosis is 
testicular cancer which has a 5 year survival rate of 97.2 % according to Cancer Research 
UK in all stages. After 10 years the survival rate is still very high at 96 %. Therefore the 97.2 
% survival rate is deemed the “cure” rate according to Cancer Research UK (Brock et al. 
1993). The statement “cured of cancer” is rarely used by medical professionals due to the 
possibility of reoccurrence with a more aggressive form of the cancer. The term “remission” 
is used instead. To say that a cancer like testicular cancer is “cured” must signify that it has 
an extremely good prognosis.  Unlike the poor prognosis history of pancreatic cancer, other 
forms of cancer like breast and prostate, have an improved prognosis over the last four 
decades. Survival rates as high as 90 % in all age brackets, after 5 years have been witnessed 
with elderly age being a significant factor in survival (Thakur et al. 2014; Fontein et al. 2013; 
Tyson & Castle 2014). Survival rates for some common cancers types have improved over 
the last 4 decades. Breast cancer for example has shown an improvement in survival rates 
from 52 % to 85.1 % since 1975 which is attributed to early detection. This is because 
medical professionals often selectively screen for these cancers during routine medical 
examinations and also because of advances in breast cancer research (Thakur et al. 2014).  
1.1. Current treatments for pancreatic cancer: 
1.1.1.   Surgical resection (Whipple’s Procedure) 
Surgical resection remains the only curative method of ensuring the complete removal of 
pancreatic cancer tumours in order to establish a remission state in a patient. However this 
option is rarely available to the majority of people diagnosed with pancreatic cancer as it’s 
often diagnosed too late when metastasis has occurred (Casadei et al. 2015). A well-known 
trait of pancreatic cancer is that it often lacks significant symptoms in early stages. The 
name of the surgical procedure for treating pancreatic cancer is called the Whipples 
procedure (Sa et al. 2010; Kang et al. 2016). This procedure is named after Allen Oldfather 
Whipple who established the resection (Sa et al. 2010). The anatomy of the pancreas and 
surrounding organs is shown in Figure 2 where the pancreas sits within the duodenal curve 
and along the duodenum and base of the stomach (Sa et al. 2010).  
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Figure 2: The preoperative anatomy of the pancreas and surrounding organs (Sa et al. 2010). 
These areas are common regions for secondary tumour sites when pancreatic cancer has 
metastasised (Paiella et al. 2016). Therefore to ensure complete removal of pancreatic 
tumours, large areas of these organs have to be removed. The Whipples procedure 
illustrated in Figure 3 involves the removal of the pancreatic head, duodenum, common 
bile duct, gall bladder, and the bottom half of the stomach (Sa et al. 2010). 
 
Figure 3: Post Whipple’s surgery anatomy (Sa et al. 2010). 
The survival rate of the Whipple procedure has improved from 70 % to 98 % over the last 
century. One study noted that patients have an 18 % chance of being readmitted to hospital 
within 30 days of discharge, which was due to post-operative complications and failure to 
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thrive (Kagedan et al. 2015). Some post-operative complications include infections at the 
surgical site, internal bleeding, delayed gastric emptying and in rare cases thrombosis of 
the superior mesenteric vein (Huťan et al. 2014). The latter is a vein that carries blood from 
the small intestine, stomach and pancreas. Thrombosis can cause intestinal necrosis, which 
can lead to patient death (Huťan et al. 2014). The quality of life diminishes noticeably in 
patients following a Whipple’s procedure. Common  issues include pancreatic/abdominal 
pain, nausea and vomiting, (Shah et al. 2013). A combination of these complications, 
coupled with the diminished post operation quality of life, factors in the eligibility of the 
Whipples procedure on a patient by patient basis.  
1.1.2. Chemotherapy 
Chemotherapy is the term used to describe the treatment of cancers such as pancreatic 
cancer with cytotoxic anti-neoplastic drugs (Batmani & Khaloozadeh 2013). Examples of 
drugs that are used to treat pancreatic cancer include: fluorouracil (5-Fu), cisplatin, 
capecitabine and gemcitabine. Cytotoxic drugs inhibit tumour growth by interacting with 
the processes involved in the synthesis of new proteins vital for cell proliferation. They also 
inhibit cell growth by also inhibiting DNA replication or causing enough stress to the cells 
leading to apoptosis (Batmani & Khaloozadeh 2013).  
1.1.2.1.   5-Fluorouracil 
NHNH
F
O
O  
Figure 4: The structure of 5-fluorouracil a structural analogue to pyrimidine. 
5-Fu is a thymidylate synthase inhibitor. This enzyme is responsible for the synthesis of 
thymidine which is a nucleoside required for DNA replication. After 5-Fu is administered, it 
is quickly metabolised to 5-fluorodeoxyuridine monophosphate (FduMP) which binds to 
thymidine synthase blocking its ability to methylate uracil. This makes 5-fluorouracil a 
prodrug. Uracil forms base pairs with adenine during DNA transcription. It is methylated to 
form thymine, which is required for DNA replication.  Without the action of thymidylate 
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synthase, the cell become starved of thymidine after multiple divisions (Mohamed & 
Safwat 2016). 5-Fu can also be triphosphorylated and become incorporated into RNA in the 
place of uracil blocking DNA transcription which ultimately stops the growth of cancerous 
cells.  
1.1.2.2.   Gemcitabine 
N
N
NH2
O
O
OH
OH
F
F  
Figure 5: The structure of gemcitabine a structural analogue to cytidine. 
In most cases of pancreatic cancer, where the patient is within their stage 4 metastatic 
phase, gemcitabine is the first line treatment because it demonstrates improved clinical 
benefits and reduced side effects when compared to 5-fluorouracil. (Brown et al. 2014; 
Heinemann 2001). Even with the increased survival rate with gemcitabine, the prognosis 
for pancreatic cancer is still abysmal and urgent improvements and novel strategies in 
pancreatic cancer chemotherapeutics are needed.  
Gemcitabine is a pro drug, which is a drug that is administered in an inactive form shown 
in Figure 5 and phosphorylated into its clinically active form gemcitabine triphosphate 
within cells after cellular uptake (Baraniak et al. 2014; Yuan Zhang et al. 2013). This active 
form inhibits DNA elongation by replacing the nucleoside cytidine leading to cell death 
(Pliarchopoulou & Pectasides 2009). On an unrelated note, this activity has also been 
exploited for antiviral treatments. Gemcitabine has been shown to inhibit the proliferation 
of enterovirus, coxsackievirus and HIV by preventing the replication of the virus’s genetic 
code. Its active form replaces cytidine in the viral code producing highly mutated non-viable 
strains (Yun et al. 2009; Kang et al. 2015).  
When gemcitabine is introduced into the body it can travel along several routes before 
reaching the target via an IV injection due to the circulatory system. It is usually injected 
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into the arm of the patient as a drip over roughly 30 minutes to several hours 
(Pliarchopoulou & Pectasides 2009). This is to prevent localised toxicity around the site of 
administration.  It may degrade or be unable to pass through certain membranes due to its 
location after administration. It may also be metabolised in the liver in significant amounts 
before reaching certain organs.  This is called first pass metabolism (Qiong Gao et al. 2014; 
Lee et al. 2013). Drugs, especially cytotoxic drugs, are dose limited which lowers the 
effective amount of active pharmaceutical ingredient working at the intended site of 
treatment. Not all cancers behave the same, and the same type of cancer may vary in 
difficulty from a patient to patient basis. One treatment may be highly effective in one 
patient and unsuccessful in another even at the same stage of progression (Santhosh & 
Ulrih 2013a). For example, gemcitabine has been described as having a response rate of 
23.8 % which means that 76.2 % of patients taking gemcitabine see no viable response to 
the drug (Hoskins et al. 2010; Burris et al. 1997) (Hoskins et al., 2010, Moore, 1995),  while 
Kim et al states that the response rate is as low as 5.4 % (Kim & Gallick 2008).   
A clinical study was carried out comparing the typical 2.2 g m-2 30 minute single dose 
infusion of gemcitabine (Arm A) with a fixed dose rate (FDR) 1500 mg m-2 administered at 
a rate of 10 mg m-2 min, over 150 min (Arm B). Arm B showed the greatest response rate 
where the overall response rate was 11.6 % compared to Arm A which had a lower response 
rate of 7.3 % (Hochster 2003).  Multiple research groups state different response rates for 
gemcitabine, some stating that it is as high as 23.8 % or as low as 5.4 % from established 
sources while others have observed intermediate values of 7.3 % and 11.6 % depending on 
their experimental method. However the conclusion remains the same regardless of the 
variation in gemcitabine response rates. Gemcitabine may be the most favourable drug for 
combating pancreatic cancer, but its response rate is too low and advances in the 
treatment of pancreatic cancer with chemotherapeutics are urgently required. 
Gemcitabine is cytotoxic and indiscriminately targets both cancerous and non-cancerous 
cells leading to the side effects associated with chemotherapy such as hair loss, nausea, 
bone marrow suppression, diarrhoea, liver problems, fever and fatigue (Zhang et al. 2011; 
W. Song et al. 2014). It has a low efficacy meaning that most of the drug is metabolised and 
excreted before being able to carry out its intended pharmaceutical activity. Even with 
significant cytotoxic effects, its dosage must be as high as possible to ensure that enough 
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pharmaceutical activity at the site of action occurs, due to its poor biocompatibility. Its 
small molecular weight contributes to its rapid renal clearance. Combating this clinically 
involves providing frequent high doses of the drug which can cause hepatic and renal 
toxicity (Sadjadi & Annamaraju 2012). If these side effects are too significant then 
treatment has to be discontinued even if there is a tumour response to the drug (Vandana 
& Sahoo 2010). Improvements with the application of gemcitabine and other cytotoxic anti-
cancer agents are achievable if methods of improving the activity and/or improving 
biocompatibility were implemented (Wagstaff et al. 2012; Vandana & Sahoo 2010). 
Localised administration via an intratumor injection route has been shown to possess 
advantages over the conventional intravenous methods (Shirley et al. 2013). For example, 
pancreatic adenocarcinomas are typically hypovascular, which means they have relatively 
less surrounding blood vessels which are the main routes for intravenously administered 
gemcitabine (Shirley et al. 2013). They also possess a dense stroma, which is a growth of 
connective tissue that reduces the diffusion and therefore accumulation of gemcitabine 
within tumours (Whatcott et al. 2012). Intratumour injections directly into the tumour 
would bypass these problems faced by the intravenous route of administration. A major 
disadvantage of the intratumour administration route, is that it will be ineffective for 
secondary cancer tumours that are too small to be detected yet. This is especially true for 
most patients diagnosed with pancreatic cancer because this occurs in the late stages of 
the disease.  
1.1.2.3.   Cisplatin 
 
Figure 6: The structure of cisplatin. 
Cisplatin is widely regarded as the first platinum containing anti-cancer drug. Other anti-
cancer drugs belonging to this group include carboplatin and oxaliplatin (Dasari & Bernard 
Tchounwou 2014). Cisplatin is a metallic coordination compound with two chlorine and 
two amine ligands in a cis conformation. It is used in the treatment of various cancers 
including ovarian, lung and neck cancers. It is also often employed in combination with 
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other chemotherapeutic drugs for the treatment of other cancers such as breast, prostate 
and pancreatic cancer (Dasari & Bernard Tchounwou 2014). The uptake of cisplatin into 
cells is carried out by the copper membrane transporter (CTR1). Once inside a cell, the 
chloride atoms are replaced by water molecules forming a very strong nucleophile which is 
a compound that donates electrons to form covalent bonds. In this form, it can bind to the 
N7 purine shown in Figure 7.  
N
N
N
7
N
H  
Figure 7: Chemical structure of purine. 
This dative covalent binding forms DNA adducts which cause DNA damage and block cell 
division which leads to apoptotic cell death (Dasari & Bernard Tchounwou 2014). The DNA 
adducts cause the DNA strand to bend 34˚, which triggers cell repair mechanisms 
(Katarzyna & Basiak n.d.; Rosenberg n.d.). Due to cisplatin’s presence, cell repair is not 
successful and cellular apoptosis occurs. 
 
Figure 8: Binding of cisplatin to DNA. 
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1.1.2.4   Multidrug resistance of cancer 
Multidrug resistance is the resistance acquired by cancerous cells to multiple 
chemotherapeutic drugs, even those that have not been exposed to the cancerous cells 
previously (Wu et al. 2014). Once this occurs, the cancerous cells are less sensitive to the 
cytotoxic drugs. Increasing the dose may improve the effectiveness because the cells gain 
resistance, not immunity to the drug. However drugs like gemcitabine and 5-FU are 
cytotoxic and therefore dose limiting (Wu et al. 2014). Multidrug resistance is the most 
common reason for failed chemotherapy treatment and can arise before treatment where 
it is described as primary or intrinsic resistance (Hagmann et al. 2010). This is due to some 
cancer cells possessing functional characteristics such as an enhanced DNA repair system, 
which prevent DNA damage caused by drugs like cisplatin, ultimately prevent apoptosis 
(Dasari & Bernard Tchounwou 2014). Alternatively, acquired resistance occurs after 
exposure to chemotherapeutics (Wu et al. 2014). A commonly observed effect of 
gemcitabine is a marked response to the drug initially, followed by a rapid increase in 
resistance. This confirms that some of the cancerous cells within tumours already possess 
intrinsic resistance to cytotoxic agents like gemcitabine before the first dose is even 
administered, which inevitably leads to poor patient outcomes (Kim & Gallick 2008). Cells 
that were not killed by the chemotherapy can also mutate conferring an acquired 
resistance to future generations. Multidrug resistance can arise because of multiple 
reasons. These include, an immune response to the drug/drug transporter, DNA repair and 
changes in the drug target caused by mutations (Ling et al. 2005). Over expression of 
proteins responsible for producing efflux pumps like p-glycoprotein is also a major 
contributor to multi drug resistance. Because cancer drugs are cytotoxic, macrophages may 
become increasingly sensitive to their presence and increase the rate of drug metabolism 
(Markman et al. 2013). The liver is responsible for much of the detoxification within the 
body and may improve the rate of drug metabolism after repeated doses (Tsume et al. 
2014). Mutations in the DNA within cancer cells can make them more resistant to cytotoxic 
drugs or even make them harder to attack due to the high specificity of certain drugs (Patel 
et al. 2013; Di Gangi et al. 2014). Pancreatic cancer cells can acquire resistance to 
gemcitabine by disrupting its conversion, to its active triphosphate form by the down 
regulation of deoxycytidine kinases (Fryer et al. 2011). The copper transporter 1 (CTR1) is 
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important for the uptake of platinum compounds. Research has shown that cisplatin 
degrades CTR1 which further inhibits its uptake. Cancer cells that already exhibit under 
expression of CTR1, display resistance to cisplatin (Shen et al. 2012). Thymidylate synthase 
is the main target of 5-Fu and their subsequent binding inhibits thymidylate synthase 
preventing the production of thymine. The overexpression of thymidylate synthase allows 
the cancer cell to continue producing thymidylate synthase, even though some are 
inhibited. This provides the cancer cell resistance to 5-Fu. This leads to higher 5-Fu dose 
requirements, which may not be possible due to its cytotoxic nature (Wang et al. 2014). 
1.2. The use of nanotechnology in drug delivery systems 
Nanotechnology is a term used to describe the engineering of materials and structures on 
the nanoscale (Y. Gao et al. 2014; Parhi et al. 2012). These can include organic nanoparticles 
like liposomes and dendrimers as well as metallic/core shell nanoparticles like silver 
nanoparticles and gold coated nanoparticles. Synthetically, a nanoscale material or 
structure is produced by self-assembly methods where components under the right 
conditions would arrange themselves to form structures. Examples of these include 
micelles, vesicles, carbon nanotubes and metallic nanoparticles which are used for drug 
delivery systems (Shu et al. 2014; Islam & Miyazaki 2010; Salameh et al. 2014). Each type 
of nanoparticle drug delivery system as shown in Figure 9 has its own advantages and 
disadvantages for the transportation of various cargoes such as chemotherapeutic drugs, 
proteins and RNA. 
 
Figure 9: Diagram showing drug delivery systems for multiple types of cargo including cytotoxic agents, proteins and 
genetic materials like RNA (Eldar-Boock et al. 2013). 
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Nano sized drug delivery vehicles and systems can be used to overcome the common 
problems associated with drug discovery such as poor bioavailability, water solubility and 
rapid clearance, which typically prevent promising drug candidates from becoming 
clinically viable. Lipid based carrier systems such as micelles and liposomes, can 
encapsulate hydrophobic drugs to aid in drug solubility and bioavailability. This is achieved 
by creating a hydrophobic cavity to transport the drug cargo, that is bordered by a 
hydrophilic shell, that increases the overall solubility of the drug carrier system (Gupta et 
al. 2013). Hydrogels which are cross linked polymer chains arranged in a grid or net 
formation (Okay n.d.). These can store water and any drugs currently dissolved during gel 
formation, physically trapping the drug molecules in between the chains. Hydrogels can 
swell during pH or temperature changes facilitating the release of their cargo through the 
larger gaps within the gel network (Vashist & Ahmad 2013; Okay n.d.). 
1.2.1.   Micelles  
Micelles are the end results of the aggregation of amphiphilic molecules in a liquid colloid. 
Amphiphiles are molecules that possess a hydrophobic (water hating) and hydrophilic 
(water loving) regions. Examples of amphiphiles include surfactants, detergents and 
wetting agents. Within an aqueous solution, these amphiphiles will first arrange 
themselves at the surface of an aqueous solution. The hydrophilic regions shown in Figure 
10 will extend into the aqueous solution while the hydrophobic regions will be positioned 
above the solution. This reduces the surface tension which can assist in the mixing of oils 
and aqueous solutions. Once the surface has been saturated with an amphiphilic 
compound it will then begin to form micelles. This occurs when the amphiphiles arrange 
themselves to form spherical conformations where the hydrophilic region interacts with 
the aqueous solution forming the outside edge of the sphere and the hydrophobic regions 
aggregate together.  
17 
 
 
Figure 10: Model depicting the reduction of surface tension as the surfactant concentration increases to the point 
micelles form, beyond the CMC. 
The further introduction of amphiphilic compounds will lead to the formation of more 
micelles. The concentration, when this occurs is called the critical micelle concentration. 
The formation of micelles depends on another attribute specific to each amphiphile 
species, which is the critical micelle temperature. This is the minimum temperature where 
micelles will form. If the critical micelle concentration is reached, the introduction of more 
amphiphilic compounds will lead to the formation of crystalline structures. If enough 
energy in the form of heat is supplied the entropic forces overcome those keeping the 
crystalline structure leading to the formation of micelles. Therefore the critical micelle 
concentration and the critical micelle temperature must be both reached to form micelles 
with the critical micelle temperature being the most important criteria. The critical micelle 
concentration and temperature can be determined experimentally (Chakraborty et al. 
2011). The characteristics of surfactant containing solutions displays a sudden fall in 
concentration related properties when the critical micelle concentration and temperature 
is reached. These characteristics can include the change in surface tension, due to surface 
saturation of surfactants and the change in the absorption of water insoluble dyes, which 
decreases as emerging micelles encapsulate them (Chakraborty et al. 2011). One of the 
biggest detriments a novel drug can have is poor aqueous solubility. Drugs must have 
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(b) 
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aqueous solubility if they are going to pass through the various biological barriers that can 
exist such as the lining of the stomach and small intestine. If a hydrophobic species such as 
a hydrophobic drug is introduced into an aqueous solution above the critical micelle 
concentration and temperature, these micelles may spontaneously form around these 
drugs encapsulating them. This provides micelles with the ability to act as drug carriers. 
Micelles are often called detergents because of their ability to promote the mixing of oily 
and aqueous solutions which often do not mix. 
The treatment of pancreatic cancer with micelle based nano drug delivery vehicles has 
been established in literature (Kesharwani et al. 2015). Curcumin is a naturally occurring 
dye that has been reported to possess anti-proliferative and apoptotic effects on pancreatic 
cancer cells, as well as increasing the chemo sensitivity of these cells (Kesharwani et al. 
2015). However, like many promising anti-cancer agents, the poor aqueous solubility and 
rapid clearance makes it unsuitable for clinical use. Styrene-maleic acid is an amphiphilic 
compound that was utilised as a micelle to encapsulate and transport curcumin. The results 
of this study noted a 162-fold improvement in its systemic half-life (Kesharwani et al. 2015). 
Curcumin has yet to successfully complete a clinical trial due to its poor bioavailability, 
solubility rapid clearance (Nelson et al. 2017). Research into styrene-maleic acid micelles is 
as drug carriers for curcumin to neutralise these unfavourable characteristics is ongoing, 
but has not reached the clinical trial stage (Alsaab et al. 2017).  
1.2.2.   Liposomes 
Before the term “nanoparticle” was coined by Norio Taniguchi in 1974, they were referred 
to as “ultrafine particles”. This term was mainly used to describe liposomes and micelles. 
Liposomes are largely composed of phospholipids and are prepared by the solvent 
evaporation of lipid solutions to form thin lipid films. Hydration and subsequent agitation 
(sonication) of the stacked lipid layers cause them to break and reform as liposomes. 
Cholesterol can be added prior to agitation to confer membrane stability to the liposomes 
(Yu et al. 2001). 
Like biologically occurring vesicles, liposomes are used to surround and capture substances 
such as active pharmaceutical ingredients and compounds in aqueous solutions. Their 
greatest advantage is that their structure is very similar to cell membranes (Wang et al. 
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2013). At their biological target their lipid bilayer could fuse with cancerous cell membranes 
releasing their contents in the process into the cell cytoplasm. Their cargo is often DNA, 
hydrophilic drugs and charged substances that dissolved into the aqueous solution within 
the liposome structure. Substances that did not readily pass through the lipid membrane 
surrounding cells now had a means to, through the use of liposomes. Figure 11 depicts the 
increasing complexity of liposomes as drug delivery systems. Initially (A) the traditional 
structure is a simple lipid bilayer with an entrapped hydrophilic drug like gemcitabine (a) 
within the cavity, or an incorporated lipophilic drug (b) within the membrane (Yang et al. 
2011). Currently (E) liposomes can be surface protected with polymers (i) in which some 
are functionalised with antigens for targeted delivery (j) or peptides (p). Within the cavity 
the liposomes can carry their hydrophilic drugs as traditionally intended but also magnetic 
nanoparticles for targeted delivery (r) and colloidal silver or gold nanoparticles for 
microscopic analysis(s) (Yang et al. 2011). 
 
Figure 11: The evolution of liposomes in nanomedicine (Yang et al., 2011). 
GemLip, a novel liposomal formulation of gemcitabine has been found to possess improved 
pharmacodynamics and pharmacokinetics than conventional gemcitabine (Yang et al. 
2011). Theories for the improved efficacy include the passive tumour targeting and 
sustained release of gemcitabine. Passive tumour targeting is achievable with 
nanoparticles of a sufficiently small size because the capillaries supplying tumours are more 
porous and nanoparticles will remain in the bloodstream until they arrive and are able to 
pass through these pores into tumours (Martin et al. 2010; Yang et al. 2011). Sustained 
release of gemcitabine has also been linked to improved response rates in another clinical 
study (Hochster 2003). The difference between these two studies is that (Hochster 
2003)utilised fixed dose rates to administer gemcitabine, while (Yang et al. 2011) 
reproduced this effect with the use of liposomes. The use of GemLip stalled the progression 
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of pancreatic cancer tumour growth from 2.7 months to 4.6 months and improved median 
survival times from 7.2 months with gemcitabine monotherapy to 9.4 months with the use 
of gemcitabine. Fixed dosing by (Hochster 2003) meant the patient had to receive the 
treatment over 150 min instead of the typical 30 min. The median survival time of fixed 
dose rate patients was improved to 8 months from the 5 months they observed. This is a 
significant improvement on the life extension of gemcitabine, but it still falls short of the 
life extension potential of GemLip. These liposomes can also be infused with magnetic 
nanoparticles to image their movement through the body and magnetically target them 
towards tumour sites (Yang et al. 2011). N,N'- bis(salicylidene)ethylenediamine iron 
(Fe(Salen)) possesses both anti-cancer and magnetic properties (Eguchi et al. 2015). 
Magnetic guidance of (Fe(Salen)) within micelles was shown to improve its cytotoxicity, 
compared to non-magnetically guided trials by concentrating them around tumours, 
improving their uptake by 10-fold (Eguchi et al. 2015).   
The disadvantage of utilizing liposomes is that they can be expensive to produce, have poor 
drug loading, limited shelf life and can only slowly release their cargo (Gupta et al. 2008). 
They tend to aggregate at lower concentrations than other compartmental drug delivery 
systems like amphiphilic block copolymers (Hoskins, Paul Kong Thoo-Lin & Cheng 2012a). 
Because their synthesis is based on the agitation of lipid layers, the structure and size of 
individual liposomes can vary leading to poor yields of suitable liposomes (Yu et al. 2001). 
Slow release of drugs like gemcitabine has been shown to improve the effect of treatment, 
but mainly because it helps reduce the proportion of gemcitabine that is metabolised by 
the liver allowing it to build up in tumour cells (Kiew et al. 2010). Methods of rapidly 
exposing tumour cells to gemcitabine while bypassing metabolism in the liver and removal 
by the kidneys will prove superior to slow release methods (Affram et al. 2015). 
1.2.3.   Amphiphilic polymers  
Amphiphiles are molecules that contain both hydrophilic and lipophilic regions. 
Phospholipids are an example of amphiphiles containing a hydrophilic phosphate head and 
a lipophilic lipid tail. When arranged into specific structures such as liposomes, they allow 
the compartmental storage of hydrophilic and charged substances (Yang et al. 2013). Block 
copolymers are polymers derived from more than one type of polymeric monomer subunit. 
These can range from simple repeating ABABAB block polymer chains shown in Figure 12 
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to branched systems where polymer chains are branched with different polymeric 
monomers subunit (Hoskins, Paul Kong Thoo-Lin & Cheng 2012a; Yan et al. 2012) 
 
Figure 12: Simplified structure example of an amphiphilic block copolymer (Hoskins, Paul Kong Thoo-Lin & Cheng 
2012b). 
If the block copolymer contains both hydrophilic and lipophilic subunits then it can be 
described as an amphiphilic block copolymer (Hoskins, Paul Kong Thoo-Lin & Cheng 2012b). 
Like liposomes, these can arrange themselves into structures such as polymeric micelles 
useful for drug encapsulation and nanodelivery systems as described by (Xiong et al. 2012) 
in Figure 13.  
 
Figure 13: Schematic representation of the self-assembly of amphiphilic block co-polymers to polymeric micelles (Xiong 
et al. 2012). 
An advantage of utilizing amphiphilic block copolymers is that their properties can be 
modified by changing the length of block copolymer chains, type of monomer subunits used 
and the addition of functional groups at specific regions within the block copolymer 
structure that can affect hydrophobicity, stability at certain pHs and for conjugation to 
substances such as metallic nanoparticles (Vukovic et al. 2013; Ma’Radzi et al. 2014; 
Sugihara et al. 2010). Future chapters within this thesis will discuss how gold coated iron 
oxide nanoparticles, can be functionalised with Diels Alder cycloadducts linkers via a thiol-
Polymeric micelles 
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Au dative covalent bond. These Diels Alder linkers could potentially be attached to 
amphiphilic block copolymers as side chains. Unlike liposomes, the properties of each block 
copolymer are identical from structure to structure as they are built in a stepwise manner 
(Sugihara et al. 2010). This has been known to confer improved biocompatibility, low 
immunogenicity and improve the lifespan of these structures as they are quite stable when 
compared to liposomes (Xiong et al. 2012). Specific targeting of cancerous cells by 
functionalization of amphiphilic polymer structures, could aid in the improved uptake of 
cytotoxic agents like gemcitabine into cells (Xiong et al. 2012). Another type of amphiphilic 
polymer is graft or “comb shaped” polymers as shown in Figure 14. These are polymers 
comprised of a hydrophilic polymer backbone attached hydrophobic side polymer chains. 
The polymer backbone of a block copolymer can be made up of two or more types of 
polymers. 
 
Figure 14: Simplified structure example of an amphiphilic comb shaped polymer with a homopolymer backbone (left) 
and a block copolymer backbone (right) (Hoskins, Paul Kong Thoo-Lin & Cheng 2012a). 
Comb shaped polymers can self-assemble into micelle-like structures encapsulating 
hydrophobic drugs within the core (M. Barnett 2013). Like liposomes, these micelle-like 
polymers can carry multiple types of cargo including magnetic IONP’s for magnetically 
guided therapies and diagnostic imaging. Poly(allyamine) (PAA) polymer backbones were 
chosen by (M. Barnett 2013) because of their established potential as universal drug 
solubilisers evaluated by (Hoskins, Paul Kong Thoo Lin, Tetley, et al. 2012b) These were 
grafted with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol (Ox5) to produce the comb like 
polymer structure in Figure 15. Addition of the magnetic nanoparticles in the form of Au-
IONP’s was achievable due to gold’s affinity to covalently bond with thiol groups. Au-IONP’s 
were described as hybrid nanoparticles (HNP’s) and their addition to the PAA-Ox5 led to 
the production of PAA-Ox5-HNP’s in Figure 15 (Hoskins, Paul Kong Thoo Lin, Tetley, et al. 
2012b). 
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Figure 15: Synthesis route of PAA-Ox5-HNP’s from a PAA backbone (Hoskins et al., 2012). 
In vitro drug release comparisons of the PAA nano-aggregates with model drugs including 
Propofol, Griseofulvin, BNIPDaoct, 6-TG was carried out by (M. Barnett 2013). All of the 
drug formulations displayed a spike in drug release in Figure 16 within the first 4 hours with 
some formulations having 100 % of the drug being released within 72 hours including both 
forms of Propofol. 
 
Figure 16: Drug release from optimal formulations over 72 h. Study carried out in PBS under sink conditions at 37 °C 
with constant stirring (n=3, ±SD) (M. Barnett 2013). 
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The formulations containing the HNP’s displayed slower release rates than with PAA-Ox5. 
Prolonged release of cytotoxic drugs like gemcitabine has been linked with enhanced 
patient life extension (Yang et al. 2011; Hochster 2003). BNIPDaoct has a 25 % release over 
72 hours held by hydrophobic-hydrophobic interactions with PAA-Ox5, most of this 
occurring within the first few hours of the experiment. The use of HNP’s with PAA-Ox5 
decreased the release rate to 18 %. After the initial burst release of BNIPDaoct, these comb 
like polymers displayed a prolonged ability to contain their payload.  
BNIPDaoct cytotoxicity tests on BxPC-3 pancreatic adenocarcinoma cells with the PAA 
nano-aggregates revealed a 10-fold and 13-fold decrease in IC50 values compared with the 
free drug forms (C. Barnett et al. 2013). This highly significant increase in cytotoxicity on 
pancreatic adenocarcinoma cells displays the potential of PAA-Ox5 and PAA-Ox5-HNP 
encapsulated BNIPDaoct (M. Barnett 2013). Reduction of the dose required to elicit the 
same therapeutic response as a method of improving life extension was stated as a 
significant criteria in improving current treatments of pancreatic cancer (Vandana & Sahoo 
2010; Wagstaff et al. 2012). These PAA nano-aggregates as described by (M. Barnett 2013) 
only allowed the partial release of BNIPDaoct due to their hydrophobicity. Therefore they 
energetically favour the hydrophobic core. Because gemcitabine is also a hydrophobic drug, 
it may display the same drug retention properties within the PAA nano-aggregates (M. 
Barnett 2013). 6-TG, also known as thioguanine is a cytotoxic drug for the treatment of 
leukaemia (Karim et al. 2013). 6-TG was completely released from the PAA-Ox5 nano 
aggregates within minutes of testing, due to its solubility in aqueous environments. This 
makes it unsuitable with PAA-Ox5, because total release of the drug would occur as soon 
as the formulation was injected into the aqueous environment of the circulatory system. 
The 6-TG PAA-Ox5-HNP formulation had the opposite behaviour and only showed a 2 % 
release due to its covalent bonding to the HNPs preventing its release. These results 
suggest that PAA formulations are effective when the drugs are bound with hydrophobic-
hydrophobic interactions (M. Barnett 2013) but not with hydrophilic drugs freely dissolved 
within the aqueous compartment. 
An alternative to encapsulating drugs like gemcitabine with comb shaped polymers like 
PAA (M. Barnett 2013) was tested and evaluated by (Vandana & Sahoo 2010) in Figure 17, 
where they opted to attach polyethylene glycol (PEG) directly to gemcitabine. 
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Gemcitabines small molecular weight, means that it has a short plasma circulation time of 
150 min (peaking at 60 min) after administration and is rapidly cleared by the kidneys after 
its conversion to the inactive 2′, 2′-difluorodeoxyuridine (Vandana & Sahoo 2010). To 
combat this, gemcitabine is given in frequent high doses, contributing to the toxicity and 
associated side effects. PEG is a water soluble amphiphilic polymer known for its high 
biocompatibility (Vandana & Sahoo 2010). It can be synthesised into a myriad of molecular 
weights for different purposes. PEGylated gemcitabine is synthesised by reacting 
polyethylene glycol-N-hydroxysuccinimide (PEG-NHS) with gemcitabine hydrochloride in 
dimethyl sulfoxide (DMSO) in the presence of triethylamine in a molar concentration of 
1:2:20 respectively under a nitrogen atmosphere (Vandana & Sahoo 2010).  
 
Figure 17: Schematic illustration of the reaction involved in the synthesis of the PEGylated gemcitabine (Vandana & 
Sahoo 2010). 
The PEGylation of gemcitabine increased size and reduces its uptake rate into cells leading 
to slower renal clearance (Vandana & Sahoo 2010). Therefore less PEGylated gemcitabine 
is absorbed by healthy cells. Tumours have leaky blood vessels that allow PEGylated 
gemcitabine to penetrate tumours and be loaded into cancerous cells over time. The leaky 
blood vessels that feed tumours are generated by angiogenesis signalling by cancerous cells 
which promote the rapid growth of new but defective blood vessels (Nagy et al. 2009). 
Ultimately this reduces the systemic toxicity while increasing the circulation time of 
gemcitabine in this form. In vivo experiments in mice showed that PEGylated gemcitabine 
remained in circulation after 24 hours after administration into the tail vein. From Figure 
18 we can see that after 30 min of administration, the retention of PEGylated gemcitabine 
within the blood plasma was 1.7 times that of the native dosage form. After 60 min, this 
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difference was now 21-fold between the levels of PEGylated and native gemcitabine. After 
24 hours (Vandana & Sahoo 2010) reported no native gemcitabine while PEGylated 
gemcitabine was still detectable.  
 
Figure 18: Comparison of PEGylated and native gemcitabine concentrations in the blood plasma of mice after 
administration (Vandana & Sahoo 2010). 
PEGylated gemcitabines potential as a drug delivery system for pancreatic cancer 
treatment is established by (Vandana & Sahoo 2010). Increasing the retention time of 
gemcitabine within the circulatory system by attachment to PEG, improves the total uptake 
of gemcitabine which has the potential of improving the life extension properties of 
gemcitabine as discussed by (Yang et al. 2011; Hochster 2003).  This attribute of improved 
retention time is shared with PAA (M. Barnett 2013). PAA-Ox5-HNPs also improve the 
cytotoxicity of their formulations as well compared to PAA-Ox5 (M. Barnett 2013). PEG has 
also been used as a polymer coat on nanoparticles with attached antibodies and should 
have the potential to attach drugs like gemcitabine to nanoparticles via PEG linkers (Sinha 
et al. 2014). However the PAA nano-aggregates display limitation to only drugs bound by 
hydrophobic-hydrophobic interactions. Propofol, another hydrophobic drug required 72 
hours to completely release from its PAA formulation which is significantly longer than 
current blood plasma retention times (Hochster 2003) and with PEGylated formulations 
(Vandana & Sahoo 2010). Polymers, display significant potential in improving the efficacy 
27 
 
of existing cytotoxic drugs for the treatment of pancreatic cancer. This applies to both 
micelle like graft polymers for hydrophobic drug formulations (M. Barnett 2013) and 
PEGylated drugs like gemcitabine (Vandana & Sahoo 2010). The addition of HNPs, and the 
potential attachment of HNP’s to PEGylated drug formulations boosts this efficacy further. 
However drugs encapsulated in graft polymers formulations are superior to PEGylated drug 
formulations in that they are able to improve circulatory retention, especially with 
hydrophobic drugs for longer than the 24 hour period PEGylated drugs can (Vandana & 
Sahoo 2010; Hochster 2003). 
1.2.4.   Iron oxide nanoparticles 
Nanoparticles have gathered increased scientific interest due to their high surface to 
volume ratio and unique properties that can differ from bulk forms (Li et al. 2012; Salameh 
et al. 2014). Nanoparticles typically range from 1 to 1000 nm in diameter and have shown 
great promise in biomedical applications in the form of nanomedicines, diagnostic imaging 
tools and drug delivery systems (Li et al. 2012; Salameh et al. 2014; Markman et al. 2013). 
Figure 19 displays graphically how interest in nano-science, medicine and technology 
increased over the last 18 years. While these were known under different names such as 
ultra-fine particles, the interest in nano related research only saw a significant increase at 
the turn of the century, where it flourished and rapidly expanded from 64 references to 
over 7000 in 12 years (Anada et al. 2009; Markman et al. 2013). 
 
Figure 19: The number of references under the research topics of “nanomedicine,” “nanoscience,” and 
“nanotechnology” from 1996 to 2012. (Markman et al. 2013). 
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Iron oxide nanoparticles (IONP’s) have applications in many medical related fields such as 
cancer treatment, cancer detection, drug transportation, cell labelling and magnetic cell 
sorting (Saritas et al. 2013). They come in multiple shapes such as spherical, hexagonal, 
cubic and also in the form of nanorods as shown in Figure 20s TEM images (de Montferrand 
et al. 2013). 
 
Figure 20: TEM images for (A) spherical, (B) hexagonal, (C) cubic and (D) rod-shaped ferrite nanoparticles. Scale bar 50 
nm (de Montferrand et al. 2013). 
IONPs of different shapes can be synthesised by using a precursor called iron (III) 
acetylacetonate at a high temperature in the presence of 1, 2-hexadecanediol and the 
surfactants oleic acid and oleylamine. Altering the amount of each component of this 
mixture led to the different IONP shapes (de Montferrand et al. 2013).  
IONPs smaller than 20 nm are superparamagnetic which means that they gain magnetism 
under a magnetic field. Unlike ferromagnetic materials, they do not retain their magnetism 
after the magnetic field is removed (Xie et al. 2010; Rosen et al. 2012). 
Superparamagnetism only occurs with nanoparticles because their size is small enough to 
occupy a single magnetic domain, which are small regions within a magnetic substance 
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where all the atoms are magnetically aligned in the same direction. Paramagnetic material 
of sufficient size contains several magnetic domains. The atoms within each domain align 
themselves in the same direction (uniform magnetism). Adjacent domains align in different 
directions which reduce the overall magnetostatic energy of the bulk paramagnetic 
material causing permanent magnetism. IONPs can be produced at a small enough size, 
that the entire nanoparticle occupies a single domain (Santhosh & Ulrih 2013a). By being 
superparamagnetic the IONPs and attached drugs can be magnetically guided to their 
target, but the real advantage is that they lose their magnetism upon the removal of a 
magnetic field, causing the IONPs to disperse. This prevents aggregation and reduces the 
rate that macrophages identify and subsequently engulf them, rendering them useless 
(Santhosh & Ulrih 2013a). 
Guiding the drug directly to its target increases the amount of active pharmaceutical 
ingredients at work. This leads to either more effective treatment and/or a lower dose 
requirement, which can help avoid or reduce some side effects associated with larger 
doses. Multidrug resistance is a constant problem when treating cancer with cytotoxic 
drugs. These cells become resistant but not immune to cytotoxic agents. Increasing the 
amount of cytotoxic agents such as gemcitabine with the use of magnetic IONPs at the 
intended target, improves the efficacy of the drug per dose administration. 
Magnetic IONPs will generate heat when subjected to strong magnetic fields. Magnetic 
crystal suspensions of IONPs store the energy of alternating magnetic fields and release 
this energy as heat causing hyperthermic stress in cancer cells (Laurent et al. 2011). To 
prevent systemic hyperthermia, liposomal IONPs were injected directly into tumours of 
hamsters by (Matsuoka et al. 2004). Application of an external alternating magnetic field 
increased the temperature of the tumours to 42˚C. They reported complete tumour 
regression in 100 % of the treated hamsters with the average tumour size of 1/1000 of 
control hamsters after 12 days of treatment as shown in Figure 21. 
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Figure 21: Typical photographs of hamsters on day 20 after injection with 0.4 mL of the cationic magnetoliposomes (net 
magnetite weight 3 mg). (A) Treatment group. (B) Control animals without alternating magnetic field treatment 
(Matsuoka et al., 2004, Laurent et al., 2011). 
Magnetic particle imaging (MPI) involves the imaging of superparamagnetic iron oxide 
nanoparticles by using the generated magnetic fields as tracers (Khandhar et al. 2013; 
Saritas et al. 2013). It is a new technique, still in the development stages but is showing 
great promise as a potentially useful biomedical imaging technique (Borgert et al. 2012; 
Saritas et al. 2013). The mouse in Figure 22 was injected with Resovist a superparamagnetic 
contrast agent. The volume-rendered MPI image (a) and the photo of the mouse injected 
with 100 μL undiluted Resovist via tail vein and sacrificed 30 sec post-injection (b). The 
heart and liver can be clearly seen as the Resovist flows along the circulation system and 
becomes filtered within the liver (Saritas et al. 2013). 
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Figure 22:  3D projection reconstruction MPI image showing the Resovist tracer flowing to the heart and filtering in the 
liver of a mouse (Saritas et al. 2013). 
In Figure 23, a helical phantom was constructed to test the effectiveness of MPI. Medical 
phantoms are apparatus constructed to be scanned or imaged to test the capabilities of a 
particular imaging technique or imaging equipment. Image (c) in Figure 23 shows a bare 
helical phantom and the subsequent MPI image (a). Tissue is used to surround the phantom 
(d) and the resultant MPI image is shown in (b). 
 
Figure 23: Imaging of helical phantoms to elucidate the effectiveness of Resovist as a tracer in the presence (d) and 
absence (c) of animal tissue (Saritas et al. 2013). 
A 3D MPI experiment shown in Figure 23 demonstrated no depth attenuation or tissue 
contrast. (a–b) Projection Reconstruction 3D MPI images show no attenuation with depth 
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for the phantom embedded in tissue, nor any tissue contrast. Helical phantom (c) was filled 
with SPIOs and (d) the same phantom was embedded in animal tissue (wild turkey)(Saritas 
et al. 2013). Note that the MPI images appear identical regardless of whether the phantoms 
were surrounded by animal tissue. Certain tissues have a tendency of contrasting 
biomedical images. These include bones such as the ribcage when the abdomen for 
example is imaged (Saritas et al. 2013). However the clinical use of iron oxide nanoparticles 
has come under scrutiny following the discontinuation of several iron oxide contrasting 
agents including Feridex, Combidex, Clariscan and Ferropharm. Resovist is still available in 
some countries as of 2015 (Wang 2015). Feridex was reportedly discontinued due to poor 
sales, while Resovist has seen reduced use in many countries due to more efficient MRI 
options available to consumers (Wang 2015). 
1.2.5.    Gold nanoparticles 
Gold nanoparticles have shown promise as useful components in targeted drug delivery.  
This includes iron oxide nanoparticles which are coated in a layer of gold (C. M. Barnett et 
al. 2013; Vigderman & Zubarev 2013). Like IONP’s, gold nanoparticles also come in a variety 
of shapes including, spheres, rods and tetrapods displayed in Figure’s 24 and 25.  
 
Figure 24: Typical TEM photographs of different GNPs (Das et al. 2014). 
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Figure 25: SEM images of three gold particles (a. tetrahedral, b. cubes and c. icosahedral) (Dong et al. 2011). 
Gold as an element is generally regarded as non-toxic (Teixeira et al. 2016). It is a noble 
metal that has filled electronic d-bands. This makes gold resistant to oxidation, corrosion, 
and acidic conditions that can be found within the body. Gold can be strongly bonded 
covalently to thiol groups, an organic functional group that can be found on drug 
compounds or attached via the use of linkers (Wang et al. 2013). One example of such a 
linker is polyethylene glycol (PEG). Thiolated PEG can be attached to a gold nanoparticle at 
one end and a drug compound at another. Therefore one gold nanoparticle can be used to 
carry multiple drug compounds via a PEG linker as illustrated in Figure 26 by (Wang et al. 
2013). This allows for higher doses of certain drugs which have significant side effects such 
as gemcitabine to be used (Wagstaff et al. 2012). 
 
Figure 26: Structure of thiol-PEG-modified AuNPs (PEGylated AuNPs) (Wang et al., 2013a). 
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The use of gold nanoparticles as cancer cell imaging was researched by (Lima et al. 2014). 
An illustration of their process is shown in Figure 27. They produced these gold 
nanoparticles using established methods (Gasparotto et al. 2012) and conjugated two 
antibodies called anti-β-catenin and anti-E-cadherin, which specifically bind to colorectal 
carcinoma cells (Lima et al. 2014).  
 
Figure 27: The schematic for the binding of conjugated gold nanoparticles to colorectal carcinoma cells (Lima et al. 
2014). 
Figures 28 and 29 show the difference in fluorescence in the healthy and cancerous cells. 
The cancerous cells have a higher expression of both β-catenin (A1-3 on both Figure 28 and 
29) and E-cadherin (B1-3 on both Figure 28 and 29). Therefore the conjugated anti-β-
catenin and anti-E-cadherin on the nanoparticles attach more readily to the cancer cells. 
This shows that the use of conjugated nanoparticles is a powerful tool for the diagnostic 
imaging of cancer cells (Lima et al. 2014). 
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Figure 28: Confocal images of healthy cells acquired at an excitation laser of 520 nm. Left column: images acquired with 
the conjugate of β-catenin. The conjugates had β-catenin/AuNPs ratios of (A1) 6.1 × 10−3, (A2) 4.1 × 10−3 and (A3) 3.0 × 
10−3. Right column: images acquired with the conjugate of E-cadherin. The conjugates had E-cadherin/AuNPs ratios of 
(B1) 6.1 × 10−3, (B2) 4.1 × 10−3 and (B3) 3.0 × 10−3. Magnification: 10×. Scale bar = 100 μm (Lima et al. 2014). 
Non-Cancerous Cells 
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Figure 29: Confocal images of cancerous cells. Left column: images acquired with the conjugate of β-catenin. The 
conjugates had β-catenin/AuNPs ratios of (A1) 6.1 × 10−3, (A2) 4.1 × 10−3 and (A3) 3.0 × 10−3. Right column: images 
acquired with the conjugate of E-cadherin. The conjugates had E-cadherin/AuNPs ratios of (B1) 6.1 × 10−3, (B2) 4.1 × 
10−3 and (B3) 3.0 × 10−3. Magnification: 40×. Scale bar = 100 μm (Lima et al. 2014). 
Cancerous Cells 
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Gold is not magnetic and therefore lacks the potential magnetic guidance of IONP’s. 
However its biocompatibility, ability to carry drug formulations, ease of synthesis and 
surface plasmon resonance properties make it a powerful tool in the treatment of 
pancreatic cancer. One characteristic of gold is its ability to absorb near infra-red (NIR) 
radiation and generate heat due surface plasmon resonance (SPR). SPR is the term used to 
describe the oscillation of free electrons when light is shone on a metal surface. These 
resonating free electrons produce an electromagnetic wave (light) that travels away from 
the bulk phase of the solid (Zhang et al. 2007; Verma et al. 2012). Generating heat using 
NIR radiation via SPR is ideal considering the high transparency of tissue at that wavelength. 
A laser emitting NIR radiation can be used to target a specific area where gold nanoparticles 
are situated, such as within a cluster of neoplasia in the pancreas. Heat generated from the 
photo thermal effect will raise the temperature of the cancer cells killing them. Because 
the lasers area of effect is small, this would also prevent damage being caused to nearby 
healthy tissues (Vigderman & Zubarev 2013).  
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1.2.6.   Silver nanoparticles 
Like gold nanoparticles, silver nanoparticles also display surface plasmon resonance (Liang 
et al. 2012). Silver nanoparticles are more visible than gold, to optical sensors (Miao et al. 
2014). Silver nanoparticles have antimicrobial properties and their cytotoxic effects are 
already an established fact (Mukherjee et al. 2012; Meyer et al. 2010). They are currently 
used in wound dressings, contraceptive devices and as surgical instruments coatings 
(Mukherjee et al. 2012). Silver nanoparticles are synthesised from silver nitrate reduced 
with sodium citrate. While heating, sodium borohydride is added to the stirring mixture 
before the heat is switched off and the mixture is allowed to continue stirring for several 
hours (Hayden et al. 2013). The shapes of silver nanoparticles is important for their desired 
use as described by (Chen et al. 2011) in Figure 30. 
Shapes Preparation 
methods 
Potential applications 
Nanosphere Chemical reduction 
Laser ablation 
Bactericide, SERS-based sensing 
Nanowire Wet chemical 
synthesis 
Soft solution 
method 
Opto-electronics 
Nanobelt Chemical reduction 
Laser ablation 
Photonics, electronics 
Nanoplate Chemical reduction 
Photochemical 
method 
Catalysis, opto-electronics, 
biological sensing 
Nanocube Chemical reduction Photonics, catalysis, SERS-based 
sensing 
 
Figure 30:  A summary of different shapes of Ag NPs and their potential applications (Chen et al. 2011). 
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The metal nanoparticles iron oxide, gold and silver have their own properties that make 
them suitable as drug delivery, imaging and therapeutic agents for the treatment of cancers 
such as pancreatic cancer. Iron oxide is magnetic and can be guided to its target with the 
use of external magnetic field (Santhosh & Ulrih 2013a). They can also be used as excellent 
contrasting agents to study the movement of IONP formulations within the body or image 
specific areas such as tumours when guided by magnetic fields. Silver nanoparticles are also 
highly visible to optical sensors. They can also be used to generate heat by SPR causing 
hyperthermia in cells (Liang et al. 2012). However they are not magnetic and therefore 
cannot be guided to specific regions and held there with magnetic fields. Gold 
nanoparticles also lack the magnetic properties of IONPs but share in silver’s SPR 
properties. More importantly, gold is very biocompatible; an advantage it has over IONPs 
and silver nanoparticles. Combining the properties of these metals into nanoparticles, such 
as silver-gold and iron oxide-gold, which will be discussed in the next section. 
1.2.7.   Silver-gold nanohybrids 
Hybrid nanoparticles are nanoparticles comprised of nanocomponents within a 
nanoassembly. One example of hybrid nanoparticles is silver-gold core-shell nanoparticles. 
Hybrid nanoparticles are utilised to fulfil multiple roles such as drug delivery, imaging, or 
conferring useful properties such as reduced toxicity. Research into the detection of 
carcinoembryoic antigen (CEA) using silver-gold core shell hybrid nanoparticles was carried 
out by (Miao et al. 2014). Increased levels of CEA can signal the presence of various types 
of cancer including pancreatic cancer. Typical amounts range from 3-5 ng mL-1 in a healthy 
individual and rapid detection methods such as dynamic light scattering have been utilised 
by (Miao et al. 2014) to detect CEA. An antigen called anti-CEA selectively binds to CEA. 
Attachment of core shell nanoparticles like iron-silver nanoparticles to anti-CEA, will allow 
the imaging of areas showing heightened levels of CEA (Miao et al. 2014) due to CEA 
binding to anti-CEA. Silver nanoparticles are not considered biocompatible but are known 
for having a 100x molar extinction coefficients compared to gold nanoparticles making the 
overall core shell nanoparticles more sensitive to optical sensors. The surface gold layer on 
these core shell nanoparticles provides biocompatibility, something that silver 
nanoparticles lack. Silver-gold core shell nanoparticles make up for the deficiencies of 
individual gold and silver nanoparticles (Miao et al. 2014). The average size of the core shell 
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nanoparticles shown in Figure 31 is 63.3 nm determined with dynamic light scattering 
(Miao et al. 2014). Addition of 1 ng mL-1 and 10ng mL-1 of CEA increased their sizes to 138.7 
and 201.6 nm respectively due to the attachment of anti-CEA in the core shell 
nanoparticles, to the CEA in the PBS buffer (Miao et al. 2014). 
 
Figure 31: The size distribution (A) and TEM images (B) of 4.0 μg/mL of Ag@Au/anti-CEA probes in the presence of 0 
ng/mL (a), 1.0 ng/mL (b) and 10.0 ng/mL (c) of CEA. Experiments were conducted in 10 mM of PBS buffer (pH 7.4) (Miao 
et al. 2014). 
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1.2.8.   Iron oxide gold nanohybrids 
The gold coating around the iron oxide core such as the one shown in Figure 32 provides 
the structure with non-immunogenic properties. Gold is highly unreactive and nontoxic, an 
attribute that it confers to the nanohybrid structure (Wagstaff et al. 2012). The gold coating 
does not diminish the magnetic properties of the iron oxide core, retaining the potential 
for magnetic guidance to the target site of action. The magnetic iron oxides can be used as 
a tracer during magnetic particle imaging. Au-IONPs have been described as having 
cytotoxic effects as well (Guo et al. 2013). Therefore Au-IONPs both have a therapeutic and 
diagnostic role in the treatment of cancers and can be described as theranostic agents.  
 
Figure 32: Diagram of a gold coated iron oxide nanoparticle (Wagstaff et al. 2012). 
The physical stability of HNPs was evaluated by (C. M. Barnett et al. 2013) by suspending 
them in solutions of pH 7.2 and 4.5 to mimic blood and lysosomal physiological conditions 
after drug administration.  
Blood is comprised of many components including plasma, cells, proteins, mineral ions and 
platelets. These components interact with one another, undergo metabolism and move 
through the circulatory system. Depending on their location within the body, their 
composition and characteristics can change significantly. Blood in the pulmonary arteries 
is oxygen poor and blood vessels around the small intestine are rich in digested nutrients. 
The sheer level of complexity in blood makes it difficult to accurately measure the 
relationship between known variables due to the potential of unknown mechanisms 
affecting results.  This is why cell media, a relatively simple solution is used for in vitro 
experiments.  
The solutions were stirred over a 14 day period within a dialysis membrane and analysed 
frequently for Fe and Au using inductively coupled plasma-optical emission spectroscopy 
(ICP-OES). Figure 33 displays the relationship between the attachment of PEG on HNP’s and 
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the rate of release over a 2 week period at two biological pHs (7.2 for blood and 4.6 for 
lysosomes).  
 
Figure 33: Stability of HNPs in solution under in biological conditions at pH 7.2 and 4.6. (A) HNP and (B) HNP-PEG. Study 
carried out under in sink conditions over 2 week period and percentage initial Au determined (n = 3 ± SD) (C. M. Barnett 
et al. 2013). 
A rapid increase in the rate of release of gold occurs within a few hours. Non-PEG HNPs 
rapid increase in the rate of gold release promptly stabilizes at 0.007 %. This is maintained 
at a pH of 4.6 (lysosome) and gradually rises to 0.008 % at a pH of 7.2 (blood). Barring the 
initial rapid release of gold, the HNPs display a high amount of stability at these two pHs. 
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When PEG is attached to the HNPs, less gold is released across the dialysis membrane than 
without PEG. A sharp increase in gold release within the first few hours occurs with the 
addition of PEG, but like the non-PEG HNPs this quickly stabilizes. In the case of PEG HNPs 
this stabilization occurs after lower amounts of gold has been released. The HNPs display 
higher stability at a pH of 7.2 (blood) of around 0.0016 compared to the amount of gold 
released at pH 4.6 (lysosome), which is still gradually releasing gold, although at a much 
lower rate beyond 0.002 % release and at an even lower rate after 0.0043 %. With PEG, the 
HNPs are therefore 2.7 times more stable over 2 weeks at a pH of 7.2 compared to 4.6 
(Barnett et al., 2013). Overall the HNPs remain stable in terms of the amount of gold being 
released over a 2 week period. Different conditions and the presence of PEG affect the 
onset stabilization with PEG providing improved stability by reducing the amount of gold 
release (C. M. Barnett et al. 2013). Au-IONPs were also stored in solution for 6 months at 
room temperature in order to determine their physical stability over an extended period 
of time. The data acquired from this experiment is shown in Figure 34. 
 
Figure 34:  Results for the physical stability study of Au-IONP’s stored in solution at room temperature for 6 months (C. 
M. Barnett et al. 2013). 
After 6 months the nanoparticles retained their size of 70 nm and showed no loss of gold 
coating due to no differences in the zeta potential. Therefore Au-IONPs display excellent 
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chemical stability and shelf life. TEM images confirmed that the Au-IONPs also retained 
their particle morphology as well (C. M. Barnett et al. 2013).  
The method for synthesizing Au-IONPs was described by (C. M. Barnett et al. 2013). First, 
iron oxide nanoparticles were produced by an established co-precipitation method. The 
IONP’s are coated with a polymer called poly (ethylenimine) (PEI) with a molecular weight 
of roughly 750000g mol-1. This allows the gold seeds to attach to the iron oxide cores easier. 
Gold seeds were produced by reducing HAuCl4 solution with NaBH4. Purification during the 
Au-IONP synthesis involved magnetic separation and multiple decanting steps aided by the 
magnetic properties of the IONPs and subsequent Au-IONPs as shown in Figure 35. 
 
Figure 35:  Photographic images of (a) gold-coated iron nanoparticles (Au@FeNPs) demonstrating the purple colour 
associated with the presence of metallic gold and (b) the magnetic separation of the Au@FeNPs which leaves in 
solution any pure gold nanoparticles which form during the coating of the FeNPs (Wagstaff et al. 2012). 
30 nm Au-IONPs were synthesised by established methods and tested on pancreatic cancer 
cell cultures at different concentrations (Guo et al. 2013). Determination of the effect of 
the laser light (808 nm) on the pancreatic cancer cells after 5 min of exposure revealed no 
reduction in cell proliferation and a temperature increase of 12.89˚C from 20˚C (Guo et al. 
2013) in Figure 36 (A). A wavelength of 808 nm was chosen due to iron oxide having a very 
low absorption at this range. Therefore all absorbed light from the laser, would be 
attributed to the gold layer (Guo et al. 2013). The laser provided a surface power density 
of 7.9W cm-2. The effect of changing the surface power density on the rate and extent of 
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cell culture heating is displayed graphically in Figure 36 and with microscopic imaging in 
Figure 37.  
Figure 36: Photothermal response of 0 (A), 25 (B), and 50 (C) µg/mL nanoparticle samples at 3.2, 4.7, 6.3, and 7.9 W cm-
2 (Guo et al. 2013). 
 
Figure 37: PaNc-1 cells exposed to 0, 25, and 50 µg mL-1 dose of nanoparticles, respectively, without laser irradiation 
(A–C) and with laser irradiation at 7.9 W cm-2 power density (D–F) (Guo et al. 2013) 
Addition of 25 µg mL-1(B) and 50 µg mL-1(C) Au-IONP’s without photothermal ablation 
reduced cell proliferation to 71.3 % and 47 % respectively. Photothermal ablation at the 
same concentrations reduced cell proliferation to 21.9 % (E) and 2.3 % (F) revealing that 
the cytotoxic properties of Au-IONP’s coupled with heat generation has a significant 
increase in the reduction of pancreatic cancer cell proliferation. The heat generated by the 
7.9W laser was not the main contributor to the temperature rise of the irradiated cells. This 
heat generation was due to the surface plasmon resonance properties of gold (Guo et al. 
2013). 
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1.3.   The Diels Alder reaction 
The Diels Alder reaction is a [4+2] cycloaddition reaction between a diene and a substituted 
dienophile, which forms a substituted cyclohexene. It was first described in 1928 by Otto 
Diels and Kurt Alder (Diels & Alder 1929). Ethene, the dienophile shown in Figure 38, is 
analogous to maleimide, while 1.3-butadiene is analogous to furan. After Diels Alder has 
taken place, the resulting cycloadduct retains the secondary amine, and carbonyl groups of 
the maleimide as well as the ether oxygen of the furan. This is because they were not 
involved in the 4+2 cycloaddition. 
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Figure 38: The simplest cycloaddition between ethene and 1,3-butadiene to produce cyclohexene (a). Analogous Diels 
Alder reaction between maleimide and furan (b). 
Drug formulations in clinical use must be tested to ensure every conceivable reaction that 
could possibly take place is recorded and evaluated. In regards to drug formulation for 
chemotherapy, the Diels Alder reaction conservation of atoms is an advantageous 
property. This is because the only compounds of interest are the cycloadduct, diene and 
dienophile when ascertaining their individual effect upon introduction into the body. A 
cycloaddition like the example in Figure 39 is pericyclic reaction. These reactions have a 
transition state where all of the bond breaking and formation occurs simultaneously in a 
cyclic fashion (Sauer & Sustmann 1980). 
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Figure 39: Diagram depicting the pericyclic transition state of a Diels Alder reaction between ethene and 1,3-butadiene 
to produce cyclohexene. 
(a) 
(b) 
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The diene has 4 π electrons (2 π bonds) and the dienophile has 2 π electrons (1 π bond) 
involved in this pericyclic reaction. Three π bonds break as a new π bond and 2 σ sigma 
bonds form. Figure 40 above shows the π orbitals of the diene and dienophile. The 
dienophiles single π bond has two possible conformations while the diene has four. The 
LUMO within the dienophile matches the arrangement of the HOMO of the diene. The 
energy gap is also similar enough to allow electrons from the HOMO of the electron rich 
diene to transfer to the LUMO of the electron poor dienophile. 
High
Low
LUMO
HOMO
(a) Dienophile
              
LUMO
HOMO
(b) Diene
High
Low
             
(c)
 
Figure 40: π orbital interaction around a single π bond (a), two π bonds (b) and the interaction of LUMO (a) and HOMO 
(b). 
The orbitals have to be orientated specifically, in order for the bond forming electron 
transfers to occur, during the concerted transition state. This requires the diene to be in an 
s-cis (-C=C-) conformation. It is possible for the diene to be electron poor if it has an 
electron withdrawing group such as (-CH2=CH2-CH=O) carbonyl group. A dienophile in this 
condition can still undergo Diels Alder with an electron rich dienophile. This is called inverse 
Diels Alder (Knall et al. 2014).  Three π bonds are still broken to form a new π bond and two 
σ bonds. The Diels Alder reaction between furan and maleimide can produce both endo 
and exo products. This is due to maleimide being able to arrange itself in two possible 
orientations and still have its π orbitals line up with furans. The endo isomer is formed from 
the endo transition state where the substituents of the dienophile are facing towards the 
π bond of the diene. In the exo isomer the substituents are facing away from the diene π 
bond. 
The potential outcome of any chemical reaction is based on two aspects. The first is the 
thermodynamic energy of the product and this governs the stability of the product(s) in a 
reaction. In terms of ΔG which is Gibbs free energy, if the reaction releases energy, it can 
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be described as exothermic and spontaneous. This is shown in the Gibbs free energy 
equation:[𝛥𝐺 =  𝛥𝐻 − 𝑇𝛥𝑆] where the free energy of a system (G) is equal to its enthalpy 
(H) at normal pressure minus the product of the temperature (T) and entropy (S) of the 
system. If ΔG is negative the reaction is spontaneous and Diels Alder will occur. This is the 
case with Diels Alder where the product has a lower energy than the starting material. 
Figure 41 goes on to illustrate that the thermodynamic product is more energetically stable 
than the reactants. 
 
Figure 41: Reaction energy diagram of a Diels Alder reaction. Note that the endo product has more potential energy and 
forms faster. 
The thermodynamically more stable product will be the exo isomer due to having less steric 
congestion. The second factor influencing the outcome of a chemical reaction is the kinetic 
aspect. The kinetics of a reaction describe the rate in which products are formed. Overall, 
the Diels Alder reaction between furan and maleimide produces a mixture of endo and exo 
isomers. The endo transition state in Figure 42, is produced faster because of non-bond 
forming interactions between the electron withdrawing carbonyls π orbitals of the 
maleimide and the middle two π orbitals of the diene. This lowers the activation energy 
leading to a faster reaction as shown in Figure 41. 
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Figure 42: Diagram showing the endo and exo isomer products produced by a Diels Alder reaction between furan and 
maleimide. 
The Diels Alder reaction requires an activation energy threshold to be reached before it can 
proceed (Boutelle & Northrop 2011a).  In some cases, especially in the presence of electron 
withdrawing group, the activation energy may be low enough for the [4+2] cycloaddition 
to occur spontaneously. Therefore some Diels Alder reactions can proceed at room 
temperature (Scheltjens et al. 2013). In terms of the cycloaddition between furan and 
maleimide, both the exo and endo isomers form because conditions satisfy both outcomes. 
The endo isomer is the major product however because it forms faster (Boutelle & 
Northrop 2011a).  
Under elevated temperatures a cycloadduct formed from a Diels Alder reaction will reverse 
forming the diene and dienophile (Kuramoto et al. 1994). This can be explained with the 
Gibbs free energy equation:  [𝛥𝐺 =  𝛥𝐻 − 𝑇𝛥𝑆] where elevated temperatures can surpass 
the enthalpy component causing the free energy (ΔG) to be positive. This allows the reverse 
reaction to occur spontaneously (Boutelle & Northrop 2011a). As stated previously, the 
endo isomer has a higher enthalpy than the exo isomer. If enough energy is supplied to the 
system the endo isomer having reached a positive ΔG will be able to undergo retro Diels 
Alder (Boutelle & Northrop 2011a). The rate of this reversal is temperature dependant and 
the equilibrium ratio between starting materials and cycloadduct increases at higher 
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temperatures. The exo isomer as the more thermodynamic product is more stable, 
possessing a lower enthalpy. In order to undergo retro Diels Alder it will require more 
energy than the endo isomer. As a result there is a temperature range unique to each 
cycloadduct where only the endo isomer will undergo retro Diels Alder. Therefore the 
starting materials are regenerated and some will undergo Diels Alder again via the exo 
transition state. Over time the exo isomer accumulates and becomes the major product 
(Boutelle & Northrop 2011a).  
The Diels Alder cycloadduct is the key attribute that a suitable thermally labile linker 
possesses that meets the requirements. However said thermally labile linker also has a 
pharmaceutical agent (gemcitabine) and thiol group in order to attach to the gold surfaces 
of hybrid nanoparticles. Because a suitable thermally labile linker structurally rests in 
between the pharmaceutical component and the thiol group it must have the ability to 
covalently bond to both. The thiol group in particular can pose a problem for the formation 
of a Diels Alder adduct between a substituted furan and maleimide, as it specifically 
undergoes a Michael addition with maleimides producing a highly stable thioether 
(Onbulak et al. 2012). This reaction will remove the π bonds of maleimide rendering a Diels 
Alder reaction impossible, as shown in Figure 43. 
NH
O
O
+ O
SH
O
S
N
H
O
O
 
Figure 43: Thiol-Michael addition between maleimide and 2-furanmethanethiol. 
Therefore the introduction of a thiol group must either occur after Diels Alder has taken 
place or only after the present thiol group has been protected. As described in Figure 44, 
this will ensure Diels Alder takes place with no competing reactions. With the commercially 
availability of 2-furanmethanethiol, the choice to protect its thiol group was chosen. As 
such, 2-furanmethane thiol was first protected with either a benzoyl or boc group in all 
instances before it was used in a Diels Alder reaction.  
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Figure 44: Diels Alder reaction between maleimide and boc protected 2-furanmethane thiol. 
In order to observe the effects of the thermally labile linkers activity on cell proliferation, 
the presence of a known cytotoxic agent is required. Gemcitabine is the most common first 
line chemotherapeutic agent for treating pancreatic cancer (Hoskins et al. 2010). This 
makes it the best candidate to fill criteria as the pharmaceutical agent component of a 
suitable thermally labile linker.  Gemcitabine (2′,2′-difluoro-2′-deoxycytidine) is a prodrug 
that is converted intracellularly to the monophosphate by deoxycytidine kinase and then 
the diphosphate by pyrimidine nucleoside monophosphate kinase at the 5 position 
hydroxyl group (Song et al. 2016a). The three and five position hydroxyl group shown in 
Figure 45, must be free to covalently bond to the phosphate group of the neighbour nucleic 
acids. As a result these groups must be present and unsubstituted by the time the thermally 
labile linker is covalently bonded to the hybrid nanoparticles via a thiol-gold bond. 
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Figure 45: Diagram depicting a section of DNA where the highlighted active form of gemcitabine (2’, 2’-difluoro-2’-
deoxycytidine triphosphate) has substituted deoxycytidine triphosphate during DNA synthesis. 
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1.4.   Current research on thermoresponsive drug delivery systems 
The slight hyperthermia experienced by cancerous cells is caused by their accelerated 
growth and metabolic activity. A recent study in the exploitation of this trait involves 
Celsion Corporations development of a liposomal formulation called ThermoDox which is 
in its stage III trials. This formulation capitalises on the leaky vasculature of cancerous 
tissues which allows for the accumulation of liposomal formulations (Alexander et al. 2013; 
Nagy et al. 2009). The polymeric structure of ThermoDox is stable at 37 °C but undergoes 
a phase transition above 40 °C which facilitates the release of doxorubicin an antitumour 
drug directly at the intended site of action (Alexander et al. 2013). Magnetic iron oxide 
nanoparticles (IONP’s) with surface attached Diels Alder cycloadducts were used to 
facilitate the release of a fluorescent dye called tetramethylrhodamine-5-C2- maleimide 
(RhD) which acted as a model drug. Heat generated by the IONPs subjected to an 
alternating magnetic field increased their surface temperature to 80 °C which allowed the 
retro Diels Alder reaction to occur. This caused the release of 85 % of the attached RhD 
compound over a 48 h time period. The Diels Alder reaction is known to proceed at 
temperatures of 90 °C and above but the close proximity of the Diels Alder reaction was 
hypothesised to allow the initiation of the retro Diels Alder at lower temperatures (N’Guyen 
et al. 2013).  
1.5.   Substituent effects on reactivity and reversibility of the Diels Alder reaction 
The Diels Alder reaction can be promoted further with the presence of certain substituents. 
Electron withdrawing groups attached to the sp2 carbon(s) of dienophiles, such as the 
carbonyl groups in maleimide, cause the dienophile to be more electron poor than ethene. 
The Diels Alder cycloadduct formed from the reaction between furan and maleimide 
proceeds with ΔG = -1.1 kcal mol-1 for the exo isomer and -3.6 kcal mol-1 for the endo isomer 
(Boutelle & Northrop 2011b). A similar reaction between 2-methoxyfuran and maleimide 
in Figure 46, has a ΔG value of -6 kcal mol-1 for its endo adduct. This difference of 2.4 kcal 
mol-1 makes the cycloadduct of 2-methoxyfuran and maleimide favourable for adduct 
formation (Boutelle & Northrop 2011b). 
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Figure 46: Diels Alder reaction between 2-methoxyfuran and maleimide. 
This is because of the strong electron donating property of the methoxy group acting on 
the diene (furan) promoting adduct formation at the cost of completely hindering 
reversibility. As such, the use of a methoxy substituted furan for this projects aims was 
deemed highly unfavourable. The presence of alkyl chain substituents on the furan also 
promotes the adduct formation, at a lesser extent when compared to a strong methoxy 
electron donating group. The Diels Alder cycloadduct shown in Figure 47, formed from 2-
methylfuran and maleimide has a ΔG value of -2.4 kcal mol-1 for the endo isomer, which is 
a difference of 1.3 kcal mol-1 when compared Diels Alder reaction of furan and maleimide 
(Boutelle & Northrop 2011b). 
O
CH3
NH
O
O
+ NH
O
O
O
CH3  
Figure 47: Diels Alder reaction between 2-methylfuran and maleimide. 
The effect is a Diels Alder reaction that can proceed to produce a stable cycloadduct that is 
still capable of retro Diels Alder at elevated temperatures. This trait is highly beneficial for 
fulfilling the requirements in synthesizing a thermally labile linker. Electron withdrawing 
groups such as aldehydes as substituents on the diene may raise the ΔG energy enough for 
it to be positive. This is the case with the Diels Alder cycloaddition of 2-furaldehyde and 
maleimide shown in Figure 48. No adduct formation has been recorded and it is speculated 
that any adducts formed immediately undergo retro Diels Alder (Boutelle & Northrop 
2011b). 
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Figure 48: Diels Alder reaction of 2-furaldehyde and maleimide. 
All of these examples clearly prove that the presence of substituents affect the Diels Alder 
and its reversibility. However the position of the substituent, not just the type also affects 
the forward and backwards Diels Alder reaction. Substitution on the 3 position of furans 
also has an effect on the formation of the cycloadduct. The Diels Alder reaction of 2 and 3-
methylfuran with maleimide will proceed to form a cycloadduct, but the 3 position 
substitution will yield an adduct that is more stable than the 2 position. This is reflected in 
its endo isomers higher free energy (ΔG) of -3.6 kcal mol-1 at the 3 position compared to -
2.4 kcal mol-1 for the 2-position (Boutelle & Northrop 2011b). The 2-position within furan 
is more electropositive than the 3 position. Therefore the presence of electron donating 
groups such as methoxy will favour the Diels Alder more at the 3-position (Boutelle & 
Northrop 2011b).  
1.6.   Aims and objectives 
The aim of this project involves the attachment of a clinically relevant drug (gemcitabine) 
to the surface of gold coated iron oxide nanoparticles via a thermally labile linker. This 
linker would contain a Diels Alder adduct capable of facilitating the release of attached 
drugs at elevated temperatures. The heat required for this process would be generated by 
the gold coated iron oxide nanoparticles. The bioavailability, chemical stability and surface 
plasmon resonance properties of gold as a coating of magnetic iron oxide nanoparticles will 
prove invaluable in a potential novel drug formulation for treating pancreatic cancer. By 
utilizing the thermal reversibility of Diels Alder cycloadducts, the thermal release of drug 
compounds can proceed due to the heat generated by the surface plasmon resonance of 
gold coated iron oxide nanoparticles. These hybrid nanoparticles serve as theranostic 
agents capable of both diagnostic and therapeutic activity. In terms of synthesizing a 
thermally labile linker based on a Diels Alder adduct, it is preferable to use a 3-substituted 
furan. However the increased free energy of a cycloadduct formed from a 3 substituted 
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furan with maleimide will also lead to higher temperature requirements to initiate retro 
Diels Alder. One of the criteria a Diels Alder adduct will need, to meet the requirements as 
a suitable thermally labile linker, is to readily undergo retro Diels Alder at 45 °C. Therefore 
a balance has to be struck to ensure that the forward Diels Alder reaction to produce a 
cycloadduct is thermodynamically possible and the resulting cycloadduct is capable of 
undergoing retro Diels Alder at the required temperature range. The synthesis of a suitable 
thermally labile linker, attached to a clinically relevant drug (gemcitabine) and to the 
surface of gold coated iron oxide nanoparticles was carried out. Characterisation of the 
products of each chemical reaction step and final linker was carried out with nuclear 
magnetic resonance (NMR), fourier transform infrared spectroscopy (FTIR) and thin layered 
chromatography (TLC). The charge and particle size changes were monitored throughout 
hybrid nanoparticle synthesis with a zeta sizer and inductive coupled plasmon – atomic 
emission spectroscopy (ICP-AES) was used to characterise the atomic gold and iron ratio of 
hybrid nanoparticles. The synthesis process for this novel drug formulation, drug release 
experiments and in vitro experiments on pancreatic cancer cells, will be displayed in the 
next chapters of this study.  
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CHAPTER 2: SYNTHESIS OF THERMALLY LABILE 
DRUG LINKERS 
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2.0. Introduction 
Hybrid iron oxide-gold (HNPs) have shown potential as drug carriers for pancreatic cancer 
therapy (Sailor et al. 2012; C. M. Barnett et al. 2013). In order to further investigate the 
potential of these particles the drugs must first be conjugated onto the surface of the 
particles. This conjugation may be due to physical or chemical bonding. Physical binding of 
onto the surface of the HNPs has been previously reported. This study showed that 
positively charged drug molecules were capable of binding onto the HNP with reversible 
effect under heating (Eskandari & Ghourchian 2012). However, electrostatic binding may 
work in some circumstances but many factors such as change in pH, addition of electrolytes 
and temperature may contribute to the breakdown of bonds (Eskandari & Ghourchian 
2012). Hence, it is desirable to develop a means of chemical binding onto the HNPs to 
ensure stability. It is well reported that thiolated molecules can bind to gold nanoparticles 
using dative covalent binding (Salihov et al. 2015; Zhu et al. 2006; Arora et al. 2014). A 
typical covalent bond involves the sharing of electrons between two atoms where each 
atom supplies one electron to form the bond. In dative covalent bonds, both of the 
electrons are supplied by one atom (Atkins 2006a).  The presence of thiols or disulphides 
on a drug compound will allow the formation of a dative bond with the gold surface of 
HNPs. Drug molecules containing thiols or disulphide bonds may exploit this chemistry, 
however, this is non-reversible and hence it may hinder the active site of the molecule and 
inhibit activity. Drug molecules which do not contain such functional groups may be 
chemically attached to the surface of the HNPs via linker. The linker molecules themselves 
may be developed to be stimuli responsive i.e. Linker breakdown occurs upon alteration of 
conditions such as pH or temperature (Zhu et al. 2006; Gobbo & Workentin 2012; Engel & 
Kickelbick 2013).  
Hybrid iron oxide-gold (HNPs) have shown potential as drug carriers for pancreatic cancer 
therapy (Sailor et al. 2012; C. M. Barnett et al. 2013). The first task is the conjugation of 
drugs to their surface in order to improve our understanding of their drug carrier potential. 
HNPs have a negative charge and can form electrostatic bonds with positively charged 
drugs (Eskandari & Ghourchian 2012). The effects of enzymatic action, presence of 
electrolytes and changes in pH can affect the zeta potential which in turn could prematurely 
release the loaded drug or make the formulation unsuitable for long term storage 
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(Eskandari & Ghourchian 2012). Due to the cytotoxic nature of chemotherapeutic drugs, it 
is imperative that a method of drug loading is utilised that promotes stability.  It has already 
been reported that thiolated materials are capable of forming dative covalent bonds with 
gold coated iron oxide nanoparticles (Salihov et al. 2015; Arora et al. 2014; Zhu et al. 2006). 
A typical covalent bond involves the sharing of electrons between two atoms where each 
atom supplies one electron to form the bond. In dative covalent bonds, both of the 
electrons are supplied by one atom (Atkins 2006a).  Drug compounds lacking a thiol group 
for an Au-S dative covalent bond, may be chemically attached to one, via a linker. The 
properties of the linker could also be designed in order to further promote the activity of 
released drugs under specific conditions such as changes in temperature (Zhu et al. 2006; 
Gobbo & Workentin 2012; Engel & Kickelbick 2013). Using a temperature sensitive linker 
would be ideal due to the surface plasmon resonance (SPR) property of gold. SPR is a 
phenomenon involving the oscillation of surface electrons caused by the conversion of 
absorbed electromagnetic energy of a specific wavelength into light of a different 
wavelength. Gold undergoes SPR at the near infrared range of the electromagnetic 
spectrum (H. Zhang et al. 2013). As a result, exposure to near infrared radiation will cause 
a rise in the surrounding temperature around the HNPs. The use of a Diels Alder 
cycloadduct was selected as a potential thermally labile linker to fit this criteria and 
promote drug release following the HNPs exposure to near infrared radiation. 
The substituted groups present on furans and maleimides is retained after cycloaddition 
which further displays the customisable nature of these cycloadducts. In fact, all structural 
atoms present on reagents undergoing the Diels Alder reaction are present within the 
cycloadduct. These cycloadducts will reverse back into their original diene and dienophile 
reagents in elevated temperatures (Gandini 2005). This reaction has been exploited in drug 
delivery predominantly in polymer chemistry.  
One such example is with the use of Diels Alder adducts to construct dendrimers by (Szalai 
et al. 2007). Their aim was to synthesize self-assembly systems with thermal 
responsiveness. They noted its reliability to form up to 4th generational dendrimers based 
on the furan-maleimide Diels Alder reaction shown in Figure 49. A 1,1′-(methylenedi-4,1-
phenylene)- bismaleimide served as the dendrimer core and as a reactive dienophile. 
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Figure 49: Reaction scheme of the synthesis of first, second, third and fourth generation dendrimers attached to a 
substituted furan and the subsequent reaction with a bismaleimide core (Szalai et al. 2007). 
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These dendrimers degraded at temperatures of 95 °C and reassembled over three days at 
60 °C displaying the reversibility of the Diels Alder reaction for potential use in “self-
healing” dendrimers (Szalai et al. 2007).  
The Diels Alder reaction can also be exploited for preparing thermally reversible cross 
linked polymers. These polymers have been synthesised by mixing a molar equivalent of 
poly(furfuryl methacrylate) (PFMA) and 1,1’-(Methylenedi-4, 1-phenylene)bismaleimide 
(BM) in dichloromethane at room temperature (Kavitha & Singha n.d.).  
A rigid film of the cross linked polymer shown in Figure 50, was cut with a knife and then 
heated to 120 °C. This allowed the polymer to improve its mobility due to its cross linking 
Diels Alder adducts reversing, filling in the notch left by the knife mark. 
 
Figure 50 : Preparation of thermally amendable cross linked polymers using the Diels Alder reaction                       
(Kavitha & Singha n.d.). 
Upon cooling the cross linker reformed via the Diels Alder reaction and evidence of damage 
caused by the knife had disappeared, showing the self-repairing potential of polymers 
utilizing Diels Alder adducts as cross linkers (Kavitha & Singha n.d.).   
In this study a Diels Alder cycloadduct was attached to gemcitabine, a clinically used 
chemotherapeutic agent via an alkylated ester linker. The diene component of the Diels 
Alder adduct possessed a free thiol group that facilitated dative covalent bonding to the 
gold surface of hybrid nanoparticles. The rate of the retro Diels Alder reaction shown in 
Figure 51, directly translates to the rate of the drug delivery. Therefore the faster retro 
Diels Alder takes place, the quicker the loaded drug is released from the surface of the 
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hybrid nanoparticle formulation. As a result the ability of a suitable Diels Alder adduct to 
readily undergo retro Diels Alder, due to the heat generated via SPR is critical. 
Figure 51: Schematic of a Diels Alder cycloadduct linker that undergoes retro Diels Alder in elevated temperatures to 
facilitate in drug release from the HNP surface. The heat required for this is generated via SPR of the gold coated HNPs 
after exposure to NIR radiation. 
The synthesis of a suitable thermally labile linker was carried out over multiple reaction 
steps. The monitoring of the synthesis and breakdown of the linker were carried out using 
commonly used analytical techniques described below. 
2.0.1 Fourier transform infra-red spectroscopy 
FTIR spectroscopy is a non-destructive analytical technique used to measure the 
absorbance of infrared radiation of a given sample in order to ascertain its composition and 
structure of components (Lachenal 1995; Williams & Fleming 2007). When molecules are 
exposed to infra-red radiation the atoms absorb specific frequencies and vibrate due to the 
received energy (Williams & Fleming 2007). On a typical IR spectrum the frequency is 
displayed in wavenumbers 400-4000 cm-1, which is the inverse of frequency (1/frequency) 
in cm-1 (Andersen et al. 2016). The percentage transmission of specific wavenumbers 
provides a strong indication to the functional groups of the analyte.  
Covalent bonds are not like the rigid bridges we commonly see in literature and text books 
(Hart 2003; Williams & Fleming 2007). The diagrams shown are often a depiction of two 
nuclei being held together by the mutual attraction to a pair of electrons. When molecules 
are exposed to infra-red radiation their atoms vibrate in different ways called vibrational 
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modes. The methylene group (R=CH2) C-H bonds will produce the vibration modes shown 
in Figure 52. With enough energy provided these nuclei can move and vibrate without their 
covalent bonds breaking (Williams & Fleming 2007). 
     
Figure 52: Vibrational modes of a methylene group -CH2-. 
The energy that causes the nuclei to vibrate depends on the mass of the two bonded nuclei 
and their bond length (Williams & Fleming 2007). Vibrating nuclei of similar masses tend to 
vibrate at lower frequencies (e.g. N-O at roughly 1500 cm-1) than bonded nuclei of 
significant mass differences (e.g. O-H at roughly 3300+ cm-1) (Williams & Fleming 2007). 
Bonds are easier to bend than stretch or compress. Stretching frequencies are therefore 
higher than bending ones and will have higher wavenumbers.  
Some covalent bond vibrational modes (such as O-H) may produce broad absorptions due 
to hydrogen bonding (Williams & Fleming 2007). Hydrogen bonding involves parts of the 
electrons in the (O-H) bond for example, being shared with the hydrogen bond acceptor. 
This periodically causes the O-H bond strength to change which in turn, changes the 
vibrational energy of that bond. This effect broadens the range of vibrational energies the 
O-H bond has, which causes the broad absorptions seen on IR spectra (Williams & Fleming 
2007). This also explains why other bond types with weaker hydrogen bonding (N-H) have 
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smaller broad peaks compared to (O-H).  One disadvantage that IR spectroscopy has, is that 
it cannot be used to observe single atoms. Single atoms have no bonds, they do not vibrate 
and absorb infra-red radiation in order to produce an absorption signal (Williams & Fleming 
2007). In homonuclear diatomic molecules (molecules comprised of one element) like O2 
there is no IR absorption signal on an IR spectrum because stretching does not cause a 
dipole moment (Williams & Fleming 2007). While IR spectroscopy is useful for discerning 
the structure of an analyte, it is often used with other analytical techniques such as mass 
spectrometry and nuclear magnetic resonance spectroscopy to correctly ascertain the 
structural identity of analytes. 
FTIRs use an interferometer which fires a beam that is split into two identical beams. One 
beam travels through the sample and the other is redirected at a 90 ° angle. These beams 
are then reflected back and combined. Because one beam travelled through a sample, its 
travel time has changed which causes interference when combined with the other beam 
(Dean et al. 2002a). Light behaves like a wave and therefore the fusion of the two beams 
generates an interference pattern unique to each compound. In FTIR the wavelength of the 
beams is a mixture of frequencies across the IR spectrum. The resultant interference 
pattern contains information across this range, allowing analysis to take place across the IR 
spectrum simultaneously. This greatly reduces the time required to analyse a sample 
compared to dispersive spectrometers (Dean et al. 2002a). 
2.0.2 Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) is a capable and versatile analytical spectroscopic 
technique utilised to ascertain the physical structure(s) and purity of a sample (Torres & 
Price 2016). NMR can be used to determine the percentage composition of a mixture of 
known compounds. Alternatively it can be used to match unknown compounds against a 
literature source, library of spectral data or by deducing a likely structure based on the 
spectral data. NMR spectroscopy works by analysing the free induction decay, which is a 
signal generated by the spinning of atomic nuclei within an applied magnetic field. Different 
atomic nuclei within the same magnetic field will spin at different frequencies (Veeman 
1997; Torres & Price 2016). This causes recognisable chemical shifts on NMR spectra. 
Protons (H+) within a compound will have the same magnetic spin, however the presence 
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of electrons will cause these spins to provide different resonance signals (Schanda & Ernst 
2016). 
The motion of electrons opposes the applied magnetic field causing nuclear shielding. In 
order to achieve magnetic resonance, the strength of the applied magnetic field has to 
increase to overcome nuclear shielding (Torres & Price 2016). This cause shifts (in ppm) 
which explains why electronegative groups such as hydroxyls, have higher ppm values and 
peaks that appear further down on an NMR spectra than hydrocarbons. Some atomic nuclei 
such as C12 do not spin at all, due to an equal number of protons and neutrons. Atomic 
nuclei of H1, C13, N15 and F19 have a spin frequency of ½ (Lens & Hemminga 1998). These 
are often used for NMR spectroscopy because the analysis of their spin states is 
straightforward.   
In H-NMR the protons can either be aligned with or opposing the applied magnetic field 
(Jones & Mulloy n.d.; Lens & Hemminga 1998; Torres & Price 2016). Since each proton can 
be described as a small magnet, its own magnetic field can deshield neighbouring protons, 
marginally shifting its NMR spectra peak downwards or it can enhance its nuclear shielding 
shifting it slightly up field (Jones & Mulloy n.d.; Lens & Hemminga 1998). This leads to the 
appearance of a split peak on a spectra. This is called spin- spin coupling or J-coupling (Dean 
et al. 2002b).  Increasing the number of nearby protons will lead to more J-couplings 
causing further peak splits. The number of peaks to signify one proton environment is n+1, 
where n is the number of neighbouring protons to the hydrogen in question (Dean et al. 
2002b). NMR can also be used to identify the presence and ratio of isomers within a sample. 
One example is with the Diels Alder reaction where products may be a mixture of endo and 
exo isomers. The orientation of protons changes between the two forms which is clearly 
visible on NMR spectrum (Goussé et al. 1998). This property further aids in the structural 
identification of analytes and proved invaluable for this work.  
2.0.3. Thin layer and column chromatography 
Chromatography is the term used to describe several techniques for separating materials 
within a mixture (Dean et al. 2002c). The mixture is dissolved in a solution called the mobile 
phase. This carries the mixture through a porous material called the stationary phase. 
Different components of the mixture will have a different affinity to the mobile and 
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stationary phase causing them to travel through the porous stationary phase at different 
speeds (Dean et al. 2002c). The properties of the mobile phase can be changed by using 
different solvent mixtures in order to fine tune separation of mixtures. If the stationary 
phase is of sufficient length then each component of the mixture can be collected 
individually. This is the prime objective of column chromatography, which is a technique 
used to purify mixtures containing a desired compound(s) after chemical synthesis. Column 
chromatography is often employed in the purification of reaction mixtures in order to 
separate the desired products from other materials (Dean et al. 2002c). A column like the 
one in Figure 53 is packed with a stationary phase such as silica gel, followed by the addition 
of the dried reaction mixture. The mobile phase is then added to carry the different 
components of the mixture down the column. 
 
Figure 53: Diagram depicting column chromatography separation of a mixture of compounds. 
Each component has their own unique affinity for the mobile and stationary phase. When 
the mobile phase reaches the bottom of the column it can be collected as a fraction along 
with any dissolved material. Evaporation of the desired fractions is then carried out to 
isolate the purified compound (Dean et al. 2002c).  
Thin layer chromatography is another example of a chromatography technique. It is 
performed on sheet of aluminium, glass or paper, coated with a material that acts as the 
stationary phase. Examples of these materials include silica gel, aluminium oxide and 
cellulose (John et al. 2015; Pikul et al. 2013; Dean et al. 2002c). In organic chemical 
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synthesis TLC serves two main functions. The first is to monitor the progression of a 
reaction and the second is to ensure the end product is free of impurities. This is shown in 
Figure 54 where the starting materials, reaction mixture and product is spotted onto the 
baseline of the plate. 
 
Figure 54: Diagram of a typical TLC plate for monitoring reaction progress. 
Carrying out TLC involves taking a spotted TLC place and placing it within a separation 
chamber containing the mobile phase (Dean et al. 2002c). The mobile phase will travel up 
the plate via capillary action. The mobile phase must be below the baseline to prevent the 
dissolution of the sample mixtures. Upon meeting the spots, it will carry up the components 
of each spot up the plate, separating them out depending on their affinity for the mobile 
and stationary phase. When the mobile phase has nearly reached the top, the plate is 
removed to prevent inaccurate results (Dean et al. 2002c). The point where the mobile 
phase reached is then immediately marked and referred to as the solvent front. This is done 
to allow an accurate calculation of the retention factor value (Rf) of each spot on the plate 
(Dean et al. 2002c) . Rf value is calculated as:  
𝑅𝑓 =
Distance travelled by compound
Distance from baseline to solvent front
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The characteristics of TLC and column chromatography are very similar. TLC can be 
described as an upside-down version of column chromatography. As a result, TLC is often 
used to correctly identify the most suitable mobile phase in order to carry out a subsequent 
column chromatography with good separation of materials (Dean et al. 2002c). This makes 
both TLC and column chromatography vital in the monitoring and purification of reaction 
mixtures in this study. Other forms of chromatography include, gas chromatography for 
the separation and analysis of non-decomposing vaporised substances and ion 
chromatography, which separates ions and polar materials (Gras et al. 2017; Chi et al. 
2017).  
2.0.4. Mass spectrometry 
Mass spectrometry is an analytical technique that involves ionising a sample with a filament 
in order to generate ions. These secondary ions are then accelerated and magnetically 
deflected and detected by a mass analyser. These charged ions will be deflected depending 
on their mass/charge ratio. As the charge is a known constant, the mass can be determined 
based the amount of deflection these charged particles experience. The collision of primary 
ions or electrons on a compound would break bonds producing secondary ions. As a result 
every compound will produce their own unique fragmentation pattern which can be used 
to identify them. A mass spectrum may look chaotic at first, but certain patterns quickly 
become apparent to experienced users. For example, one way of elucidating the spectra of 
a hydrocarbon would be to look for two peaks that differ by 14. Peak differences of 14 are 
common in organic chemistry which are attributed to two fragments differing in the 
possession of a CH2. 
Mass spectrometry is often used in conjunction with other analytical techniques. Examples 
of such techniques includes gas chromatography-mass spectrometry (GC-MS) and 
inductively coupled plasma – mass spectrometry (ICP-MS). Standalone mass spectrometry, 
GC-MS and ICP-MS all require the sample to be under a high vacuum. The ambient 
surrounding air contains various gases that would add to the resulting mass spectrum as 
these would be ionised by the mass spectrometry filament. Secondly, the secondary ions 
generated by the samples ionisation may collide against background gas molecules. This 
might give rise to charge neutralisation reactions for example. Ultimately the presence of 
gas molecules may alter the true mass/charge ratio of secondary ions reducing the 
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sensitivity and accuracy of the analysis. For this reason, mass spectrometry is rarely carried 
out with ambient or high pressure analytical techniques such as liquid chromatography or 
HPLC. 
2.1. Aims and objectives 
The aim of this study is to design and fabricate a thermally labile chemical linker to enable 
gemcitabine conjugation onto the surface of hybrid iron oxide-gold nanoparticles based on 
the retro Diels-Alder reaction. The linker will be synthesised and then characterised using 
NMR Spectroscopy, FTIR Spectroscopy and TLC. 
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2.2. Materials and methods 
2.2.1. Materials used 
Material Supplier 
Maleimide Lancaster Synthesis, UK 
Furan Alfa Aesar, UK 
Benzoyl Chloride Sigma-Aldrich Co., UK 
Triethylamine Fisher Scientific, UK 
Boc Anhydride Alfa Aesar, UK 
Maleic Anhydride Alfa Aesar, UK 
Beta Alanine Alfa Aesar, UK 
Gamma amino butyric acid Alfa Aesar, UK 
Epsilon aminocaproic acid Alfa Aesar, UK 
Gemcitabine Fluorochem, UK 
N-hydroxysuccinimide Alfa Aesar, UK 
1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide  Alfa Aesar, UK 
Diisopropylethylamine Sigma-Aldrich Co., UK 
2-furanmethanethiol Alfa Aesar, UK 
Trifluoroacetic acid Sigma-Aldrich Co., UK 
N-Dicyclohexyl-carbodiimide  Acros Organics, UK 
EDC HCl Fluorochem, UK 
Furfurylamine Alfa Aesar, UK 
Organic Solvents Fisher Scientific, UK 
Deuterated Solvents Cambridge Isotope Laboratories., USA 
Sodium Chloride Fisher Scientific, UK 
Magnesium Sulphate Fisher Scientific, UK 
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Sodium Bicarbonate Fisher Scientific, UK 
Potassium Carbonate Fisher Scientific, UK 
Celite Sigma-Aldrich Co., UK 
1,4 Dioxane Alfa Aesar 
Anhydrous DMF Sigma-Aldrich Co., UK 
Anhydrous Acetonitrile Fisher Scientific, UK 
Silica Gel Fisher Scientific, UK 
Potassium Hydroxide Fisher Scientific, UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
2.2.2. Methods 
2.2.2.1. Diels alder synthesis of 3, 6 – Endo/exo-tetrahydropthalide 
The synthesis of 3, 6 – Endo/exo-tetrahydropthalide is described in Figure 55. Maleimide 
(1 g, 10.3 mmol) was dissolved in diethyl ether (15 mL) and stirred at room temperature 
within a sealed tube. Furan (1.05 g, 15.5 mmol) was added and the sealed tube was sealed 
shut. The mixture was stirred at 95 °C for 12 h before being allowed to cool in an ice bath. 
The formed precipitate was filtered, rinsed with cold diethyl ether three times (20 mL × 3) 
and dried under suction yielding 3,6 – endo/exo-tetrahydropthalide as a white powder 
(0.154 g, 9 % yield) (Zhu et al. 2006).   
O N
H
O
O
NH O
O
O
+ Diethyl Ether, 95°C
 
Figure 55: Reaction scheme for the Diels Alder Synthesis of 3, 6 – Endo/exo-tetrahydropthalide. 
2.2.2.2. Synthesis of S-(Furan-2-ylmethyl) benzothioate 
The synthesis of S-(Furan-2-ylmethyl) benzothioate is described in Figure 56. Benzoyl 
chloride (7.03 g, 50 mmol) was dissolved in toluene (125 mL). The mixture was stirred while 
2-furanmethane thiol (5.71 g, 50 mmol) was added. The mixture was cooled to 0 °C and 
triethylamine (6.33 g) was added dropwise over 1 h before the mixture was allowed to stir 
for a further 1 h. The resultant slurry was filtered and the filtrate was diluted with toluene. 
This mixture was then washed with distilled water and dried with magnesium sulphate 
before being filtered. 
The filtrate was then evaporated with the use of a rotary evaporator leaving a dark brown 
oil as the product (2.953 g, 36 % yield) (Uno et al. 2012). 
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Figure 56: Reaction Scheme for the synthesis of S-(Furan-2-ylmethyl) benzothioate. 
2.2.2.3. Synthesis of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate  
The synthesis of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate is described in Figure 57. Maleimide (0.245 g, 2.5 mmol) and S-
(Furan-2-ylmethyl) benzothioate (0.546 g, 2.5 mmol) was dissolved in diethyl ether (10 mL) 
in a sealed tube at room temperature. The mixture was heated to 95 °C and left to stir for 
12 hours. The mixture filtered then washed with cold diethyl ether (20 mL × 3) and the solid 
product was left to dry under suction within a fume hood producing a light brown powder 
(0.12 g, 29 % yield). 
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Figure 57: Reaction scheme for the synthesis of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate. 
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2.2.2.4. Synthesis of 3-maleimidopropanoic acid 
The synthesis of 3-maleimidopropanoic acid is described in Figure 58. Maleic anhydride 
(0.98 g, 10 mmol) was dissolved in glacial acetic acid (20 mL) followed by β-alanine (0.89 g, 
10 mmol). The mixture was vigorously stirred resulting in a slurry that was stirred for 8 h at 
room temperature under a nitrogen atmosphere. The white precipitate was collected by 
filtration and washed with water (20 mL × 2). The white solid was then dispersed in 20 mL 
of water and refluxed at 110 °C. Once a clear solution had formed after 15 mins, the mixture 
was further refluxed for an additional 30 mins. The solution was then left to cool to room 
temperature before most of the water was evaporated with the use of a rotary evaporator. 
A white precipitate formed which was washed with chilled water and filtered. The resultant 
white powder was then dried under high vacuum. 3-maleimidopropanoic acid was 
obtained as a white powder (1.51 g, 89 % yield) (Song et al. 2009a).   
NH2
O
OH OO O
+
N
O
O O
OH
1. AcOH, rt
2. H2O, reflux
 
Figure 58: Reaction scheme for the synthesis of 3-maleimidopropanoic acid. 
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2.2.2.5. Synthesis of 4-maleimidobutyric acid  
The synthesis of 4-maleimidobutyric acid is described in Figure 59. Maleic anhydride (0.98 
g, 10 mmol) was dissolved in glacial acetic acid (20 mL) followed by γ-aminobutyric acid 
(1.03 g, 10 mmol). The mixture was vigorously stirred resulting in a slurry in fifteen minutes, 
which was stirred for a further 8 h at room temperature under a nitrogen atmosphere. The 
white precipitate was collected by filtration and washed with water (20 mL × 2). The white 
solid was then dispersed in 20 mL of water and refluxed at 110 °C. Once a clear solution 
had formed after 15 mins, the mixture was further refluxed for an additional 30 mins. The 
solution was then left to cool to room temperature before most of the water was 
evaporated with the use of a rotary evaporator. A white precipitate formed which was 
washed with chilled water and filtered. The resultant white powder was then dried under 
high vacuum. 4-maleimidobutyric acid was obtained as a white powder (1.72 g, 94 % yield 
) (Song et al. 2009a).  
NH2 O
OH
OO O
+
N
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2. H2O, reflux
 
Figure 59: Reaction scheme for the synthesis of 4-maleimidobutyric acid. 
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2.2.2.6. Synthesis of 6-maleimidohexanoic acid 
The synthesis of 6-maleimidohexanoic acid is described in Figure 60. Maleic anhydride 
(1.176 g, 12 mmol) was dissolved in glacial acetic acid (20 mL) followed by ε-aminocaproic 
acid (1.31 g, 10 mmol). A slurry formed within minutes and the mixture was left to stir for 
6 h at 120 °C. The mixture was allowed to cool to room temperature and then poured into 
water (20 mL) before being extracted with ethyl acetate (40 mL × 3). The organic layers 
were washed with brine (15 mL) and dried with magnesium sulphate. The mixture was then 
filtered and the filtrate was evaporated under reduced pressure to give the crude product. 
The crude residue was purified into a white solid by column chromatography in 1:6 ethyl 
acetate/petroleum ether (v/v) (1.26 g, 60 % yield) (Han et al. 2013). Subsequent synthesis 
of this compound was carried out with the same procedure used for the synthesis of 3-
maleimidopropanoic acid by (Song et al. 2009a) with improved yields.  
NH2
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Figure 60: Reaction scheme for the synthesis of 6-maleimidohexanoic acid. 
 
 
 
 
 
 
77 
 
2.2.2.7. Synthesis of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine 
The synthesis of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine is described in Figure 61. 
Boc Anhydride (4.36 g, 20 mmol) was dissolved in 1, 4 dioxane (40 mL) and added dropwise 
to a solution of gemcitabine hydrochloride (0.6 g, 2 mmol) in a stirred solution of 1M KOH 
(40 mL) over 10 minutes. The mixture was stirred for 40 minutes at room temperature 
while being closely monitored with TLC. After TLC confirmed a 50:50 ratio of the desired 
product and 3′-O-Bis (tert-Butoxycarbonyl) gemcitabine, the reaction mixture was 
extracted with ethyl acetate (80 mL × 3), washed with brine (20 mL × 2) and dried with 
magnesium sulphate. The mixture was then filtered to remove the magnesium sulphate 
and the filtrate was evaporated with the use of a rotary evaporator leaving a clear oily 
residue. 
The oily residue was  dissolved in 1,4 dioxane (40 mL) in a round bottom flask followed by 
the addition of boc anhydride (4.36 g, 20 mmol) and 1M KOH (40 mL). The mixture was 
stirred at room temperature and closely monitored with TLC. After 30 minutes of stirring, 
TLC analysis confirmed no more 3′-O-Bis(tert-Butoxycarbonyl)gemcitabine remained within 
the reaction vessel. The reaction mixture was extracted with ethyl acetate (80 mL × 3), 
washed with brine (20 mL × 2) and dried with magnesium sulphate. The mixture was then 
filtered to remove the magnesium sulphate and the filtrate was evaporated with the use 
of a rotary evaporator leaving a slightly yellow oily residue. 
3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine was obtained as a white solid (0.326g, 63 %) 
after purification with column chromatography with 1:1 acetone/dichloromethane solvent 
system (Guo & Gallo 1999).   
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Figure 61: Reaction scheme for the synthesis of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine. 
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2.2.2.8. Synthesis of 3-maleimido propionic acid N-hydroxysuccinimide ester 
The synthesis of 3-maleimido propionic acid N-hydroxysuccinimide ester is described in 
Figure 62. Β-alanine (2.32 g, 26 mmol) is dissolved in anhydrous DMF (35 mL) followed by 
the addition of maleic anhydride (2.9 g, 29 mmol). The mixture was stirred under nitrogen 
for 3 h at room temperature before being cooled to 0 °C for 30minutes. N-
hydroxysuccinimide (3.7 g, 32 mmol) was added followed by 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (11 g, 71 mmol). The mixture was stirred for 30 mins 
at 0 °C before the mixture was allowed to gently return to room temperature. The mixture 
was then left to stir overnight under nitrogen at room temperature. 
The solvent was evaporated with the use of a rotary evaporator and the residue was 
dissolved in chloroform (300 mL) and washed with saturated sodium bicarbonate (100 mL). 
The organic layer was dried with magnesium sulphate and filtered. The filtrate was then 
evaporated yielding a crude brown powder. 
3-maleimido propionic acid N hydroxysuccinimide ester was obtained as a white powder 
(3.5 g, 51 %) after purification with column chromatography 10:1 (chloroform: methanol) 
(Song et al. 2009b).  
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Figure 62: Reaction scheme for the synthesis of 3-maleimido propionic acid N-hydroxysuccinimide ester. 
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2.2.2.9. Synthesis of 4-maleimidobutyric acid N-hydroxysuccinimide ester 
The synthesis of 4-maleimidobutyric acid N-hydroxysuccinimide ester is described in Figure 
63. Maleic anhydride (2.9 g, 29 mmol) was dissolved in anhydrous DMF (35 mL) followed 
by the addition of 4-amino butyric acid (2.68 g, 26 mmol). The mixture was stirred under 
argon for 3 hours at room temperature before being cooled to 0 °C for 0.5 h. N-
hydroxysuccinimide (3.7 g, 32 mmol) was added followed by 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (11 g, 71 mmol). The mixture was allowed to stir for 
0.5 h at 0 °C before the mixture was allowed to gently return to room temperature. The 
mixture was then left to stir overnight under argon at room temperature. 
The solvent was evaporated with the use of a rotary evaporator and the residue was 
dissolved in chloroform (300 mL) and washed with saturated sodium bicarbonate (100 mL). 
The organic layer is dried with magnesium sulphate and filtered. The filtrate was then 
evaporated yielding a crude dark green film. 
4-maleimido butyric acid N-hydroxysuccinimide ester was obtained as a white powder (4.8 
g, 66 %) after the crude dark red product was purified with column chromatography 10:1 
(chloroform: methanol) (Song et al. 2009b).  
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Figure 63: Synthesis of 4-maleimidobutyric acid N-hydroxysuccinimide ester. 
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2.2.2.10. Synthesis of 6-aminohexanoic acid N-hydroxysuccinimide ester  
The synthesis of 6-aminohexanoic acid N-hydroxysuccinimide ester is described in Figure 
64. Into a solution of 6-aminohexanoic acid (3.41 g, 26 mmol) in anhydrous DMF, was added 
maleic anhydride (2.9 g, 29 mmol). The mixture was stirred under argon for 3 hours at room 
temperature before being cooled to 0 °C for 0.5 h. N-hydroxysuccinimide (3.7 g, 32 mmol) 
was added followed by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (11 g, 71 mmol). 
The mixture was allowed to stir for 0.5 h at 0 °C before the mixture was allowed to gently 
return to room temperature. The mixture was then left to stir overnight under argon at 
room temperature. 
The solvent was evaporated with the use of a rotary evaporator and the residue was 
dissolved in chloroform (300 mL) and washed with saturated sodium bicarbonate (100 mL). 
The organic layer was dried with magnesium sulphate and filtered. The filtrate was then 
evaporated yielding a crude dark yellow powder. 
6-aminohexanoic acid N hydroxysuccinimide ester was obtained as a white powder (5.2 g, 
65 %) after the crude red product was purified with column chromatography 10/1 
(chloroform: methanol) (Song et al. 2009b).  
O
O
O
O
O
N
O
O
N
O
O
NH2
O
OH
+
EDCI, NHS
DMF, r.t, 24 hours
 
Figure 64: Reaction scheme for the synthesis of 6-aminohexanoic acid N-hydroxysuccinimide ester. 
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2.2.2.11. Amide coupling reaction of 3-maleimido propionic acid N-hydroxysuccinimide 
ester with 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine 
The amide coupling reaction between 3-maleimidopropanoic acid N-hydroxysuccinimide 
ester and 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine is described in Figure 65. Into a 
round bottom flask, anhydrous DMF (20 mL) was added followed by 3-maleimidopropionic 
acid N hydroxysuccinimide ester (1.41 g, 53 mmol). 3′, 5′-O-Bis (tert-Butoxycarbonyl) 
gemcitabine (2.753 g, 53 mmol) was added followed by diisopropylethylamine (3.7 mL, 
0.027 mmol). The reaction mixture was stirred at 40 °C for 24 h under argon. The solvent 
was evaporated with a rotary evaporator leaving a green residue. This compound is known 
as Boc-Gem-Mal.  
Boc-Gem-Mal was obtained as a pale green powder (1.45 g, 44 %) after the crude dark 
green product was purified with column chromatography 10:1 (chloroform: methanol).  
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Figure 65: Chemical reaction between 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine and 3-maleimido propionic acid N 
hydroxysuccinimide ester. 
 
 
 
 
83 
 
2.2.2.12. Synthesis of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate  
The boc protection of 2-furanmethane thiol is described in Figure 66. Into a round bottom 
flask, 2-furanmethane thiol (1 g, 8.8 mmol) and boc anhydride (1.8 g, 8.8 mmol) was 
dissolved in anhydrous acetonitrile (35 mL) followed by the addition of potassium 
carbonate (2.4 g, 17.5 mmol). The mixture was stirred at room temperature for 24 h under 
a nitrogen atmosphere. 
The mixture was diluted with ethyl acetate (200 mL) and filtered through a celite path. The 
filtrate was washed with saturated sodium bicarbonate (40 mL), dried with magnesium 
sulphate and filtered. The resulting filtrate was evaporated leaving O-tert-butyl S-(furan-2-
ylmethyl) carbonothionate as a brown oil (1.76 g, 93 %) (Temperini et al. 2010).  
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Figure 66: Reaction scheme for synthesis of O-tert-butyl S-(furan-2-ylmethy)carbonothionate. 
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2.2.2.13. Diels Alder reaction of O-tert-butyl S-(furan-2-ylmethyl)carbonothionate with 4-
maleimidobutyric acid N-hydroxysuccinimide ester 
The Diels Alder reaction of O-tert-butyl S-(furan-2-ylmethyl)carbonothionate and 4-
maleimidobutyric acid N-hydroxysuccinimide ester is described in Figure 67. O-tert-butyl S-
(furan-2-ylmethyl)carbonothionate  (1.5 g, 9 mmol) was added into a sealed tube followed 
by diethyl ether (35 mL). 4-maleimido butyric acid N hydroxysuccinimide ester (2.4 g, 9 
mmol) was added and the mixture was stirred at room temperature for 7 days under 
nitrogen. The Boc protected Diels Alder linker (BDA) was obtained as a brown greasy solid 
(2.14 g, 48.3 % yield) after purification with column chromatography (50/50) (petroleum 
ether: ethyl acetate). 
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Figure 67: Diels Alder reaction between 4-maleimidobutyric acid N-hydroxysuccinimide ester and boc protected 2-
furanmethane thiol. 
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2.2.2.14. Synthesis of boc protected Diels Alder/gemcitabine linker  
The synthesis of a boc protected thiolated thermally labile drug (Boc-TTLD) is described in 
Figure 68. Into a round bottom flask, BDA (3.94 g, 8.2 mmol) was dissolved in dry 
dichloromethane (30 mL) and stirred. 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine (3.82 
g, 8.2 mmol) was added followed by diisopropylethylamine (5.82 mL, 41 mmol). The 
reaction mixture was stirred at 0 °C for 108 h under an argon atmosphere. The solvent was 
removed under reduced pressure leaving a dark orange residue. Boc-TTLD was obtained as 
a pale green powder (4.31 g, 62 % yield) after purification with column chromatography 
10:1 (chloroform: methanol).   
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Figure 68: Reaction between 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine and BDA to produce Boc-TTLD. 
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2.2.2.15. Deprotection of Boc-TTLD  
The removal of boc groups from Boc-TTLD is described in Figure 69. Into a round bottom 
flask, the previously synthesised Boc-TTLD (4.31 g, 5.1 mmol) was dissolved in a 185 mL 
solution of 15 % trifluoroacetic acid in dichloromethane (v/v) and stirred at 0 °C for 2 h. The 
volatile solvents were removed under reduced pressure leaving a dark red residue. 
Purification with column chromatography (1:1 acetone, dichloromethane) yielded a pale 
orange powder (1.3 g, 47 % yield). This thiolated thermally labile drug compound will be 
referred to as TTLD. 
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Figure 69: Reaction scheme for the TFA deprotection of Boc-TTLD to produce TTLD. 
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2.2.3. Characterisation of synthesised compounds 
2.2.3.1 Nuclear magnetic resonance spectroscopy procedure 
1H NMR was carried out throughout all reactions from start to completion to monitor the 
consumption of starting materials and emergence of products. The samples were dissolved 
in appropriate deuterated 0.5 mL solvent solutions and analysed at 25 °C using 16 scans 
with a Bruker Avance 300 MHz NMR Spectrometer or a Bruker Avance III HD 400 MHz NMR 
Spectrometer (Bruker, Germany).  
2.2.3.2 Fourier infrared spectroscopy procedure 
FTIR analysis of purified reaction products was carried out using a Thermo Scientific 
Nicolet™ iS™ 5 FTIR fitted with an attenuated total reflectance adapter (Thermofisher, UK). 
A background correction scan was carried out to subtract data from the surrounding air. 
Following this a 10 mg solid sample of the compound was placed onto a diamond crystal 
tip and analysed with 16 scans to collect transmittance data. 
2.2.3.3 Thin layer chromatography procedure 
The individual starting materials and reaction mixture were analysed with thin layer 
chromatography by spotting a sample on a silica gel coated sheet of aluminium as shown 
in Figure 70. These TLC plates were then placed in a shallow pool of an eluent solution to 
observe the separation of materials within the reaction mixture.  
 
Figure 70: Illustration of TLC procedure. 
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The Rf value was calculated as the distance travelled by the unknown substance (a) divided 
by the distance travelled by the solvent through the TLC plate (b). Data acquired with this 
method was used to decide the best solvent system for column chromatography.   
2.2.3.4 Mass spectrometry procedure 
Mass spectrometry of the final thiolated thermally labile drug molecule (TTLD) dissolved in 
dichloromethane was carried out at Swansea University with a Xevo G2-XS Time of Flight 
Mass Spectrometer.  
2.2.3.5 Retro Diels Alder breakdown of the thermally labile linker at elevated 
temperatures 
The rate of the retro Diels Alder at elevated temperatures is directly related to the rate of 
drug release from the HNP surface. Therefore, the ability for the linker to reverse must be 
tested before attachment to the HNP occurs. This was carried out by heating the previously 
synthesised linker in several solutions of deuterated acetone in a round bottom flask at 
various temperatures. A 2 mL sample of the reaction mixture was added to a NMR tube, 
sealed with parafilm and cooled down by immersion into ice cold water for 5 min. The 
samples were then analysed with proton NMR spectroscopy.  
Aliquot samples were analysed at the 0, 5, 10, 15, 30, 60, 120 and 180 min mark and 
multiple round bottom flasks of the reaction mixture were heated to 37 °C, 45 °C and 70 °C 
in batches of threes.  
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2.3. Results 
2.3.1. Analytical data of 3, 6 – Endo/exo-tetrahydropthalide 
2.3.1.1 1H NMR spectrum of 3, 6 – Endo/exo-tetrahydropthalide 
The NMR spectrum in Figure 72 for 3, 6 – Endo/exo-tetrahydropthalide in Figure 71 showed 
the following peaks:  7.97 (broad singlet, [7] 1H), 6.54 (doublet, J=0.8Hz, [4, 5] 2H), 5.34 
(doublet, J=0.9Hz, [3, 6] 2H), 2.92 (singlet, [1-2] 2H). The proton NMR spectrum of 3, 6 – 
Endo/exo-tetrahydropthalide has a peak at δ6.54 for the two protons across the double 
bond of the cycloadduct. The two protons closest to the bridge oxygen has been shifted up 
field to δ5.34. The peak at δ2.92 arises from the two protons opposite the double bond of 
the cycloadduct. A small broad peak can also be observed at δ7.97 belonging to the proton 
of the amide. 
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Figure 71: Chemical structure of 3, 6 – Endo/exo-tetrahydropthalide.
 
Figure 72: 1H NMR spectrum of 3, 6 – Endo/exo-tetrahydropthalide in CDCl3 carried out using 300MHz NMR at 25 °C. 
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2.3.2. Analytical data of S-(Furan-2-ylmethyl) benzothioate 
2.3.2.1 1H NMR spectrum of S-(Furan-2-ylmethyl) benzothioate 
The NMR spectrum in Figure 74 for 3, 6 – Endo/exo-tetrahydropthalide in Figure 73 showed 
the following peaks:  7.98 (multiplet, [1, 5], 2H), 7.59 multiplet, [3], 1H), 7.46 (multiplet, [2, 
4], 2H), 7.37 (multiplet, [8], 1H), 6.33 (multiplet, [6, 7], 2H), 4.38 (singlet, [9], 2H). The peaks 
between δ7.4-8.0 are from the aromatic peaks of the benzoyl protecting groups. Another 
peak at δ6.33 can be observed, belonging to the two protons of carbon 2,3 of the furan. 
The peak at δ7.37 is also from the furan, shifted up field due to its proximity to oxygen. The 
CH2 protons next to the sulphur have a peak at δ4.38. 
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Figure 73: Reaction Scheme for the synthesis of S-(Furan-2-ylmethyl) benzothioate. 
 
Figure 74: 1H NMR spectrum of S-(Furan-2-ylmethyl) benzothioate in CDCl3 carried out using 300MHz NMR at 25 °C. 
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2.3.3. Analytical data of 1H NMR spectrum of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-
1-yl)methyl] benzenecarbothionate  
2.3.3.1. 1H NMR spectrum of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate  
The NMR spectrum in Figure 76 for S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate in Figure 75 showed the following peaks: 8.02 (multiplet, [7,11], 
2H), 7.89 (broad singlet, [1], 1H), 7.62 (multiplet, [9], 1H), 7.49, (multiplet, [8,10], 2H), 6.52 
(d-doublet, J=5.6Hz [5 endo/exo], 1H), 6.37 (doublet, J=5.7Hz, [4 endo/exo], 1H), 5.3 
(doublet, J=1.7z , [3], 1H), 4.02 (doublet, J=14.7Hz [2-endo], 1H), 3.71 (doublet, J=14.7Hz 
[6-endo], 1H),  3.09 (doublet, J=14.7Hz [2-exo], 1H), 3.04  (doublet, J=14.7Hz [6-exo], 1H). 
The aromatic peaks of the benzoyl group δ8.02-7.5 are still present indicating that the 
sulphur remained protected throughout the cycloaddition. A mixture of the endo and exo 
isomer formed. The protons opposite the oxygen bridge produced greatly overlapping split 
peaks at δ6.55/δ6.37 for the endo signals and δ6.52/δ6.36 for the exo isomer. Another pair 
of highly overlapped peaks at δ5.3 for the proton signal closest to the bridge oxygen, is also 
indicative of a successful Diels Alder reaction. Evidence of an endo/exo mixture is further 
observed at δ4.02/δ3.71 which are the endo peaks for the protons opposite the 
cycloadduct double bond. The exo peaks are at δ3.09 and δ3.04. There is no peak for the 
CH2 next to the sulphur. This may be due to the lack of nearby protons to resonate with. 
The broad peak at δ7.89 is for the secondary amine. 
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Figure 75: Reaction Scheme depicting the Diels Alder reaction between S-(Furan-2-ylmethyl) benzothioate and 
Maleimide to produce S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] benzenecarbothionate. 
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Figure 76: 1H NMR spectrum of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] benzenecarbothionate in CDCl3 
carried out using 300MHz NMR at 25 °C. 
2.3.3.2 FTIR of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate  
FTIR analysis of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate shown in Figure 77, was carried out in order to identify functional 
groups indicative of a successful Diels Alder reaction between a benzoyl protected furan 
and maleimide. The peaks of note are displayed in Table 1. The aromatic stretches at 3000 
cm-1 (C-H) and 1450 cm-1 (C=C) indicate that the benzoyl group is still present on the 
cycloadduct. The secondary amine stretch at 3100 cm-1 is also present, indicating a 
successful Diels Alder reaction. 
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Figure 77: FTIR (16scans) of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] benzenecarbothionate. 
Table 1: FTIR peak absorbance assignments for -[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-
1-yl)methyl] benzenecarbothionate. 
Compound (3) 
S
ON
H
O
O
O  
Wavenumber (cm-1) Bond Type Assignment 
1450 Aromatic stretch (C=C) 
1650 Conjugated Ketone (C=O) 
2800 Alkyl stretch (C-H) 
3000 Aromatic stretch (C-H) 
3025 Alkene stretch (C=C) 
3100 Secondary amine 
stretch 
(N-H) 
 
2.3.3.3. TLC analysis of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate  
TLC analysis of the S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] 
benzenecarbothionate mixture post workup was carried out to clarify its purity. An 
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illustration of the TLC plate is displayed in Figure 78. The Rf value of this compound is 0.36 
in a Petroleum Ether – Ethyl Acetate (1:1) solvent system.  
 
Figure 78: TLC plate of S-[(3,5-dioxo-10-oxa-4-azatricyclodec-8-en-1-yl)methyl] benzenecarbothionate post workup. 
2.3.4. Analytical data of 3-maleimidopropanoic acid 
2.3.4.1. 1H NMR spectrum of 3-maleimidopropanoic acid 
The NMR spectrum in Figure 80 for 3, 6 – Endo/exo-tetrahydropthalide in Figure 79 showed 
the following peaks: 7.69 (broad singlet, [1], 1H), 6.02 (singlet, [4, 5] 2H), 2.99 (triplet, 
J=6.8Hz [3], 2H), 2.56 (triplet, J=6.8Hz [2], 2H). The NMR spectrum of 3-
maleimidopropanoic acid contained two triplets for the CH2 of the alkyl chain, with one up 
field due to its proximity to the acid group. These are found at δ2.56 and δ2.99. The tall 
peak at δ6.02 is attributed to the two protons of the maleimide. There is a broad singlet at 
δ3.35 which indicative of a trace water contamination.   
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Figure 79: Reaction scheme for the synthesis of 3-maleimidopropanoic acid 
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Figure 80: 1H NMR spectrum of 3-maleimidopropanoic acid in DMSO_d carried out using 300MHz NMR at 25 °C. 
2.3.4.2 FTIR of 3-maleimidopropanoic acid 
FTIR analysis of 3-maleimidopropanoic acid was carried out to identify peaks indicative of 
a successful synthesis reaction. The peaks of note are displayed in Table 2. The peaks at 
3250 cm-1 (O-H) and 1690 cm-1 (C=O) in Figure 81 are attributed to the carboxylic acid 
group of 3-maleimidopropanoic acid. There are also two peaks for the alkyl CH2 
absorbance at 2980 cm-1 and 2940 cm-1 (C-H).  
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Figure 81: FTIR of 3-maleimidopropanoic acid. 
 
Table 2: FTIR peak absorbance assignments for 3-maleimidopropanoic acid. 
3-maleimidopropanoic acid 
N
O
O O
OH
 
Wavenumber (cm-1) Bond Type Assignment 
1100 Tertiary amine (C-N) 
1630 Alkene stretch (C=C) 
1660 Tertiary amide stretch (C=O) 
1690 Carboxylic acid stretch (C=O) 
2940 Alkyl stretch (C-H) 
2980 Alkyl stretch (C-H) 
3250 Carboxylic acid (O-H) 
 
2.3.4.3. TLC analysis of 3-maleimidopropanoic acid 
TLC analysis of the 3-maleimidopropanoic acid mixture post workup was carried out to 
clarify its purity. An illustration of the TLC plate is displayed in Figure 82. The Rf value of 
this compound is 0.41 in a Petroleum Ether – Ethyl Acetate (1:6) solvent system. A single 
spot eliminated the need for further purification. 
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Figure 82: TLC plate of 3-maleimidopropanoic acid post workup. 
2.3.5. Analytical data of 4-maleimidobutyric acid 
2.3.5.1 1H NMR spectrum of 4-maleimidobutyric acid  
The NMR spectrum in Figure 84 for 4-maleimidobutyric acid in Figure 83 showed the 
following peaks: 6.03 (singlet, [5, 6] 2H), 2.81 (triplet, [4], 2H), 2.33 (triplet, J=7.3Hz [3], 2H), 
1.74 (quintet, J=7.4Hz [2], 2H). The NMR spectrum of 4-maleimidobutyric acid contains a 
two triplets at δ2.81 and δ2.33 for the terminal CH2 of the alkyl chain and a quintet at δ1.74 
for the central CH2 of the alkyl chain. The tall singlet at δ6.03 is indicative of the maleimide 
protons. There are two trace solvent contaminants which are water and acetone, indicated 
by their peaks at δ3.35 and δ2.1 respectively.  
5
6
N
O
O
3
2
4
OH
1
O
 
Figure 83: Reaction scheme for the synthesis of 4-maleimidobutyric acid. 
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Figure 84: 1H NMR spectrum of 4-maleimidobutyric acid in DMSO_d carried out using 300MHz NMR at 25 °C. 
2.3.5.2. TLC analysis of 4-maleimidobutyric acid  
TLC analysis of the 4-maleimidobutyric acid mixture post workup was carried out to clarify 
its purity. An illustration of the TLC plate is displayed in Figure 85. The Rf value of this 
compound is 0.39 in a Petroleum Ether – Ethyl Acetate (1:6) solvent system. A single spot 
eliminated the need for further purification. 
 
Figure 85: TLC plate of 4-maleimidobutyric acid post workup. 
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2.3.6. Analytical data of 6-maleimidohexanoic acid  
2.3.6.1. 1H NMR spectrum of 6-maleimidohexanoic acid 
The NMR spectrum in Figure 87 for 6-maleimidohexanoic acid in Figure 86 showed the 
following peaks: 6.70 (singlet, [7, 8], 2H), 3.54 (triplet, J=7.2Hz [4], 2H), 2.61 (triplet, J=7.4Hz 
[6], 2H), 1.78 (quintet, J=7.6Hz [5], 2H), 1.71 (quintet, [3]) 2H), 1.41 (quintet [2], 2H). The 
NMR spectrum of 6-maleimidopropanoic acid contains two triplets for the terminal CH2 
protons of the alkyl chain, which are located at δ3.54 and δ2.61. The central alkyl CH2 
protons have a peak at δ1.41. The neighbouring CH2 closer to the tertiary amine is shifted 
up field to at δ1.71. The other neighbouring CH2 closer to the acid group is also shifted up 
field to a greater extend δ1.78 as these protons experience more deshielding from the 
carboxylic group than they would from a tertiary amine.  The two protons on the maleimide 
form a tall singlet at δ6.7. NMR analysis also indicated the presence of a trace ethyl acetate 
contaminant, attributed to its signals at δ 4.12, δ2.05 and δ1.26. 
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Figure 86: Reaction scheme for the synthesis of 6-maleimidohexanoic acid. 
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Figure 87: 1H NMR spectrum of 6-maleimidohexanoic acid in CDCL3 carried out using 300MHz NMR at 25 °C. 
2.3.6.2. TLC analysis of 6-maleimidohexanoic acid 
TLC analysis of the 6-maleimidohexanoic acid mixture post workup was carried out to 
clarify its purity. An illustration of the TLC plate is displayed in Figure 88. The Rf value of 
this compound is 0.36 in a Petroleum Ether – Ethyl Acetate (1:6) solvent system. A single 
spot eliminated the need for further purification. 
 
Figure 88: TLC plate of 6-maleimidohexanoic acid post workup. 
S 
7, 8 
ETAC 
4 6 
5 
3 
2 
ETAC 
ETAC 
101 
 
2.3.7. Analytical data of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine 
2.3.7.1. 1H NMR spectrum of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine  
The NMR spectrum in Figure 90 for 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine in Figure 
89 showed the following peaks: 7.61 (doublet J=7.5Hz [6], 1H), 6.35 (doublet [7], 1H), 5.95 
(singlet J=7.5Hz [5] 1H), 5.3 (singlet [4], 1H), 4.52, 4.46 (multiplet [3], 2H), 4.42 (doublet [2], 
1H), 1.5 (singlet [9], 9H), 1.48 (singlet [8], 9H). NMR analysis of 3′,5′-O-Bis(tert-
Butoxycarbonyl)gemcitabine showed the presence of a very tall pair of singlets at δ1.5 and 
δ1.48 which are each attributed to the nine protons of the two boc groups. Further 
evidence of successful boc protection of both hydroxyl groups was indicated by the peaks 
at δ 5.3, δ 4.52, δ 4.46 and δ 4.42 which match the literature source results for the reaction 
procedure (Guo & Gallo 1999). The peaks for the pyrimidine protons (δ7.61 and δ5.95) 
remain unchanged from literature sources (Guo & Gallo 1999) which confirm that boc 
protection of the primary amine group had not occurred. Trace amount of water (δ2.87) 
and ethyl acetate (δ 4.06, δ 1.98 and δ 1.21) were also observed in the NMR spectrum. 
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Figure 89: Reaction scheme for the synthesis of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine. 
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Figure 90: 1H NMR spectrum of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine in Acetone_d carried out using 300MHz 
NMR at 25 °C. 
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2.3.7.2 FTIR of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine  
FTIR analysis of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine in Figure 91 was carried out 
in order to ensure boc protection had successfully taken place. Noteworthy peaks are 
displayed in Table 3. FTIR analysis of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine shows 
a primary amine bend at 1650 cm-1 which indicates that the primary amine is unaffected 
by the boc protection. An indicator that both hydroxyl groups were successfully boc 
protected is the lack of a broad peak in the 3200+ cm-1 region. 
 
Figure 91: FTIR of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine. 
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Table 3: FTIR peak absorbance assignments for 3′,5′-O-Bis(tert-
Butoxycarbonyl)gemcitabine. 
3′,5′-O-Bis(tert-
Butoxycarbonyl)gemcitabine     
N
N
NH2
O
O
O
O
F
F
O O
CH3CH3
CH3
O
O
CH3
CH3
CH3
 
Wavenumber (cm-1) Bond Type Assignment 
1100 Aliphatic ether stretch (C-O) 
1280 Aromatic amine stretch (C-N) 
1650 Primary amine bend (N-H) 
1760 Carbonyl stretch (C=O) 
2980 Alkyl stretch (C-H) 
 
2.3.7.3. TLC analysis of 3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine 
TLC analysis of the 3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine mixture post workup was 
carried out to clarify its purity. An illustration of the TLC plate is displayed in Figure 92. The 
Rf value of this compound is 0.47 in a dichloromethane - acetone (1:1) solvent system. 
Three spots were visible in the resultant TLC plate for the tri boc (Rf = 1) and mono boc (Rf 
= 0.26) gemcitabine, which prompted the use of column chromatography for further 
purification.  
 
Figure 92: TLC plate of 3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine post workup. 
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Column chromatography of the reaction mixture illustrated in Figure 61 was carried out. 
The pooled fractions from that column were dried and the resulting white powder was 
analysed by TLC showing a pure compound as illustrated in Figure 93. 
 
Figure 93: TLC plate of 3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine post column chromatography. 
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2.3.8. Analytical data of 3-maleimido propionic acid N-hydroxysuccinimide ester 
2.3.8.1. 1H NMR spectrum of 3-maleimidopropionic acid N-hydroxysuccinimide ester 
The NMR spectrum in Figure 95 for 3-maleimido propionic acid N-hydroxysuccinimide ester 
in Figure 94 showed the following peaks: 7.05 (singlet [5, 6], 2H), 3.74 (triplet J=6.9Hz [2], 
2H), 3.04 (triplet J=6.9Hz [1] 2H), 2.79 (singlet [3, 4], 4H). The NMR spectrum of 3-
maleimido propionic acid N-hydroxysuccinimide ester has two expected triplets at δ3.74 
and δ3.04 for the CH2 protons of the alkyl chain. The two maleimide protons were observed 
as a tall singlet at δ7.05 while the four succinimide protons formed a broad singlet at δ2.79.  
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Figure 94: Reaction scheme for the synthesis of 3-maleimido propionic acid N-hydroxysuccinimide ester. 
 
Figure 95: 1H NMR spectrum of 3-maleimido propionic acid N-hydroxysuccinimide ester in DMSO_d carried out using 
300MHz NMR at 25 °C. 
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2.3.8.2. FTIR of 3-maleimidopropionic acid N-hydroxysuccinimide ester  
FTIR of 3-maleimidopropionic acid N-hydroxysuccinimide ester was carried out to ensure 
its successful synthesis by identifying functional groups indicative of this outcome. The 
successful synthesis of 3-maleimido propionic acid N-hydroxysuccinimide ester is 
confirmed by the maleimide alkene stretch at 3100 cm-1, the tertiary amine stretch at 1670 
cm-1 and the alkyl stretches at 2940 cm-1 and 2850 cm-1 shown in Figure 96. Noteworthy 
peaks are displayed in Table 4. 
 
Figure 96: FTIR of 3-maleimidopropionic acid N-hydroxysuccinimide ester. 
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Table 4: FTIR peak absorbance assignments for 3-maleimidopropionic acid N-
hydroxysuccinimide ester. 
3-maleimidopropionic acid  
N-hydroxysuccinimide ester 
N
O
O
O
O N
O
O
 
Wavenumber (cm-1) Bond Type Assignment 
1090 Tertiary amine stretch (C-N) 
1630 Alkene stretch (C=C)  
1670 Tertiary amide stretch (C=O) 
2850 Alkyl stretch (C-H) 
2940 Alkyl stretch (C-H) 
3100 Alkene stretch =(C-H) 
 
2.3.8.3. TLC analysis of 3-maleimidopropionic acid N-hydroxysuccinimide ester 
TLC analysis of the 3-maleimidopropionic acid N-hydroxysuccinimide ester mixture post 
workup was carried out to clarify its purity. An illustration of the TLC plate is displayed in 
Figure 97. The Rf value of this compound is 0.76 in a chloroform - methanol (9:1) solvent 
system. Two spots were visible in the resultant TLC plate which prompted the use of column 
chromatography for further purification. 
 
Figure 97: TLC plate of 3-maleimidopropionic acid N-hydroxysuccinimide ester post work up. 
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Column chromatography of the reaction mixture illustrated in Figure 62 was carried out. 
The pooled fractions from that column were dried and the resulting brown powder was 
analysed by TLC showing a pure compound as illustrated in Figure 98. 
 
Figure 98: TLC plate of 3-maleimidopropionic acid N-hydroxysuccinimide ester post column chromatography. 
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2.3.9. Analytical data of 4-maleimidobutyric acid N-hydroxysuccinimide ester 
2.3.9.1 1H NMR spectrum of 4-maleimidobutyric acid N-hydroxysuccinimide ester 
The NMR spectrum in Figure 100 for 4-maleimidobutyric acid N-hydroxysuccinimide ester 
in Figure 99 showed the following peaks: 7.01 (singlet [6, 7], 2H), 3.48 (triplet J=7.0Hz [2], 
2H), 2.80 (singlet [4, 5], 4H), 2.72 (triplet J=7.4Hz [3] 2H), 1.83 (quintet J=7.2Hz [1] 2H). NMR 
analysis of 4-maleimidobutyric acid N-hydroxysuccinimide ester indicated two triplets at 
δ3.48 and δ2.72 for the terminal CH2 protons of the alkyl chain. The central CH2 protons 
are observed as a quintet at δ1.83. Similar to the NMR spectrum of 3-maleimido propionic 
acid N-hydroxysuccinimide ester (Figure 95), there is a tall singlet attributed to the two 
maleimide protons (δ7.01) and a broad singlet for the four protons of the succinimide 
(δ2.72). There is also a trace acetone signal at δ2.1. 
 
Figure 99: Synthesis of 4-maleimidobutyric acid N-hydroxysuccinimide ester. 
 
Figure 100: 1H NMR spectrum of 4-maleimidobutyric acid N-hydroxysuccinimide ester in DMSO_d carried out using 
300MHz NMR at 25 °C. 
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2.3.9.2 FTIR of 4-maleimidobutyric acid N-hydroxysuccinimide ester 
FTIR analysis of 4-maleimidobutyric acid N-hydroxysuccinimide ester produced a spectrum 
in Figure 101, which is very similar to that of 3-maleimidopropanoic acid N-
hydroxysuccinimide ester. Table 5 displays the noteworthy signals. NMR analysis produced 
spectra that clearly distinguishes between the two compounds, which highlighted the 
importance of NMR spectroscopy as a means of correctly analysing these compounds. Due 
to the structural similarity of 3-maleimidopropanoic acid N-hydroxysuccinimide ester in 
Figure 94 and 4-maleimidobutyric acid N-hydroxysuccinimide ester Figure 99, their FTIR 
spectrum are nearly identical.  There is a maleimide alkene stretch at 3100 cm-1, a tertiary 
amine stretch at 1670 cm-1 and the alkyl stretches at 2940 cm-1 and 2850 cm-1. 
 
Figure 101: FTIR of 4-maleimidobutyric acid N-hydroxysuccinimide ester. 
 
 
 
 
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
%
T
 1000   1500   2000   2500   3000   3500   4000  
Wavenumbers (cm-1)
(C-N) 
(C=C) 
(C=O) 
(C-H) 
(C-H) 
=(C-H) 
1080 
1630 1670 
2850 2940 
3100 
O
O
N
O
O
N
O
O
112 
 
Table 5: FTIR peak absorbance assignments for 4-maleimidobutyric acid N-
hydroxysuccinimide ester. 
4-maleimidobutyric acid  
N-hydroxysuccinimide ester 
 
O
O
N
O
O
N
O
O  
Wavenumber (cm-1) Bond Type Assignment 
1080 Tertiary amine 
stretch 
(C-N) 
1630 Alkene stretch (C=C) 
1670 Tertiary amide 
stretch 
(C=O) 
2850 Alkyl stretch (C-H) 
2940 Alkyl stretch (C-H) 
3100 Alkene stretch =(C-H) 
 
2.3.9.3. TLC analysis of 4-maleimidobutyric acid N-hydroxysuccinimide ester 
TLC analysis of the 4-maleimidobutyric acid N-hydroxysuccinimide ester mixture post 
workup was carried out to clarify its purity. An illustration of the TLC plate is displayed in 
Figure 102. The Rf value of this compound is 0.71 in a chloroform - methanol (9:1) solvent 
system. Two spots were visible in the resultant TLC plate which prompted the use of column 
chromatography for further purification. 
 
Figure 102: TLC plate of 4-maleimidobutyric acid N-hydroxysuccinimide ester post work up. 
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Column chromatography of the reaction mixture illustrated in Figure 63 was carried out. 
The pooled fractions from that column were dried and the resulting dark green solid was 
analysed by TLC showing a pure compound as illustrated in Figure 103. 
 
Figure 103: TLC plate of 4-maleimidobutyric acid N-hydroxysuccinimide ester post column chromatography. 
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2.3.10. Analytical data of 4-maleimidobutyric acid N-hydroxysuccinimide ester 
2.3.10.1 1H NMR spectrum of 6-aminohexanoic acid N-hydroxysuccinimide ester  
The NMR spectrum in Figure 103 for 6-maleimidohexanoic acid N-hydroxysuccinimide ester 
in Figure 104 showed the following peaks: 6.70 (singlet [8,9], 2H), 3.54 (triplet J=7.2Hz [3], 
2H), 2.84 (singlet [6,7], 4H), 2.61 (triplet J=7.4Hz [5] 2H), 1.78 (quintet J=7.6Hz [2] 2H), 1.65 
(quintet J=7.6Hz [4] 2H) 1.41 (quintet [1] 2H). As observed with the 3 and 4-length N-
alkylated esters (Figure 36, 38), the NMR spectrum of synthesis of 6-maleimidohexanoic 
acid N-hydroxysuccinimide ester contains a broad singlet for the four succinimide protons 
(δ2.84) and a tall singlet for the two maleimide protons (δ6.7). The alkyl chain CH2 signals 
as expected contains two terminal triplets at δ3.54 and δ2.61. Three quintets are also 
observed for the central three CH2 signals at δ1.78, δ1.65 and δ1.41. There is a trace water 
contaminant at δ1.65 and signals indicating a trace amount of ethyl acetate present (δ4.12, 
δ2.05 and δ1.26). 
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Figure 104: Reaction scheme for the synthesis of 6-aminohexanoic acid N-hydroxysuccinimide ester. 
 
Figure 105: 1H NMR spectrum of 6-aminohexanoic acid N-hydroxysuccinimide ester in DMSO_d carried out using 
300MHz NMR at 25 °C. 
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2.3.10.2. FTIR of 6-maleimidohexanoic acid N-hydroxysuccinimide ester 
As expected, the FTIR analysis of 6-maleimidohexanoic acid N-hydroxysuccinimide ester in 
Figure 106 produced a spectrum that was very similar to that of the 3 and 4 alkyl length 
analogues. Table 6 lists the noteworthy peaks. The FTIR spectrum of 6-maleimidohexanoic 
acid N-hydroxysuccinimide ester therefore has IR absorbance’s similar to those of 3-
maleimidopropanoic acid N-hydroxysuccinimide ester and 4-maleimidobutyric acid N-
hydroxysuccinimide ester due to their similar chemical structure. These are the maleimide 
alkene stretch at 3100 cm-1, the tertiary amine stretch at 1670 cm-1 and alkyl stretches at 
2940 cm-1 and 2850 cm-1. 
 
Figure 106: FTIR of 6-maleimidohexnoic acid N-hydroxysuccinimide ester. 
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Table 6: FTIR peak absorbance assignments for 6-maleimidohexanoic acid N-
hydroxysuccinimide ester. 
6-maleimidohexanoic acid  N-hydroxysuccinimide ester 
 
O
O
N
O
O
N
O
O
 
Wavenumber (cm-1) Bond Type Assignment 
1080 Tertiary amine 
stretch 
(C-N) 
1630 Alkene stretch (C=C) 
1670 Tertiary amide 
stretch 
(C=O) 
2850 Alkyl stretch (C-H) 
2940 Alkyl stretch (C-H) 
3100 Alkene stretch =(C-H) 
 
2.3.10.3. TLC analysis of 6-maleimidohexanoic acid N-hydroxysuccinimide ester 
TLC analysis of the 6-maleimidohexanoic acid N-hydroxysuccinimide ester mixture post 
workup was carried out to clarify its purity. An illustration of the TLC plate is displayed in 
Figure 107. The Rf value of this compound is 0.52 in a chloroform - methanol (9:1) solvent 
system. Two spots were visible in the resultant TLC plate which prompted the use of column 
chromatography for further purification. 
 
Figure 107: TLC plate of 6-maleimidohexanoic acid N-hydroxysuccinimide ester post work up. 
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Column chromatography of the reaction mixture illustrated in Figure 64 was carried out. 
The pooled fractions from that column were dried and the resulting yellow highly viscous 
oil was analysed by TLC showing a pure compound as illustrated in Figure 108. 
 
Figure 108: TLC plate of 6-maleimidohexanoic acid N-hydroxysuccinimide ester post column chromatography. 
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2.3.11. Analytical data of Boc-Gem-Mal 
2.3.11.1 1H NMR spectrum of Boc-Gem-Mal  
The NMR spectrum (Figure 110) of Boc-Gem-Mal (Figure 109) showed the following peaks: 
7.90 (doublet [8], 1H), 7.26 (doublet [7], 1H), 6.75 (singlet [9,10], 2H), 6.23 (multiplet [11] 
1H), 5.20 (multiplet [4] 2H), 4.45-4.29 (multiplet [2,3] 3H), 3.72 (triplet [6], 2H), 2.76 (triplet 
[5] 2H) 1.36 (singlet [12] 9H), 1.35 (singlet [13] 9H). Evidence of a successful amide coupling 
reaction would be observed by noting the disappearance of the signals at δ7.61 and δ5.95 
for 3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine’s pyrimidine protons. These protons were 
up shifted to δ7.9 and δ7.26 due to their proximity to the newly formed amide group. The 
other protons remained relatively unchanged indicating the boc groups remained and 
therefore no reaction had taken place at the hydroxyls. A trace amount of water can be 
observed at δ2.74. 
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Figure 109: Reaction scheme depicting the reaction between 3′, 5′-O-Bis(tert-Butoxycarbonyl)gemcitabine and 3-
maleimido propionic acid N hydroxysuccinimide ester to produce Boc-Gem-Mal. 
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Figure 110: 1H NMR spectrum of Boc-Gem-Mal in DMSO_d carried out using 300MHz NMR at 25 °C. 
2.3.11.2. TLC analysis of Boc-Gem-Mal 
TLC analysis of the starting materials (3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine and 3-
maleimido propionic acid N hydroxysuccinimide ester) and the post workup Boc-Gem-Mal 
mixture was carried out to observe its purity. An illustration of the TLC plate is displayed in 
Figure 111. The Rf value of this compound is 0.7 in a chloroform - acetone (1:1) solvent 
system. The presence of the starting material was evident by their comparative spots in the 
resultant TLC plate which prompted the use of column chromatography for further 
purification. 
 
Figure 111: TLC plate of Boc-Gem-Mal post workup. 
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Column chromatography of the reaction mixture illustrated in Figure 65 was carried out. 
The pooled fractions from that column were dried and the resulting light green powder was 
analysed by TLC showing a pure compound as illustrated in Figure 112. 
 
Figure 112: TLC plate of Boc-Gem-Mal post column chromatography. 
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2.3.12. Analytical data of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate 
2.3.12.1. 1H NMR spectrum of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate 
The NMR spectrum (Figure 114) of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate 
(Figure 113) showed the following peaks: 7.34 (multiplet [3], 1H), 6.3 (multiplet [1], 1H), 
6.23 (multiplet J=3.2Hz [2], 1H), 4.06 (singlet [4] 2H), 1.5 (singlet [5] 9H). Successful boc 
protection of 2-furanmethane thiol was noted by the presence of a very tall singlet at δ1.5 
for the nine boc group’s protons. The furan proton neighbouring the oxygen is upshifted to 
δ7.34 compared to the other two which have a similar chemical shift of δ6.3 and δ6.23. 
There is a trace water contamination at δ1.52. 
S
4
2
1
3 O
O
O
CH35
CH3
CH3
 
Figure 113: Reaction scheme for the synthesis O-tert-butyl S-(furan-2-ylmethyl) carbonothionate.
 
Figure 114: 1H NMR spectrum of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate in CDCl3 carried out using 300MHz 
NMR at 25 °C. 
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2.3.12.2. FTIR of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate 
FTIR analysis of the product yielded a spectrum which corroborated the NMR analysis that 
2-furanmethanethiol had been successfully boc protected. Table 7 lists the noteworthy 
peaks indicative of a successful boc protection of 2-furanmethane thiol. A thiol group has 
a signal around 2550-2600 which is absent from the IR spectral analysis. The presence of a 
the conjugated alkene stretch at 1650 cm-1 (C=C) of the furan and the lack of a thiol (S-H) 
stretch at around 2550 cm-1 in Figure 115 indicates the successful boc protection of 2-
furanmethane thiol. 
 
Figure 115: FTIR of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate. 
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Table 7: FTIR peak absorbance assignments for O-tert-butyl S-(furan-2-ylmethyl) 
carbonothionate. 
O-tert-butyl S-(furan-2-ylmethyl) 
carbonothionate  
 
S
O
O
O
CH3
CH3
CH3
 
Wavenumber (cm-1) Bond Type Assignment 
1120 Aliphatic ester stretch (C-O) 
1650 Conjugated alkene 
stretch 
(C=C) 
1750 Ester stretch (C=O) 
2980 Alkyl stretch (C-H) 
 
2.3.12.3. TLC analysis of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate 
TLC analysis of the O-tert-butyl S-(furan-2-ylmethyl) carbonothionate mixture post workup 
was carried out to clarify its purity. An illustration of the TLC plate is displayed in Figure 
116.The Rf value of this compound is 0.87 in a petroleum ether – ethyl acetate (1:1) solvent 
system. Only one Spot was visible indicating a pure compound requiring no further 
purification. 
 
Figure 116: TLC plate of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate post workup. 
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2.3.13. Analytical data of BDA 
2.3.13.1. 1H NMR spectrum of BDA 
The NMR spectrum (Figure 118) of BDA (Figure 117) showed the following peaks: 6.53 
(multiplet [4-endo], 1H), 6.41 (multiplet J=3.2Hz [4-exo], 1H), 6.31 (multiplet [3-endo] 1H), 
6.24 (multiplet [3-exo] 1H), 5.24 (doublet J=1.7Hz [2], 1H), 4.06 (singlet [11] 2H), 3.61 
(triplet [7], 2H), 3.59 (multiplet J=6.2Hz [1-endo], 1H), 3.44 (doublet J=6.2Hz [5-endo], 1H), 
3.01 (singlet [1-exo] 1H), 2.95 (doublet [5-exo] 1H), 2.84 (singlet [9,10] 4H), 2.64 (triplet [8], 
2H), 2.01 (quintet [6], 2H), 1.5 (singlet [12], 9H). The cycloadduct acquired by the Diels Alder 
reaction of O-tert-butyl S-(furan-2-ylmethyl) carbonothionate and 4-maleimidobutyric acid 
N-hydroxysuccinimide ester, produced an NMR spectrum containing a lot of signals due to 
the complexity of the compound. However, specific peaks indicative of a successful Diels 
Alder reaction were present including the emergence of new signals between δ6.53-δ6.24 
for the endo/exo alkene protons of the cycloadduct. The disappearance of the maleimide 
signal of 4-maleimidobutyric acid N-hydroxysuccinimide ester at δ7.01 also confirmed this. 
As a result these two protons were downshifted to δ3.69/δ3.44 and δ3.01/δ2.95 for the 
endo/exo isomer respectively. The proton signals for the succinimide ester remained 
relatively unchanged when compared to those of 4-maleimidobutyric acid N-
hydroxysuccinimide ester. There is a trace water peak at δ1.51 and ethyl acetate peaks at 
δ4.12, δ2.05 and δ1.26. 
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Figure 117: Reaction scheme for the Diels Alder reaction between 4-maleimidobutyric acid N-hydroxysuccinimide ester 
and O-tert-butyl S-(furan-2-ylmethyl) carbonothionate to produce BDA. 
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Figure 118: 1H NMR spectrum of BDA in CDCl3 carried out using 400MHz NMR at 25 °C. 
2.3.13.2. TLC analysis of BDA 
TLC analysis of the BDA mixture post workup was carried out to clarify its purity. An 
illustration of the TLC plate is displayed in Figure 119.The Rf value of this compound is 0.42 
in a petroleum ether – ethyl acetate (1:1) solvent system. Two spots were visible indicating 
the work up mixture required further purification. 
 
Figure 119: TLC plate of BDA post workup. 
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Column chromatography of the reaction mixture illustrated in Figure 67 was carried out. 
The pooled fractions from that column were dried and the resulting brown greasy solid was 
analysed by TLC showing a pure compound as illustrated in Figure 120.  
 
Figure 120: TLC plate of BDA post column chromatography. 
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2.3.14. Analytical data of Boc-TTLD 
2.3.14.1 1H NMR spectrum of Boc-TTLD 
The NMR spectrum (Figure 122) of Boc-TTLD (Figure 121) showed the following peaks: 7.89 
(singlet [14], 1H), 7.29 (doublet J=7.2Hz [13], 1H), 6.48 (br-singlet [5-endo], 1H), 6.41 (br-
singlet J=3.2Hz [5-exo], 1H), 6.27 (doublet J=4.2Hz [4-endo] 1H), 6.24 (multiplet [17] 1H), 
6.16 (multiplet [4-exo] 1H), 5.5 (br-singlet [3-endo], 1H), 5.20 (br-singlet [12], 1H), 5.0 (br-
singlet [3-exo], 1H), 4.45-4.31 (multiplet [10,11] 3H), 3.44 (triplet J=14.3Hz [8], 2H), 3.40 
(br-singlet [2-endo], 1H), 3.29 (doublet J=14.5Hz [6-endo], H), 2.97 (br-singlet [2-exo], 1H) 
2.89 (doublet J=6.4Hz [6-exo], 1H), 2.44 (triplet [9] 2H), 1.78 (triplet [7] 2H), 1.35 (doublet 
[16,18,19] 27H). Successful amide coupling of the Diels Alder adduct in Figure 54 with 3′, 
5′-O-Bis (tert-Butoxycarbonyl) gemcitabine was indicated by the chemical shifts of the 
gemcitabine’s pyrimidine protons, which had shifted from δ7.61 and δ5.95 to δ7.89 and 
δ7.29, while the other 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine proton signals 
remained relatively unchanged. This reaction was carried out 0 °C due to the cycloadducts 
ability to undergo retro Diels Alder. Assurances of this was evident in the presence of 
signals at δ6.48/δ6.27 and δ6.41/δ6.16 for the endo and exo isomers respectively. This 
coupled with the lack of a signal for the maleimide protons show that no detectable retro 
Diels Alder had taken place over the 108 hour reaction and that the synthesis of a boc 
protected thermally labile linker with an attached gemcitabine was successful. 
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Figure 121: Reaction scheme for the amide coupling between 3′,5′-O-Bis(tert-Butoxycarbonyl)gemcitabine and BDA to 
produce Boc-TTLD 
Figure 122: 1H NMR spectrum of Boc-TTLD in acetone_d carried out using 400MHz NMR at 25 °C. 
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2.3.14.2. TLC analysis of Boc-TTLD 
TLC analysis of the Boc-TTLD mixture post workup was carried out to clarify its purity. An 
illustration of the TLC plate is displayed in Figure 123. The Rf value of this compound is 0.61 
in a petroleum ether – ethyl acetate (1:1) solvent system. Three spots for the two starting 
materials and product were visible indicating the work up mixture required further 
purification. 
 
Figure 123: TLC plate of Boc-TTLD post work up. 
Column chromatography of the reaction mixture illustrated in Figure 68 was carried out. 
The pooled fractions from that column were dried and the resulting dark orange solid was 
analysed by TLC showing a pure compound as illustrated in Figure 124.  
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Figure 124: TLC plate of Boc-TTLD post column chromatography. 
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2.3.15. Analytical data of TTLD 
2.3.15.1 1H NMR spectrum of TTLD 
The NMR spectrum (Figure 126) of TTLD (Figure 125) showed the following peaks: 8.31 
(doublet J=7.2Hz [15], 1H), 7.38 (doublet J=7.2Hz [14], 1H), 6.63 (singlet J=0.9Hz [6], 1H), 
6.41 (doublet [5], 1H), 6.28 (triplet [16], 1H), 5.14 (doublet [4] 1H), 4.48 (multiplet [13] 1H), 
4.02 (doublet [12a,11], 2H), 3.89 (doublet J=3.8Hz [12b], 1H),  3.56 (triplet [10] 2H), 3.54 
(triplet [3], 1H), 3.46 (doublet [7], 1H), 3.11 (doublet [2], 2H), 2.56 (triplet [9], 2H), 2.29 
(triplet [1], 1H), 1.91 (quintet [8], 1H). TFA deprotection of the boc protected thermally 
labile linker was carried out to remove the boc groups. This was successfully achieved and 
noted by the disappearance of the very tall singlet at δ1.5 ensuring the complete removal 
of the boc protecting groups. The pyrimidine protons remained and had shifted to δ8.31 
and δ7.45. This was a confirmed indicator of the boc groups’ removal based on the 
literature data of 3′, 5′-O-Bis (tert-Butoxycarbonyl) gemcitabine in the paper by (Guo & 
Gallo 1999) and that the amide bond remained. The cluster of peaks for CH and CH2 protons 
around δ4.5 had shifted downwards to δ4.02 and δ3.89. The CH proton has also shifted 
down field from δ5.2 to δ4.48. These proton signal shifts around the hydroxyl groups 
indicate the removal of the boc groups that were previously present. The emergence of a 
triplet at δ2.29 for the SH proton further indicates the boc group protecting the thiol group 
has been removed.  
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Figure 125: Reaction scheme for the TFA Deprotection of Boc-TTLD to produce TTLD. 
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Figure 126: 1H NMR spectrum of Boc-TTLD in acetone_d carried out using 400MHz NMR at 25 °C. 
2.3.14.2. TLC analysis of TTLD 
TLC analysis of the TTLD mixture post workup was carried out to clarify its purity. An 
illustration of the TLC plate is displayed in Figure 127. The Rf value of this compound is 0.55 
in a dichloromethane - acetone (1:1) solvent system. Two spots were visible indicating the 
work up mixture required further purification.  
 
Figure 127: TLC plate of TTLD post work up. 
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Column chromatography of the reaction mixture illustrated in Figure 69 was carried out. 
The pooled fractions from that column were dried and the resulting orange solid was 
analysed by TLC showing a pure compound as illustrated in Figure 128. 
 
Figure 128: TLC plate of TTLD post column chromatography. 
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2.3.14.3. Mass spectrometry analysis of TTLD 
Mass spectrometry of the synthesised TTLD compound was carried out and the relevant 
area of the resultant spectrum is shown in Figure 129. The formula mass of TTLD is 542.51 
g mol-1. 
 
Figure 129: Mass spectrum of TTLD. 
The most abundant peak occurs at an m/z value of 543.136 which is the mass/charge that 
a protonated (M+H+) form of TTLD would have. This evidence supported by NMR analysis 
and FTIR is a further affirmation that the synthesis of TTLD was successfully carried out.  
2.3.16. Analytical data for the retro Diels Alder (drug release simulation) experiment of 
TTLD 
2.3.16.1 1H NMR spectrum for the retro Diels Alder (drug release simulation) experiment 
of TTLD 
The peak at δ6.41 (maleimide proton) shown in Figure 130 was monitored as its reduction 
was an indication of retro Diels Alder taking place. The integration of this peak was 
compared to another at δ4.48. The chemical shifts for the peaks in the NMR spectra shown 
in Figure 131 differ from what is stated due to a technical problem with the NMR 
equipment during the experiment.  
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Figure 130: Chemical structure of TTLD. 
 
Figure 131: Comparison of the NMR of the thermally labile linker at the 5 minute and 60 minute mark. Note the 
reduction of the peak highlighted. 
 
Figure 132 is a graph displaying the change in the integration of the peak at δ6.41 over time 
(progression of retro Diels Alder), at 20 °C, 37 °C, 45 °C and 70 °C. The application of heat 
triggers the retro Diels Alder reaction with increasing amounts depending on the 
temperature. These values could be used to demonstrate the release profile of a drug 
loaded HNP. At room temperature (20 °C) there is no detectable retro Diels Alder reaction 
which demonstrates the TTLD’s stability at ambient temperatures.  
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Figure 132: Progression of the retro Diels Alder reaction of TTLD over time at 20 °C, 37 °C, 45 °C and 70 °C. 
One thing to note is that this reaction takes place within a closed system. As a result there 
is a combination of the forward and reverse reaction occurring. Within a tumour, the 
released drug/maleimide compound would travel away from the HNP surface preventing a 
Diels Alder reaction from taking place again. Therefore the rate of retro Diels Alder is 
expected to be higher in vivo than within the closed system of a round bottom flask.  
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2.4. Discussion 
The synthesis of TTLD with an attached gemcitabine molecule was successful after a series 
of synthesis reactions. NMR, IR and mass spectrometry analysis of TTLD indicated the 
complete boc deprotection of the thiol and hydroxyl groups. Coincidentally a very strong 
garlic odour can be detected from the compound which is a common trait amongst thiol 
compounds (Node et al. 2001). Low aqueous solubility is a major problem for the 
development of new drug formulations (Savjani et al. 2012). Removal of the hydrophobic 
boc protecting groups improved the water solubility of TTLD which is an ideal attribute for 
a drug formulation to have (Savjani et al. 2012). The presence of the carbonyl and hydroxyl 
groups aid in enhancing the solubility of TTLD by increasing its hydrogen bonding with 
water molecules (Savjani et al. 2012).  
The repeated synthesis of TTLD requires the production of 4-maleimidobutyric acid N-
hydroxysuccinimide ester and the boc protection of 2-furanmethanethiol (66 % and 93 % 
yields respectively) (1st generation). The subsequent Diels Alder reaction has an average 
yield of 48 % for the cycloadduct (2nd generation). The boc protection of gemcitabine has 
an average yield of 63 % (2nd generation) and its amide coupling reaction with the 
aforementioned cycloadduct had a 62 % yield (3rd generation). The TFA deprotection step 
(4th generation) resulted in a yield of 47 % for TTLD. This 4 generational reaction synthesis 
therefore has an overall yield of 25 % when based on the lowest yield 1st generation 
reaction (synthesis of 4-maleimidobutyric acid N-hydroxysuccinimide ester).   
The retro Diels Alder experiments to simulate drug release, were successful in displaying 
the potential of TTLD for drug release at elevated temperatures. At the human body 
temperature (37 °C), the rate of retro Diels Alder was very slow where only 9 % of the 
cycloadduct had undergone retro Diels Alder after 180 mins. Increasing the temperature 
by 8 °C (from 37 °C to 45 °C) and the same amount of release would occur within 15 mins. 
The extent of the surface plasmon resonance heating effects, have already been observed 
and documented in literature (Curtis et al. 2015). A 5 μg mL-1 HNP solution when exposed 
to a 1064 nm laser, caused a temperature increase of up to 7 °C on a 2 % agar phantom 
after a 60 sec exposure time when measured with a thermal camera (Curtis et al. 2015). 
The agar phantom used (2 %) has been considered a good mimic for biological tissue (Li et 
al. 2011).  This heating effect diminishes away from the site of laser contact where no 
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heating is experienced beyond 5 mm. At a 4 mm heating range, the temperature still rises 
by 7 °C which would bring the overall temperature of cancerous cells within range to 49 °C 
(Curtis et al. 2015). Figure 133 displays the “drug release” as indicated by the percentage 
retro Diels Alder at 45 °C where 0.45 % of the TTLD will undergo retro Diels Alder after 1 
min of laser irradiation. This effect will be higher at 49 °C. This laser study reported that the 
exposed area returned to ambient temperatures within 4 min (Curtis et al. 2015). Therefore 
multiple 1 min exposures every 4 min would lead to a cumulative release of TTLD. 
 
Figure 133: Graph depicting the % retro Diels Alder over time at 45 °C as a simulation for drug release over time. 
The 0.45 % per min retro Diels Alder result was acquired by heating TTLD within a closed 
system (sealed round bottom flask). Therefore both the Diels Alder and retro Diels Alder 
was taking place establishing an equilibrium between the products and reactants, in which 
the more heat resistant exo isomer would have been forming over time (Peterson et al. 
2011). In a clinical setting, any gemcitabine molecules released due to the retro Diels Alder 
reaction, would migrate away from the HNP surface and carry out its pharmacodynamics 
purpose. This would prevent the Diels Alder reattachment to the HNP surface. Therefore it 
can be argued that the drug release recorded is lower than the potential in vitro release 
rate, which will be determined in chapter 3.  
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Gemcitabine is usually administered intravenously over 0.5 h where significant amounts 
fail to reach its intended target due to 1st pass metabolism and uptake into healthy tissues 
(Pliarchopoulou & Pectasides 2009). This causes the systemic side effects commonly 
associated with chemotherapy. The attachment of TTLD to HNPs followed by a direct 
injection into the solid tumour would eliminate the side effects associated with 
chemotherapy (Becker et al. 2013). The HNP drug formulation would accumulate inside 
cells and a clinical patient could receive multiple 1 min doses of infrared radiation with 2 
min cooling down phases at the tumour site, which would release the drug payload from 
the HNP surface.  This highlights the thermally labile nature of this linker and its potential 
as a heat triggered drug formulation. At room temperature (20 °C) there was no detectable 
retro Diels Alder taking place which gives credence to the stability of TTLD at room 
temperature for long term storage.  
2.5. Conclusion 
Synthesis and characterisation of TTLD, plus the data acquisition highlighting its potential 
as a promising formulation, for heat triggered drug release was successfully completed. 
The next task involved the attachment of TTLD to HNPs with a thiol-gold dative covalent 
bond, in order to gauge the effects of SPR on the drug release rates of this formulation and 
ultimately on cell proliferation with in vitro studies. 
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CHAPTER 3: SYNTHESIS, DRUG LOADING AND 
RELEASE STUDIES OF HYBRID NANOPARTICLE 
FORMULATIONS 
 
 
 
 
 
 
 
 
 
 
 
  
141 
 
3.0. Introduction 
Hybrid nanoparticles (HNPs) comprising of an iron oxide core with a gold coating are 
capable of strong covalent binding with thiol groups due to the dative covalent bond that 
forms between their gold shell and the sulphur atoms (Hoskins, Yue Min, Gueorguieva, et 
al. 2012; Jazayeri et al. 2016; Wang et al. 2013). As discussed previously, HNPs are 
theranostic agents due to the imaging properties of their iron oxide core which can be used 
for diagnosis purposes and their therapeutic properties, due to the surface plasmon 
resonance (SPR) attribute from the gold coating, which will be used to facilitate the 
controlled release of drug compounds via a thermally labile linker (Savka I. Stoeva et al. 
2005; C.-H. Wu et al. 2014; Santhosh & Ulrih 2013b). Production of these HNPs occurs via 
a multi-step process, starting with the synthesis of iron oxide nanoparticles using an 
established co-precipitation method (Hoskins, Yue Min, Gueorguieva, et al. 2012a) with 
subsequent gold coating. This leads to the synthesis of HNPs reported to have long term 
stability for over 6 months at room temperature as well as stability in pH ranges which 
mimic physiological conditions i.e.  lysosomes (pH 4.6) and blood (pH 7.4) (C. M. Barnett et 
al. 2013). The stability of the previously synthesised thiolated thermally labile drug (TTLD) 
which when released at various pH’s needs to be studied to ensure this formulation is 
clinically robust in cellular and systemic environments. This release leads to the formulation 
of a gemcitabine-maleimide analogue (Gem-Mal). Figure 134 shows the chemical structure 
of these two compounds. 
N
O
O
O
SH
N
N
NH
O
O
OH
OH
F
F
O
(a) 
N
O
O
N
N
NH
O
O
OH
OH
F
F
O
(b) 
Figure 134: Chemical structure of TTLD (a) and its release form Gem-Mal (b). 
The thermal effects arising from the surface plasmon resonance properties of HNPs is 
already an established fact, where a 50 μg mL-1 suspension of HNPs in 2 % agar phantom 
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raised the temperature to 82 °C (Curtis et al. 2015). This study also noted that thermal rise 
was dependant on laser exposure time and the HNPs concentration. Therefore a lower 
concentration and/or shorter laser exposure time would increase the temperature to the 
desired value of 44 °C.  
The effect of this heating on cell proliferation has also been observed in a study that 
involved exposing HNPs to pancreatic cancer cells. Confirmation of the successful uptake 
of the HNPs was determined by washing the cells with PBS and imaging them with TEM 
(Guo et al. 2013). The result of this study concluded that the HNPs themselves had no effect 
on cell proliferation, which meant these HNPs have no cytotoxic properties (Guo et al. 
2013). The images in Figure 135, explain this further where the cells (A) remained 
unaffected after a 7.9 W cm-2 exposure for 5 min followed by a 24 h rest in image (D) (Guo 
et al. 2013).  
 
Figure 135: PaNc-1 cells exposed to 0, 25, and 50 µg mL-1 dose of nanoparticles, respectively, without laser irradiation 
(A–C) and with laser irradiation at 7.9 W cm-2 power density (D–F) (Guo et al. 2013). 
The uptake of the 25 µg mL-1 and 50 µg mL-1 suspensions in image B and C in Figure 135, 
clearly shows the presence of the HNPs within the cells. After exposure to the same 7.9 W 
cm-2 laser for 5 min, there is a clear loss of cell proliferation for the 25 µg mL-1 image (B) 
after 24 h (E) where the authors of this study stated the cell proliferation fell to 22 %. With 
the 50 µg mL-1 suspension (C), this effect is more pronounced with a cell proliferation of 
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only 2.3 % after a 5 min exposure to the 7.9 W cm-2 laser followed by a 24 h rest. The 
relationship between temperature and laser intensity is shown in Figure 136.  
 
Figure 136: Photothermal response of 0 (A), 25 (B), and 50 (C) µg mL-1 nanoparticle samples at 3.2, 4.7, 6.3, and 7.9 W 
cm-2 (Guo et al. 2013). 
The graphical data in Figure 136, shows a significant difference in temperature increase 
when HNPs are exposed to laser light, compared to the control (A) and the temperature 
increases over time. The effect of HNP concentration and laser intensity is also shown due 
to the sharper rise and plateauing of the detected temperature in the 50 µg mL-1 compared 
to the 25 µg mL-1 (Guo et al. 2013). This clearly shows that the surface plasmon resonance 
properties of HNPs can be exploited for destroying pancreatic cancer cells and that the 
HNPs concentration affects the extent of cellular destruction. Due to the close proximity of 
cancerous tumours to healthy tissue, it would not be feasible to heat up pancreatic tumours 
to a high enough temperature to cause cell death, without damaging nearby healthy tissue. 
However, if the cancer cells are not heated high enough, they will survive and regrow. The 
use of TTLD attached to HNPs will bridge these two conflicting problems. The use of SPR 
will be utilised to heat up TTLD to a high enough temperature to trigger the release of Gem-
Mal, but not too high to damage nearby healthy tissue. The pancreatic cancer cells, already 
stressed by constant replication and exposure to elevated temperatures should also be 
quite susceptible to the sudden presence of a large concentration of Gem-Mal following 
the retro Diels Alder of TTLD. This threefold exploitation of pancreatic cancer weaknesses 
should prove effective. 
Another study that evaluated the potential of hybrid iron oxide-gold nanoparticles as heat 
triggers for pancreatic cancer therapy looked at both the in vitro and in vivo outcome of 
administered HNPs and production of heat shock proteins (HSP-27 and HSP-70) which are 
produced under heat related stressful conditions in cells (Oluwasanmi et al. 2016). These 
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proteins are classed as molecular chaperones that assist various protein folding processes 
such as the folding of newly synthesised proteins and the refolding of misfolded proteins 
(Sonuç Karaboğa et al. 2016). The elevation levels of these proteins after laser irradiation 
of absorbed 5 µg mL-1 and 50 µg mL-1 HNP suspensions in Figure 137 were determined by 
ELISA and indicate that the cells are stressed by the increase in the heat generated by 
surface plasmon resonance of the gold surface (Oluwasanmi et al. 2016).  
 
Figure 137: Comparison of HSP-27 and HSP-70 levels with the addition 5 µg mL-1 and 50 µg mL-1 HNP suspensions 
before and after 60 seconds of laser exposure (Oluwasanmi et al. 2016). 
The effect of this heating on cell viability was also determined with trypan blue exclusion 
in which the results from this study was in line with those from the ELISA measurement of 
heat shock proteins in Figure 138. Cell viability remained at 100% after the 5 µg mL-1 HNP 
suspension was absorbed without laser irradiation and decreased slightly after a single 60 
second laser exposure and more so after multiple irradiation cycles. The decrease in cell 
viability after single and multiple laser exposure was more significant in the 50 µg mL-1 HNP 
suspensions where cell viability fell to 85 % after multiple laser irradiations of 50 µg mL-1 
absorbed HNPs (Oluwasanmi et al. 2016). 
 
Figure 138: Effect of HNP concentration on cell viability. From left to right: 5 µg mL-1 without laser exposure, with a 60 
second laser exposure, multiple irradiations and 50 µg mL-1 without laser exposure, with a 60 second laser exposure, 
multiple irradiations (Oluwasanmi et al. 2016). 
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The heat dissipation of HNPs within tumours was also carried out on Bx-PC3 xenograft mice. 
With the use of a thermal imaging camera, the extent of heat dissipation within and beyond 
the treated tumour was determined. In Figure 139-(D1) we can see a sharp temperature 
rise upon laser exposure which reaches its maximum after 10 seconds for the tumour 
previously treated with an injected 50 µg mL-1 HNP suspension. Without the presence of 
HNPs in Figure 139-(B1-3) there is no tissue heating being observed. Upon injection of the 
50 µg mL-1 HNP the heat maps in Figure 139-(C1-3) clearly show that the elevated 
temperatures is confined more to the tumour only (Oluwasanmi et al. 2016).  
 
Figure 139: Effect of in situ laser irradiation of HNPs injected I.T. in pancreatic xenograft models. (A) Nu/Nu xenograft 
(BxPC-3) tumour bearing mouse, (B & C) heat dissipation maps of tumours absent (B) and with 50 mg mL1 HNPs I.T. (C) 
at (1) t 1⁄4 0 s, (2) t 1⁄4 30 s and (3) t 1⁄4 60 s. (D) Quantification of (1) thermal rise at irradiation point and (2) heat 
dissipation away from laser focal point measured using a thermal imaging camera (n 1⁄4 3  SD) (Oluwasanmi et al. 
2016). 
This study confirms that in an in vivo environment, HNPs can be utilised to increase the 
temperature of tumours after laser irradiation. The 50 µg mL-1 HNP suspension was utilised 
due to the improved reduction in cell viability shown in Figure 138 compared to the 5 µg 
mL-1 HNP suspension. At 5 µg mL-1 HNP suspension the HNPs are not close enough to 
generate a high increase in bulk temperature and the cells seem capable of tolerating HNP 
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concentrations of 50 µg mL-1. The combined action of a rise in bulk temperature and the 
heat triggered release of anticancer agents should produce an enhanced effect on the 
reduction of cell viability (Oluwasanmi et al. 2016). 
The synthesis of HNPs, their drug loading and drug release studies were carried out and 
quantified by various commonly used analytical techniques such as, zeta potential 
measurements, transmission electron microscopy, high performance liquid 
chromatography, inductively coupled plasma-optical emission spectroscopy and UV-Vis 
spectroscopy. HNPs were analysed at every major step of their synthesis by measuring their 
zeta potential, their gold and iron content and their morphology using transmission 
electron microscopy. Drug loading and drug release studies were monitored with HPLC. The 
procedures used for these techniques will be described below. 
3.0.1. Zeta potential 
Zeta potential of a nanoparticulate dispersion is a measure of the electric potential energy 
or voltage of these nanoparticles at their surface and compared with the charge of the bulk 
solution (Montes Ruiz-Cabello et al. 2014). The effects of zeta potential is more prominent 
in solutions comprising of very small particles where their size promotes extended 
dispersion that can be further augmented with electrostatic interactions. With a large 
enough zeta potential, dispersed particulates will be electrostatically repulsed and resist 
aggregation. Zeta potentials between ±0-10 mV, 10-20 mV, 20-30 mV and 30+ mV are 
considered “highly unstable”, “relatively stable”, “moderately stable”, and “highly stable” 
respectively (Patel & Agrawal 2011; Bhattacharjee 2016). The zeta potential of particulate 
dispersions is very important for pharmaceutics where producing non-aggregating and 
easily dispersible formulations is highly regarded. However at increased zeta potential, 
biocompatibility issues are experienced. Therefore a balance of zeta potential and 
biological activity is required when designing pharmaceutical products. 
3.0.2. Transmission electron microscopy 
Electron microscopy like other microscopic techniques is used for observing the surface of 
materials at a detail too high for the naked eye. Conventional optical microscopes use a 
series of lenses to magnify the images of materials to a size visible with the naked eye.  
However these lenses diffract visible light and are limited by the Abbe diffraction limit, 
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which is the point where a microscope cannot distinguish two objects close to each other 
(Nature 2009). This diffraction limit is based on wavelength and is the highest magnification 
point where light can be diffracted enough to resolve two objects side by side. Blue objects 
for example can be resolved at a higher magnification than red ones due to blue lights 
shorter wavelength. This limit still allows for the imaging of objects as small as chloroplasts 
of 5 μm width (Sadava 2008). The use of electron microscopes is necessary to resolve 
images up to the 1 nm range and is made possible due to the wavelength of electrons being 
far smaller than of visible light (Sadava 2008). The two most commonly used forms of 
electron microscopy are transmission electron microscopy (TEM) and scanning electron 
microscopy (SEM). TEM involves passing a beam of electrons through a sample and using 
the detection of unaffected electrons (that passed through unimpeded), reflected and 
scattered electrons to produce an image on a fluorescent screen (Dean et al. 2002c). SEM 
also involves the use of an electron beam. The main difference is that this beam is scanned 
across the surface of the sample. This allows the topography of the sample to be mapped 
(Dean et al. 2002c).  
3.0.3. High performance liquid chromatography 
High performance liquid chromatography (HPLC) is a chromatographic technique that is 
involved in the separation and analysis of components within a mixture (Neue 2007; Dean 
et al. 2002c). It involves the passing of sample mixtures in a solvent (mobile phase) through 
a column of an adsorbent (stationary phase) with high pressure. With the same mobile and 
stationary phase, each component in a mixture will travel through the column at different 
speeds (Dean et al. 2002c).  
The specific time taken for a specific mixture component to travel through the column is 
called its retention time. This retention time can be changed depending on various factors. 
One such effect is the polarity of the column adsorbent. Columns containing polar 
adsorbents will have a higher affinity for polar components in a separation mixture. This is 
the case with normal-phase HPLC systems. These polar components will then travel slower 
than the column leading to longer retention times. Conversely if a non-polar solvent is used 
then the non-polar components of the mixture will have a greater affinity for the mobile 
phase (solvent) and travel through the column quicker which shortens their retention time. 
Reverse-phase HPLC systems use a non-polar stationary phase and an aqueous polar 
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mobile phase instead. Longer columns will increase the retention time, as it increases the 
distance components must travel before reaching the end.  Changing the relationship 
between the mobile phase (solvent) and stationary phase (column) will affect the retention 
time as well. For example, if the flow rate is increased the retention time will decrease as 
more material can be carried through the column at any one time. This is also the case with 
increasing the pressure of the solvent as it passes through the column. These factors are 
relevant in an optimised HPLC system. If the column is degraded the retention time will 
decrease overall and the extent of this retention time decrease, will depend on the mixture 
components affinity for the stationary phase.   
After a component from a mixture has travelled through the column it is often analysed 
with an analytical technique. Some techniques that can be used in conjunction with HPLC 
include the commonly used UV/Vis spectroscopy, fluorescence spectroscopy, mass 
spectrometry and electrochemical detectors (Dost & İdeli 2012; Khare et al. 2016; Ansari & 
Häubl 2016; Campos et al. 2016). In drug formulation, HPLC is commonly used for drug 
quantification studies. These may measure the extent of drug incorporation or the binding 
onto a structure or to measure drug release from a system.  
3.0.4. Inductive coupled plasma – optical emission spectroscopy 
Inductively coupled plasma – optical emission spectroscopy (ICP-OES) is an analytical 
technique used for detection and measurement of metals by analysing the emission of 
electromagnetic radiation from excited metal atoms and ions (Parham et al. 2009). 
Emission of these electromagnetic waves is achieved by exposing metal atoms to a plasma 
source. The excited electrons return to ground state emitting electromagnetic radiation at 
specific wavelengths for that atomic species (Lee et al. 2003). The sample must be a 
solution which may require acid digestion to aid in ionisation of the sample within the 
plasma (Y. Yang et al. 2016). This solution is then injected as a fine aerosol by combining it 
with a stream of argon gas which acting as a nebulizer (Todolí & Mermet 2006). This aerosol 
is carried through an argon plasma of around 7000 °C to excite the outer electrons of the 
metals within the sample. This technique is commonly used in inorganic chemistry to 
quantify metallic composition in systems such as concentration or iron and gold in hybrid 
nanoparticles. 
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3.0.5. UV/Vis spectroscopy 
UV/Vis spectroscopy is an analytical technique used to measure the absorbance of visible 
light and near ultraviolet radiation of materials, typically organic compounds with 
conjugation and transition metals (Dean et al. 2002c). Predicting the frequencies of least 
absorbances is possible because the colour of an object corresponds to the frequencies of 
light least absorbed or reflected (Dean et al. 2002c). Atoms and molecules exposed to the 
visible light and near ultraviolet range of the electromagnetic spectrum enter electronic 
transition states, as their electrons absorb the energy of the UV/Vis light and move to 
higher excited transition state (Atkins 2006b). This makes UV/Vis spectroscopy a form of 
absorbance spectroscopy (Dean et al. 2002c; Razzazan et al. 2016). UV/Vis spectroscopy is 
carried out by dissolving the material of interest in a solvent within a cuvette. After a blank 
calibration is carried out, the sample is exposed to light and UV radiation and the 
absorbance over a determined range of wavelengths is calculated. A diagram of UV-Vis 
analysis is shown in Figure 140. 
 
Figure 140: Diagram of UV-Vis schematic. 
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The amount of absorbance is proportional to the concentration of the sample which makes 
this technique valuable for producing calibration curves and determining the concentration 
of unknown samples (Dean et al. 2002c). This relationship is described using the Beer 
Lamberts law:   
𝐴 =  𝜀 𝑙 𝑐 
Where A is the absorbance, ε is the molar absorptivity, l is the path length (e.g. width of 
cuvette) and c is the concentration of the sample (Atkins 2006c). The molar absorptivity is 
value of the absorbance under standard conditions such as (A when l and c = 1) in a 
calibration series for a specific dissolved species (Atkins 2006c). Once this is established, 
the concentration of unknowns can be acquired by rearranging the above equation:                                   
 
𝑐 =  
𝐴
𝜀 𝑙
 
This technique is commonly used in drug quantification, especially in conjunction with 
HPLC. In this study, UV-Vis will be used in order to determine the state of gold coating onto 
the HNPs and indicate the SPR wavelength which is equivalent to the λmax value. 
3.1 Aims and objectives 
The aim of the following study was to synthesize hybrid nanoparticles capable of surface 
modification with TTLD, a gemcitabine analogue with a thiolated thermally labile linker with 
and without a thiol capped polyethylene glycol (Thiol-PEG). The HNP-drug system 
developed will be tested in vitro for their ability to act as thermally responsive drug delivery 
vehicles for delivery of a novel gemcitabine analogue. The degree of loading and heat 
triggered release will be determined with HPLC.  
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3.2 Materials and methods 
3.2.1 Materials used 
Material Supplier 
RPMI Media Fisher Scientific (UK) 
Hydrochloric Acid Fisher Scientific (UK) 
Sodium Hydroxide Fisher Scientific (UK) 
Acetonitrile Fisher Scientific (UK) 
O-[2-(3-Mercaptopropionyl amino) ethyl]-
O′-methylpolyethylene glycol  Sigma Aldrich (UK) 
Potassium Nitrate Sigma Aldrich (UK) 
Iron (II) Sulphate  Sigma Aldrich (UK) 
Sulphuric Acid Sigma Aldrich (UK) 
Polyethylene Imine  Sigma Aldrich (UK) 
Chloroauric Acid Alfa Aesar (UK) 
Sodium Borohydride Sigma Aldrich (UK) 
Hydroxylamine Sigma Aldrich (UK) 
Dialysis Bag Medicell (UK) 
Nitric Acid Fisher Scientific (UK) 
Formvar  Sigma Aldrich (UK) 
Copper grids Agar Scientific (UK) 
Chloroform Sigma Aldrich (UK) 
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3.2.2. Methods 
3.2.2.1. Synthesis of iron oxide nanoparticles 
Sodium hydroxide (1.03 g, 0.026 mols) and potassium nitrate (1.82 g, 0.018 mols) were 
dissolved in deionised water (180 mL) in a 3 neck round bottomed flask with a fitted 
condenser. A syringe adaptor was used to bubble nitrogen into the mixture for 15 min 
before the mixture was heated to 90 °C for a further 20 min. A solution of Iron (II) Sulphate 
(3.89 g, 0.026 mols) in sulphuric acid (20 mL, 0.01 M) was prepared with the use of 
sonication to aid in dissolution. This solution was then combined with the previous mixture 
and heated to 90 °C with nitrogen bubbling through for a further 1 h. The nitrogen pump 
was removed after 1 h of stirring and the mixture was left to stir for an additional 24 h at 
90 °C. The iron oxide nanoparticles (IONPs) were magnetically separated and washed with 
deionised water 10 times before being suspended in 100 mL deionised water and 
refrigerated for future use. (Hoskins, Yue Min, Gueorguieva, et al. 2012).  
3.2.2.2. PEI coating of iron oxide nanoparticles 
The previously synthesised iron oxide nanoparticle (IONP) suspension (10 mL) was added 
to 100 mL of poly(ethyleneimine) (PEI) (5 mg mL-1) and sonicated for 2 h with a MSE 
Soniprep 150 Plus Disintegrator. The excess PEI was removed by repeatedly washing and 
magnetically separating the PEI coated IONPs (IONP-PEI) with deionised water. The IONP-
PEI were then suspended in 10 mL deionised water (Hoskins, Yue Min, Gueorguieva, et al. 
2012a).  
3.2.2.3. Synthesis of gold seed solution 
Chloroauric acid HAuCl4 (375 µL, 4 %) and Na2CO3 (500 µL, 0.2 M) were dissolved in 100 mL 
of water chilled to 5 ˚C. After 5 min of stirring, 5 mL of sodium borohydride solution (0.5 
mg mL-1) was added over 5 min (1 mL per min). The observation was a colour change from 
pale yellow to deep red indicating the presence of 2 nm gold seeds. The gold seed solution 
was stirred for a further 10 min before being immediately utilised or refrigerated (Hoskins, 
Yue Min, Gueorguieva, et al. 2012).  
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3.2.2.4. Synthesis of gold coated iron oxide nanoparticles  
The previously synthesised IONP-PEI suspension (10 mL) was added to the gold seed 
solution (100 mL) and stirred for 2 h at room temperature. The nanoparticles were washed 
and magnetically separated with deionised water before being suspended in a 100 mL 
solution of PEI (MW 2000) (0.1 mg mL-1) and sonicated for 10 min. The gold seeded particles 
(Au-seed-IONP’s) were then washed 10 times with deionised water before being 
suspended in 10 mL of deionised water. In order to reduce gold onto the nanoparticle 
surfaces, the 10 mL suspension of the Au-seed-IONP’s was suspended in a solution of 
sodium hydroxide (0.01M, 110 mL) and stirred. HAuCl4 (0.5 mL, 1 %) was added followed 
by 0.2M hydroxylamine (0.75 mL) and stirred at room temperature. This step was repeated 
with 10 min intervals 4 times with 1 % HAuCl4 (0.5 mL) and 0.2 M hydroxylamine (0.25 mL) 
followed by additional stirring for 30 min. The final solution was then washed 5 times with 
deionised water and the gold coated iron oxide nanoparticles (HNPs) were suspended in 
10mL deionised water (Hoskins, Yue Min, Gueorguieva, et al. 2012a). 
3.2.3. Characterisation of synthesised nanoparticles 
3.2.3.1. Zeta potential measurement procedure 
The surface charge of nanoparticles throughout their synthetic route was measured by 
introducing very dilute suspensions into folded capillary zeta cells and inserting these cells 
into a Malvern Zetasizer Nano ZS. The zetasizer was then programmed to analyse samples 
100 times at 25 °C (n=3). The overall average zeta potential is used when describing the 
zeta potential of nanoparticles from now on, unless otherwise stated. 
3.2.3.2. Transmission electron microscopy procedure 
TEM imaging of the synthesis stages for HNPs was carried out using the Jeol Jem-1230 
transmission electron microscope using anaLYSIS software, at the University of Keele. This 
allowed visualisation of the nanoparticulate size and morphology. Prior to imaging, formvar 
coated copper grids were prepared. Glass slides were dipped in formvar, and dried using 
mild heat from a light source. The edges were filed to help raise the film before the glass 
slides were gently submerged to separate the film from the glass slide surface. The grids 
were then carefully placed on the floating formvar film. The next step involved taking a 
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fresh glass slide and slowly slipping the slide under the film so that it attaches to the glass 
slide surface. The slide was then dried using mild heat from a light source. The samples 
were pipetted (10 µL) onto the grids and allowed to air dry before imaging with a JEOL, 
JEM-1230.  
3.2.3.3. Inductively coupled plasma – optical emission spectroscopy procedure 
Inductively Coupled Plasma – Optical Emission Spectroscopy (ICP-OES) was used to 
measure the metal content of the HNPs. Samples were prepared first by adding 0.4 mL of 
suspended nanoparticles to a 1.6 mL solution of 1:1 hydrochloric acid/nitric acid (1:5 
dilution of 0.4 mL nanoparticles) to make up a 2 mL mixture, which was gently heated for 
a few min until dissolution of nanoparticles was achieved. 0.01 mL of this solution was then 
added to 9.99 mL of deionised water (1:5000 v/v from original 0.4 mL nanoparticle sample). 
This 10 mL solution was then analysed by an Agilent Technologies 700 series ICP-OES. All 
intensities were therefore multiplied by 5000 to acquire the concentration of the original 
0.4 mL nanoparticle sample based on a calibration curve (R2 = 0.9997) for iron and (R2 = 
0.9981) for gold. Iron and gold was analysed at a wavelength of 261.187 nm and 242.794 
nm respectively. 
3.2.3.4. UV-Vis spectroscopy procedure 
Uv-Vis spectroscopy characterisation of HNPs was executed by filling a cuvette of path 
length 10 mm with a solution of the nanoparticles in water. Initially a blank analysis of just 
water was carried out to eliminate the absorbance of background material in the water. 
The samples were then analysed with a Varian Cary 50 Bio Uv-Vis spectrophotometer (64 
scans) over a wavelength range of 400-700 nm (1 nm, stepwise), in order to determine the 
lambda max of the HNPs within this range.  
3.2.3.5. Drug loading of HNPs procedure 
Into a sample tube, 5 mg of HNPs (based on iron mass only) was added followed by 25 mg 
(based on gemcitabine mass only) of the thiolated thermally labile drug (TTLD) both with 
and without 25 mg of the O-[2-(3-Mercaptopropionyl amino) ethyl]-O′-methylpolyethylene 
glycol (PEG-Thiol). The mixture was diluted to 5 mL with deionised water and stirred for 2 
h at room temperature. The drug loaded HNPs were magnetically separated and washed 
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with 5 mL of deionised water. The overall 10 mL “waste solution” was retained and 
analysed using reverse phase HPLC for drug content. The peak area was used to calculate 
drug content from a calibration curve (R2 = 1). Drug attachment onto HNP surface was 
deduced by subtraction of the unbound drug content from the starting drug weight. 
3.2.3.6. High performance liquid chromatography procedure 
High Performance Liquid Chromatography (HPLC) was carried out by first injecting an 
unknown sample solution, comprised of an unknown mixture in a 1:1 v/v water:acetonitrile 
solvent, into a HPLC vial. The vial(s) were loaded into a Perkin Elmer Flexar LC Autosampler. 
The flow rate for the solvent phase solution which was isocratically eluted, was 1 mL min-1 
(1:1 v/v water:acetonitrile) for all samples unless otherwise stated and the sample injection 
amount is 10 μL. Sample fractions were analysed with UV-Vis spectroscopy in which the 
lambda max value selected was 268 nm, where gemcitabines pyrimidine is strongly 
absorbed by UV-Vis spectroscopy. This lambda max is used for all HPLC analysis unless 
otherwise stated. The retention time of the released drug is 0.77 min with the use of a 
Pinnacle DB C18 reverse phase column (100 mm length, 1.9 µm particle size, 140 Å pore 
size, 2.1 mm internal diameter), and the amount of drug released was calculated with 
comparisons to a previously produced calibration curve of standard drug solution 
concentrations. The R2 value of this calibration curve is 1.  
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3.2.3.7. In vitro drug release studies procedure 
A dialysis membrane (12-14 kDa, 0.04 mm wall thickness, 31.7 mm diameter, 24 Å pore 
size) was filled with 2 mL of HNP-drug or HNP-drug-PEG solution. The filled membrane was 
placed into 200 mL water or cell media at varied pH (7.4, 5.6) under sink conditions. The 
solutions were stirred and the rate of drug release measured at varied temperature. This 
procedure was applied to the following experimental parameters in Table 8:  
Table 8: Experimental parameters for the dialysis drug release studies 
pH Drug Loaded 
HNPs 
Drug + PEG 
Loaded HNPs 
pH 7 (Water) 20°C, 37°C, 
44°C 
20°C, 37°C, 
44°C 
pH 5.6 (Cell 
Media) 
20°C, 37°C, 
44°C 
20°C, 37°C, 
44°C 
pH 7.4 (Cell 
Media) 
20°C, 37°C, 
44°C 
20°C, 37°C, 
44°C 
Aliquots (1 mL) of the solution were taken at various time points (1 min, 2 min, 5 min, 10 
min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 24 h, 48 h, 72 h and 96 h) and placed in HPLC vials. 
Fresh 1 mL of deionised water/cell culture media of appropriate pH was placed back into 
the conical flask. Total drug release was analysed using HPLC as described in section 3.2.3.6. 
3.2.3.8. Stability assessment procedure of HNPs 
Into a vial containing 3 mL of a 1:1 (v/v) solution of deionised water and acetonitrile, was 
added 3 mg of TTLD attached to 0.6 mg of HNPs. This process was repeated seven more 
times producing eight identical drug/NP suspensions. Four vials were stored at room 
temperature away from direct sunlight and the other four was refrigerated away from 
direct sunlight. Every day the vials were shaken and every seven days a 0.1 mL aliquot of 
each vial was acquired and analysed with HPLC to calculate the amount of GEM-MAL that 
had released from the HNP surface.   
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3.3. Results 
3.3.1. Synthesis and characterisation of HNPs 
The synthesis of HNPs was successful, based analytical results from a combination of zeta 
potential measurements, ICP-OES analysis and TEM imaging. These were carried out at 
every synthesis step from iron oxide nanoparticle synthesis to the final gold coated hybrid 
nanoparticles. Uv-Vis analysis was carried out on both the iron oxide nanoparticles and the 
gold coated nanohybrids as well. 
3.3.1.1. Zeta potential measurement results 
The average zeta potential of the uncoated IONPs was measured to be -14.8 mV with a 
deviation of 4.37 mV as shown in Figure 141. 
 
Figure 141: Zeta potential distribution graph showing the average and range of zeta potentials over 100 runs at 25°C for 
IONP’s. 
PEI coating of the IONP’s led to a change in the surface charge from -14.8 mV to +23.7 mV 
(3.93 mV deviation) shown in Figure 142.  
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Figure 142: Zeta potential distribution graph showing the average and range of zeta potentials over 100 runs at 25°C for 
IONP-PEI. 
Gold reduction on the surface of the PEI coated IONPs reduced the overall surface charge 
due to the negative charge of the gold atoms leading to a zeta potential of 16.2 mV (3.95 
mV deviation) for the final HNPs in Figure 143.  
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Figure 143: Zeta potential distribution graph showing the average and range of zeta potentials over 100 runs at 25°C for 
HNPs. 
The zeta potential measurements and shift in surface charge at each step of the synthetic 
route suggest HNP synthesis had been successful. The negative charge of -14.8 mV for the 
IONPs is due to sulphate association resulting from the synthesis route and is indicative of 
successful IONP synthesis (C. Barnett et al. 2013). Addition of the PEI coat was successful, 
as shown by a change in the surface charge, from -14.8 mV to 23.7 mV. This overall positive 
charge is due to the positive amine functional groups within the cationic PEI backbone (C. 
Barnett et al. 2013). Gold seeding and the final gold reduction step reduced the surface 
charge to 16.2 mV due to the electronegative charge of colloidal gold (C. Barnett et al. 
2013). 
3.3.1.2. Transmission electron microscopy results 
The TEM image in Figure 144 of the IONPs were acquired which confirmed their size to be 
approximately 150 nm in diameter shown at a magnification of x40000.   
       
 
Figure 144: TEM image of IONPs at a magnification of x40000. 
TEM images of the gold seeded IONPs were acquired which confirmed their presence on 
the surface of IONPs as shown in Figure 145(a) at a magnification of x40000 where the 
seeds are visible on the surface. In Figure 145(b) these same nanoparticles were magnified 
to x250000 and here, the 2 nm gold seeds can be clearly observed attached onto the IONP 
surface. 
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Figure 145: TEM image of gold seeded IONP’s at A) x40000 and B) x250000. 
The acquisition of TEM images at x40000 and x250000 was carried out for all batches of 
synthesised HNPs to ensure gold seeding was successful before gold reduction took place.  
After the gold reduction step, the gold seeds are no longer present in any meaningful 
amount on the surface and the gold has formed a solid smooth shell around the iron oxide 
nanoparticle as shown in Figure 146 at x40000 magnification. The average size of the HNPs 
is roughly 150 nm. These images suggest that HNP synthesis was successful. 
 
Figure 146: TEM image of HNPs. 
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3.3.1.3 UV-Vis spectroscopy results 
UV-Vis spectroscopy of HNPs between 400 nm and 700 nm shown in Figure 147 led a λmax 
of 573 nm which is within the observed λmax  of 540 nm to 575 nm from literature sources 
(Hoskins, Yue Min, Gueorguieva, et al. 2012a; Robinson et al. 2010). This result coupled 
with the zeta potential measurements earlier, indicates that complete gold shell coating 
had been achieved and the HNP synthesis was successful. The calculation of the λmax for 
HNPs is important as it provides the optimal wavelength to expose HNPs to which will lead 
to the largest conversion of this electromagnetic energy to thermal energy. In the event 
that using the specific λmax of gold is improbable, the UV-Vis spectrum will still provide 
information on suboptimal yet highly effective wavelengths for the exploitation of the 
surface plasmon resonance property of gold. ICP-OES will be used to further confirm the 
successful production of HNPs. 
 
Figure 147: UV-Vis spectrum of IONPs and HNPs. 
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3.3.1.4. Inductively coupled plasma – optical emission spectroscopy results 
In order to quantify the elemental composition of the HNPs, the gold and iron 
concentrations were measured using ICP-OES. A calibration curve was first produced from 
a range of 0.05 ppm to 10 ppm from standard solutions and with a blank solution, 
producing the calibration curve for iron in Figure 148 and gold in Figure 149. The equation 
of these graphs was used to resolve the unknown concentration of iron and gold in HNPs.  
Iron and gold was analysed at a wavelength of 261.187 nm and 242.794 nm respectively. 
 
Figure 148: Calibration curve of dissolved iron concentration vs optical emission spectroscopy intensity. 
 
Figure 149: Calibration curve of dissolved gold concentration vs optical emission spectroscopy intensity. 
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The equation for the calibration curve for gold is:  
𝑦 = 5784.2𝑥 + 136.32 
The equation for the calibration curve for iron is:  
𝑦 = 9281.6𝑥 + 320.08 
An overview of the gold and iron content of the Au-IONP synthesis path is shown in Table 
9 below. 
Table 9: The Au-IONP Synthesis Steps 
Synthesis 
Step 
Gold 
Intensity 
Iron 
Intensity 
Gold 
Concentration 
(mg mL-1) 
Iron 
Concentration 
(mg mL-1) 
Gold:Iron 
Ratio 
IONPs 66 30835 0 15.44 - 
Gold Seed 
Step 
2864 6386 2.24 3.32 2:3 
Gold 
Reduction 
Step 
2246 22398 1.82 11.89 2:13 
 
The iron oxide nanoparticles analysed, only contained a negligible amount of gold after 
elemental analysis, which can arise from numerous sources. Introduction of a gold seed 
solution to the PEI coated IONPs post wash, led to the gold content rising forming a ratio 
of 2:3 for gold and iron concentrations respectively.  After the gold reduction step the gold 
content fell as the smooth outer shell was formed. This ultimately led to a ratio of 2:13 for 
the gold and iron concentrations levels respectively in the synthesised Au-IONPs. The 
sample for the gold reduction ICP-OES analysis came from a sample suspension that was 
diluted from 10 mL to 2 mL causing the Fe concentration to increase. Ultimately, the aim 
of the ICP-OES analysis, was to determine the ratio of iron and gold in a suspension of 
known volume.  
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3.3.2. HNP drug loading  
3.3.2.1. Drug loaded onto HNPs 
A calibration curve was generated via the analysis of known drug concentrations using HPLC 
connected to a UV detector at a lambda max of 268 nm for the detection of TTLD (Jaidev 
et al. 2015; Razzazan et al. 2016). Examples of Uv-Vis spectrums generated by HPLC analysis 
for TTLD and gemcitabine is shown in Figure 150 and 151 respectively (H. Song et al. 2014). 
 
Figure 150: Uv-Vis spectra generated by HPLC analysis of TTLD at 268 nm. 
 
Figure 151: Uv-Vis spectra generated by HPLC analysis of gemcitabine at 268 nm. 
The y-axis displays the absorbance at 268 nm over time (x-axis). With the use of HPLC, a 
calibration curve based on the area under the curve of the peak, at a retention time of 0.77 
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min for gemcitabine was plotted in Figure 152. This was performed in order to acquire the 
relationship equation between the peak area and drug concentration. The equation of this 
curve is: 𝑦 =  22702849.34𝑥 
 
Figure 152: Graph of the calibration curve for drug concentration against HPLC retention peak area. 
Drug loading of the HNPs was carried out in 5 mL of deionised water. The reaction mixture 
was washed once with another 5 mL of deionised water (1:2 v/v dilution). Based on the 
equation of the calibration curve (𝑦 =  22702849.34𝑥 + 𝑐), where c = 0, the concentration 
and therefore mass of the drug in the “wash solutions” was acquired. The amount of the 
leftover drug was used to ascertain the amount of drug loading that has occurred and the 
results are displayed in Table 10. 
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Table 10: The drug loading calculations for TTLD only and TTLD+PEG loaded HNPs. 
 TTLD 
Mass (mg) 
Calculated 
Intensity 
Dilution 
Factor 
Mass of TTLD 
remaining 
% Drug 
Loading 
TTLD without 
PEG-Thiol 
25 504423 2x 0.45 98 
TTLD with 
PEG-Thiol 
25 1526264 2x 1.4 94 
  
3.3.3. Drug release studies 
3.3.3.1. In vitro drug release at 20 °C 
Drug release at increasing temperature was carried out at pH 7 (water), 5.6 (cell media) 
and 7.4 (cell media). These three pH were chosen due to their biological and 
pharmaceutical relevance. Human blood has a pH of 7.4 and this environment is an 
important factor when attempting to mimic biological conditions (Ameri et al. 2016; C. M. 
Barnett et al. 2013). At a pH of 7 the TTLD+HNP formulation will be in neutral conditions to 
determine if drug release is pH sensitive. One of the processes involved in gemcitabines 
uptake is by receptor mediated endocytosis into endosomes. These early stage endosomes 
can release their contents and/or fuse together to form late stage endosomes where the 
interval pH ranges from 5-6. Therefore pH 5.6 was chosen to mimic the potential 
environment that the TTLD+HNP formulation would experience intracellularly. The same 
experimental procedures were used for the TTLD+PEG loaded HNPs. The graph in Figure 
153 shows the percentage release of detected Gem-Mal over time from the TTLD and 
TTLD+PEG loaded HNPs formulations, at 20°C and pH 7. 
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Figure 153: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 7 (water) and at 20°C (n=3, ±0.13 % and 
0.42 % respectively). No statistical difference observed between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-
PEG+HNP, nor any change over time (P < 0.05). 
The graph in Figure 153 for TTLD loaded and TTLD+PEG loaded HNPs, show no major Gem-
Mal release over the time period tested (P < 0.05). This indicates that the linker does not 
undergo retro Diels Alder breakdown at low temperatures over time, a physiological pH 
and that the formulation was still intact. The tiny amounts of Gem-Mal release observed in 
the PEGylated sample may be attributed to TTLD compounds that was not covalently 
bonded to the gold HNP surface but was instead entangled around the long chain PEG 
during drug loading, which became separated upon dialysis. Small amounts of TTLD 
approaching during drug loading may have been physically hindered from reaching the HNP 
surface.  
The graph in Figure 154 is of the TTLD and TTLD+PEG formulation release study at 20°C at 
pH 7.4 with cell media. Just like the graphical data of pH 7 (water) no major release was 
observed over the time period tested. 
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Figure 154: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 7.4 (cell media) and at 20°C (n=3, ±0.01 
% and 0.06 % respectively). No statistical difference observed between Gem-Mal from TTLD+HNP and Gem-Mal from 
TTLD-PEG+HNP, nor any change over time (P < 0.05). 
The graph in Figure 155 shows how the percentage Gem-Mal release changes over time 
when the pH is at 5.6 at 20 °C.  
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Figure 155: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 5.6 (cell media) and at 20°C (n=3, ±0.02 
% and 0.03 % respectively). No statistical difference observed between Gem-Mal from TTLD+HNP and Gem-Mal from 
TTLD-PEG+HNP, nor any change over time (P < 0.05). 
An initial burst release was observed with between 1 to 2 % of the Gem-Mal released within 
the first 1 min in the PEGylated and non-PEGylated formulations respectively is likely 
attributed to dislodged TTLD instead of surface attached TTLD and is not attributed to pH 
or temperature. Hence, it can be concluded that at 20 °C and at a pH of 5.6, no retro Diel-
Alder was taking place and that the linker remained intact with the gemcitabine remaining 
fully bound onto the HNP surface (P < 0.05).  
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3.3.3.2. In vitro drug release at 37 °C 
Subsequently, drug release was carried out at 37 °C in order to mimic what may happen at 
body temperature. These studies were carried out at varied pH (7, 7.4, & 5.6 as previously 
discussed). The graph in Figure 156 shows the Gem-Mal release over time of TTLD and 
TTLD+PEG loaded HNPs at 37°C at pH 7. 
 
 
Figure 156: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 7 (water) and at 37°C (n=3), ±0.35 % and 
0.78 % respectively). No statistical difference between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-PEG+HNP 
observed (P < 0.05). Every time point is statistically higher [*] compared to those at 20 °C (P < 0.05) (Figure 153). 
Both the TTLD and TTLD+PEG formulations show a direct correlation between % Gem-Mal 
release vs time. There is an initial burst release where 13 % and 14 % of the Gem-Mal 
released within 1 min for the TTLD and TTLD+PEG formulations respectively. The rate of 
release gradually decreases until a linear correlation is established beyond the 60 min time 
point. The only difference between the experimental variables for the graph in Figure 153 
with Figure 156 is the temperature. Overall at 37 °C the % Gem-Mal release increases over 
time for TTLD and TTLD+PEG loaded HNPs when compared to the formulation at 20 °C 
where no release takes place (P < 0.05). Therefore this 13-14 % burst release is an effect of 
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temperature only. It is worth noting that the amount of Gem-Mal released from the 
TTLD+PEG is about 2.5 % “released” higher than with just TTLD. This again may be due to 
the entangling effect mentioned earlier as there is no statistical significance between both 
sets of data (P < 0.05). 
The same parameters for Figure 157 were repeated with the difference being the use of 
cell media at a pH of 7.4 instead of water at a pH of 7. 
 
Figure 157: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 7.4 (cell media) and at 37 °C (n=3), ±0.13 
% and 0.22 % respectively). No statistical difference between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-
PEG+HNP observed (P < 0.05). Every time point is statistically higher [*] compared to those at 20 °C (P < 0.05) (Figure 
154). 
The initial burst release of Gem-Mal at pH 7.4 in 37 °C cell media is 13 % and 14 % 
respectively for TTLD and TTLD+PEG loaded HNPs, which is also the outcome in water at 
pH 7 at 37 °C. These results show that the slightly more alkaline blood pH of 7.4 will not 
affect the % release of Gem-Mal.  
The graph below in Figure 158 is based on the same experimental conditions as those used 
in Figure 157, but the pH is at 5.6 and the bulk solution is cell media. 
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Figure 158: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 5.6 (cell media) and at 37°C (n=3, ±0.57 
% and 1.03 % respectively). No statistical difference between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-
PEG+HNP observed (P < 0.05). Every time point is statistically higher [*] compared to those at 20 °C (P < 0.05) (Figure 
153). 
The initial burst % release of Gem-Mal at pH 5.6 is 14 % for TTLD and 15 % for TTLD+PEG at 
pH 5.6 (cell media). This is an average difference of 1 % release compared to pH 7 (water). 
The decrease in pH from 7 to 5.6, coupled with the presence of PEG may be the cause for 
this 1 % difference in initial burst % Gem-Mal release, when comparing the pH 5.6 and 7 
release data with only TTLD HNPs at 37 °C (P < 0.05) There is no statistical difference 
between pH 5.6 and 7 for TTLD+PEG loaded HNPs at 37 °C (P < 0.05). After 5 days of heating 
the percentage release is 29 % for the TTLD+PEG at pH 5.6 formulation which is 3 % higher 
than in water (pH 7). With the effects of cell media ruled out, it can be concluded that at a 
pH of 5.6 there is a tiny effect on the percentage Gem-Mal release with an elevated 
temperature still being the major contributing factor.  
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3.3.3.3. In vitro Gem-Mal release at 44 °C 
The Gem-Mal release was analysed at 44 °C, this temperature was used to mimic the 
temperature of HNPs after laser irradiation. These studies were carried out at varied pH (7, 
7.4, & 5.6 as previously discussed). The graph in Figure 159 demonstrates the rapid release 
of Gem-Mal from the HNPs surface when heated to 44°C at pH 7. 
 
Figure 159: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 7 (water) at 44°C (n=3, ±1.55 % and 1.49 
% respectively). No statistical difference between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-PEG+HNP 
observed (P < 0.05). Every time point is statistically higher [*] compared to those at 20 °C (P < 0.05) (Figure 159). 
The TTLD+HNP formulation released 80 % of the Gem-Mal within 1 min while the 
TTLD+PEG+HNP released 82 % in the same time frame at 44 °C. Within 60 min over 99 % of 
the Gem-Mal in both formulations had released. The graph in Figure 160 expanded for the 
first 60 mins of this experiment displays this clearer. The TTLD+PEG remains 2-3 % higher 
in percentage released initially indicating that the difference between TTLD and TTLD+PEG 
is based on non-surface attached TTLD instantly unhooking from surface TTLD and PEG. If 
all non-surface attached TTLD was removed (with a more vigorous wash after drug loading) 
then it is likely the difference between percentage drug release from TTLD and TTLD+PEG 
formulations would be zero or too negligible to detect. At 44 °C the effect of temperature 
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is so high that it renders the marginal 2-3 % initial release between TTLD and TTLD+PEG 
formulations and overall percentage release/time trend statistically negligible (P < 0.05). 
 
Figure 160: Graph of TTLD and TTLD+PEG loaded HNPs release over 60 min at pH 7 (water) at 44°C (n=3, ±1.55 % and 
1.49 % respectively). No statistical difference between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-PEG+HNP 
observed (P < 0.05). Every time point is statistically higher [*] compared to those at 20 °C (P < 0.05) (Figure 153). 
At a pH of 7.4 at 44 °C in Figure 161 the percentage release of Gem-Mal over time is very 
similar to pH 7 with TTLD and TTLD+PEG formulations (P < 0.05). The initial burst 
percentage release of 80 % is the same as pH 7 for TTLD and 82 % for TTLD+PEG 
formulations. TTLD+PEG also required 60 min of heating to reach 99 % TTLD release but the 
TTLD only formulation required 24 h. Note that the point at which 99 % release was 
achieved would have been between 4 h and 24 h. Either way both the TTLD and TTLD+PEG 
formulations have negligible differences in their release rate and show a rapid rate of 
release approaching 100 % within minutes. 
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Figure 161: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 7.4 (cell media) at 44°C (n=3, ±1.59 % 
and 0.77 % respectively). No statistical difference between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-
PEG+HNP observed (P < 0.05). Every time point is statistically higher [*] compared to those at 20 °C (P < 0.05) (Figure 
151). 
At a pH of 5.6 shown in Figure 162 the initial burst percentage release of Gem-Mal is 1 % 
higher than TTLD+PEG when compared to pH 7 and the percentage released reached 99 % 
within 15 min compared to the 60 min it took at pH 7. Even with these tiny differences the 
effect of pH is negligible at a temperature of 44 °C (P < 0.05). 
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Figure 162: Graph of TTLD and TTLD+PEG loaded HNPs release over 96 h at pH 5.6 (cell media) at 44°C (n=3, ±1.84 % 
and 0.96 % respectively). No statistical difference between Gem-Mal from TTLD+HNP and Gem-Mal from TTLD-
PEG+HNP observed (P < 0.05). Every time point is statistically higher [*] compared to those at 20 °C (P < 0.05) (Figure 
152). 
These findings indicate that temperature is the major factor which influences the induction 
of retro Diels-Alder and hence liberation of Gem-Mal molecules. Hence, these systems have 
potential as thermally triggered drug delivery vehicles. 
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3.3.4. Stability determination of TTLD+HNP formulations 
The stability of the TTLD+HNP formulation was observed by storing it as a suspension at 5 
°C and 20 °C over a 4 week period. The amount of Gem-Mal detected as a function of drug 
release during storage conditions is displayed graphically in Figure 163. 
 
Figure 163: Graph of the release of TTLD over four weeks at 5 °C and 20 °C. No statistical significance was observed 
between 5 °C and 20 °C nor over time (P < 0.05). 
The graphical data presented in Figure 163 does not indicate any trend between the 
percentage release of Gem-Mal and time for the TTLD+HNP formulation at 20 °C. There is 
some release shown which ranges from 0.33 % to 0.36 % but these do not follow a time 
dependant trend. Similar results occur at a storage temperature of 5°C. There is no 
statistical difference between the percentage release of Gem-Mal at 5°C or 20°C (p <= 
0.01). The experimental observations at 20°C are akin to those of 5°C where the size of the 
errors for each average weekly results is higher than the overall range of percentage 
release results over the four week experiment. Hence, it can be deduced that storage of 
the HNP-gemcitabine formulations would result in stable systems over a 4 week period. 
Obviously prolonged studies are required in order to estimate the realistic shelf life of these 
systems over longer time periods, as well as studies at higher and sub zero temperatures. 
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3.4. Discussion 
The synthesis of the HNPs was deduced to be successful from all the characterisation 
carried out. The results indicated the final HNPs to be composed of 1.82 mg mL-1 Fe and 
11.89 mg mL-1 Au giving a ratio of Fe:Au 13:2.   
Reports on the fabrication of HNPs have described a Fe:Au ratio of 3:1 (Hoskins, Yue Min, 
Gueorguieva, et al. 2012).  In our study, the Fe:Au ratio was 13:2. Our iron oxide cores 
produced 150 nm nanoparticles. In the literature the iron oxide produced was 30 nm in 
diameter. Therefore with a higher surface area to volume ratio, more gold seeds can attach 
to the smaller reported 30 nm iron oxide cores and subsequently more gold is present after 
the coating step. Additionally, the gold coating thickness may have influenced the overall 
gold composition, a comparison between the two studies cannot be made due to lack of 
published information. Nevertheless, for this study the TEM images confirmed that 
complete gold coating had occurred and that the synthesis of HNPs had been successful. 
HPLC confirmed that the gemcitabine analogue was successfully conjugated onto the HNP 
surface. The 98 % and 96 % drug loading of TTLD and TTLD+PEG respectively indicates that 
the HNP surface was not completely saturated and that more drug loading may have been 
achievable at a higher drug feed : particle ratio. Therefore these HNPs may be capable of 
carrying more than 5 mg TTLD per 1 mg HNPs. However, this was not investigated.  
The aim of this study was to develop a system which acted in a stimuli responsive manner 
and released Gem-Mal molecules upon external trigger. In this instance upon heat. Hence 
the effect of temperature on Gem-Mal release was observed over varied pH which 
mimicked biological conditions. 
At 20 °C there was a negligible change in release across the three mentioned pH values. At 
a temperature of 37 °C and 44 °C there is a definite increase in percentage release of Gem-
Mal as seen in the graph in Figure 164.  
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Figure 164: Comparative graph of all TTLD and TTLD+PEG formulations at 20, 37 and 44 °C, at a pH of 7 (water) over 60 
min. Standard deviation of TTLD+HNP at 20 °C, 37 °C and 44 °C was 0.13 %, 0.35 % and  1.55 % respectively. Standard 
deviation of TTLD-PEG+HNP at 20 °C, 37 °C and 44 °C was 0.42 %, 0.78 % and 1.49 % respectively.  Statistically significant 
data points for temperature mediated release is denoted with * and for 37 °C and 44 °C respectively when 
compared to 20 °C.
The initial burst release experienced at 37 °C and 44 °C must be temperature dependant 
due to the significant difference in percentage Gem-Mal release after 1 min of heating. This 
burst release behaviour is extremely beneficial for clinical use at 44 °C as it ensures the 
majority of the dose is released within minutes intracellularly. This prevents lengthy 
chemotherapeutic sessions often experienced by pancreatic cancer patients who will 
receive a therapeutic dose intracellularly without the systemic side effects. Overall this 
thermal responsive formulation is already displaying attributes that highlight its potential 
as a future first line treatment for pancreatic cancer. It also enables patients who are not 
able to be administered gemcitabine intravenously the opportunity to receive treatment 
intratumorally.   
While a burst release is experienced at 37 °C, it is less significant (14 %) compared to the 
80 % at 44 °C. This is a crucial factor as it prevents the sudden release of Gem-Mal before 
target laser irradiation. If this was to occur, then healthy cells surrounding the tumour site 
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would also experience the cytotoxic effects of the Gem-Mal compounds. Another 
advantage of a significantly lower percentage release at 37 °C is that the remaining TTLD is 
still attached to the HNP allowing them to enter the cancer cells before being released. 
Therefore it stands to reason that roughly 15 % of the dose is lost while the remaining 85 
% of the formulation is able to enter the cell intracellularly. The TTLD that is prematurely 
released at 37 °C may still have cytotoxic activity like gemcitabine due to their structural 
similarities and in vitro experiments later on in this study will highlight the pharmaceutical 
activity of Gem-Mal against gemcitabine.  
The lack of Gem-Mal release at room temperature (20 °C) is a good indicator of this 
formulations physical stability in storage conditions. Drug formulations should typically be 
inactive until introduction into the recipient occurs. This ensures that once the formulation 
has been packaged and stored, it no longer requires analytical testing and should remain 
effective and unchanged, throughout its shelf life.  
Thermal responsive drug delivery systems for the transport and release of gemcitabine is 
already an established advancement in nanotechnology. However the mode of transport, 
mechanism of release and overall performance of such systems varies considerably. The 
use of magnetoliposomes to encapsulate gemcitabine has been shown to only have a stable 
lifespan of 4 days determined by dynamic light scattering, before aggregation and drug 
release occurs (Ferreira et al. 2016). This formulation is called gem-ML and this is a much 
shorter potential shelf life than the 4+ weeks of high stability shown for the TTLD+HNP in 
section 3.3.4. This means that clinically, gem-ML would have to be produced in situ prior to 
administration. Both TTLD+HNP and gem-ML formulations have been shown to reach the 
target temperature of 44 °C in order to induce hyperthermia in pancreatic cancer cells. As 
stated previously, the method of reaching this temperature for TTLD+HNP is with the use 
of SPR triggered by infra-red exposure. Gem-ML utilises iron oxide nanoparticles which 
have been encapsulated alongside gemcitabine into liposomes. These iron oxide 
nanoparticles will generate external heat when exposed to an alternating magnetic field 
allowing the formulation to be heated to 56 °C (Ferreira et al. 2016).  
The difference between the core body temperature (37 °C) and the desired therapeutic 
temperature of 44 °C is only 7 °C. The aim of a thermal responsive drug delivery system is 
to have a strong activity at 44 °C with a considerably lower activity at 37 °C which proved 
181 
 
to be a difficult criteria to complete when designing and synthesizing a thermally labile 
linker. Gem-ML has been reported to only release 17 % of its contents after 72 hr at 37 °C 
compared to the 23 % release shown for the TTLD+HNP formulation, a difference of 5 %. 
However virtually 100 % of the HNPs would have surface attached TTLD compared to only 
54 % of gem-ML encapsulation. Magnetoliposomes without encapsulated gemcitabine was 
shown to have cytotoxic effects bringing the percentage cell viability down to 60 % after 72 
hr during incubation at 37 °C. The authors state that this is unlikely due to the inherent 
cytotoxic effects of iron oxide nanoparticles and more to do with the liposomes (Ferreira 
et al. 2016). The in vitro experimental results shown later on in this study for TTLD+HNP 
will be compared to those of gem-ML to fully compare the two.  
Another thermally sensitive drug delivery system for gemcitabine, is a liposome called HaT-
GEM, which was shown to achieve a 100 % release of its cargo at 41 °C over 2 min, with no 
detectable release occurring at 37 °C (May et al. 2013). While this is an impressive display 
of thermal stability at core body temperature, its rapid release also occurs at 39 °C where 
80 % of the encapsulated gemcitabine is release after 30 min (20 % after 2 min). As this 
formulation is administered intravenously rather than intratumourally with TTLD+HNP, any 
clinical patient with fever would be at risk of rapid systemic release of gemcitabine from 
this formulation. At best this would render its antitumor activity inert and in some cases 
cause serious side effects. However, intravenous treatment compared with intratumour 
has obvious benefits such as lack of requirement for minimally invasive surgery, infection 
risk etc. 
GEM-TSLnps, another liposome based drug delivery system for gemcitabine, released 25 % 
of its gemcitabine cargo at 37 °C after 10 mins, which is a significantly shorter release time 
compared to TTLD+HNP which required 60 mins to release a similar amount. Also, the 
amount of gemcitabine release from the GEM-TSLnps formulation seems to stabilise 
between 42 °C to 52 °C at 60 % release compared to the 100 % release after 30 mins for 
the TTLD+HNP formulation at 44 °C. This shows that TTLD+HNP proves superior in both 
stability at core body temperature and rapid drug release at the target therapeutic 
temperature of 44 °C. 
GEM-TSLnps, HaT-GEM and gem-ML are the most noteworthy known thermally sensitive 
drug delivery systems for gemcitabine and they are all liposome based. These all suffer 
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from inefficient encapsulation levels, poor long term stability and either poor stability at 
37 °C and/or lower rapid release profiles at 44 °C. This is due to the physical requirement 
of the liposomes to encapsulate their cargo and physically morph their structure at 44 °C 
in order to allow their cargo to escape. TTLD+HNP is a metallic nanoparticle based drug 
delivery system which achieved a near 100 % loading of 5 mg of a gemcitabine analogue 
(TTLD) per 1 mg of HNPs as well as a similar loading efficiency when TTLD was 
simultaneously loaded onto the HNP gold surface alongside PEG-Thiol. Attachment of TTLD 
and PEG-Thiol is achieved chemically rather than with physical encapsulation leading to a 
uniform and stronger interaction between the carriers (HNPs) and their cargo (TTLD). The 
release is also a chemical process that does not occur at physiological pHs of 5.6 and pH 7.4 
as well as pH 7. Mode of release is purely temperature dependant in a biological setting 
where the thermal stability remains higher than most mentioned liposome based systems 
at 37 °C but has a superior rapid release profile at 44 °C.  
There are no indications of a metallic nanoparticle delivery system for the transport and 
thermal release of gemcitabine in literature to date which suggests that TTLD+HNP is a first 
of its kind as a metallic based thermal sensitive drug delivery system for gemcitabine, as 
well as one that utilizes chemical reactions rather than physical changes to elicit 
temperature dependant drug release. 
Studies have already shown that laser irradiation of HNPs will achieve temperatures of 44 
°C which further highlights the potential of HNPs with surface modified Diels Alder 
cycloadducts as drug carriers and facilitators of thermally driven drug release (Curtis et al. 
2015). Here, the effect of pH on the TTLD+HNPs formulation was minimal between a pH of 
7.4 and 5.6. This finding indicates that no matter what location the nanoparticulate 
formulation is in i.e. Intracellular location, which drug release will only occur after thermal 
rise. Hence a truly triggered release system has been developed.    
The stability of the TTLD+HNP formulations was observed and the results show us that at 
typical storage temperatures of clinical medicines (room temp/cupboards and 
refrigeration) the TTLD+HNP formulations remained stable over four weeks with no 
observable trend in percentage release. At 20 °C the percentage release is roughly 0.31 %. 
This differs to the 0.69 % to 0.9 % release observed in the dialysis release studies. However 
this is not significant (p>0.05). 
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Previous retro Diels Alder experimental data shown in Figure 132 as well as dialysis release 
studies in Figures 153-155 at 20 °C both showed that TTLD remains stable over several days. 
However the medium term stability of the TTLD+HNP formulation which will be indicative 
of the potential shelf life needed to be ascertained. Medicinal formulations are often 
refrigerated or stored away from sunlight within cupboards at room temperature. This is 
to ensure that the composition of the formulation doesn’t change over time. Changes can 
include the degradation of excipients or modification of the active pharmaceutical 
ingredient, which can reduce the potency of the drug (Qun Gao et al. 2014). In the case of 
thermally triggered systems the storage temperature is particularly relevant. 
The TTLD+HNP formulations remained stable over four weeks with no observable trend in 
percentage release. At 20 °C the percentage release is roughly 0.31 %. This differs to the 
0.69 % to 0.9 % release observed in the dialysis release studies.  
3.5. Conclusion 
The production of HNPs and their subsequent surface modification with TTLD and/or 
TTLD+PEG has been successful. The rate of Gem-Mal release from these formulations at 
various pHs and temperatures have yielded clinically promising results. The next stage of 
this study will be the observation of uptake and subsequent effects of the cell proliferation 
of pancreatic cancer cells.  
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CHAPTER 4: DRUG UPTAKE AND CELL VIABILITY 
STUDIES OF HYBRID NANOPARTICLE 
FORMULATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
185 
 
4.0. Introduction 
The ultimate goal of a pharmaceutical research and development study is to prove the 
effectiveness and safe use of novel treatments on patients (Lemke 2008). Human testing 
of unknown compounds and formulations would be extremely dangerous and highly 
unethical without some evidence of safety and efficacy before administration. Therefore 
drug discovery paths often originate with the chemical study of the desired drugs 
behaviour, followed by its activity in different simulated biological conditions, in vitro 
activity in cellular environments and finally in vivo animal testing (Lemke 2008; Pathania et 
al. 2014; Megha et al. 2015). Drug compounds and formulations that pass through these 
preclinical pathways with clear evidence of benefit are then eligible for human testing 
before they can be made available for clinical use. The in vitro phase of preclinical screening 
is important as it involves the use of living cells or tissues to evaluate the pharmacological 
activity of novel drug formulations (Aulton 2007). 
Biological systems are a collection of complicated chemical systems and 
microenvironments which can have an effect on active ingredients and their constituents. 
Therefore novel drug formulations have to be observed in chemical environments which 
can mimic these physiological conditions (Wijdeven et al. 2014; de la Escosura et al. 2015). 
These environments can include the various biological pHs such as blood and the gastro 
intestinal tract (Lemke 2008; Aulton 2007). These are often tested individually to fully 
understand their effects on the drug formulation being tested without the interference of 
other chemical variables, such as testing a novel drug in a series of biological pHs without 
changing the temperature, concentration etc. 
One critical step in this transition from chemical interactions to biological ones is the in 
vitro testing of novel drug formulations. This involves the growth of human cells outside 
the body which are then exposed to the drug formulations in different conditions to 
determine their effects (Lemke 2008). Like with the chemical testing performed prior, the 
advantage of in vitro testing is that the cells are isolated away from other biological effects 
that would be present in vivo allowing the focus of the interactions to take intracellularly 
(Vinken & Blaauboer 2016; Aulton 2007). Lastly, there has been a growing worldwide move 
away from animal testing with bans taking place for certain groups of chemicals such as 
cosmetics research in the EU (Vinardell 2015). The general consensus though is that in vivo 
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experiments are crucial in ensuring the safety of humans inoculated with unproven 
chemicals for clinical use only when suitable in vitro testing is not available (Garattini & 
Grignaschi 2016; Vinardell 2015).  As a form of compromise, the expanded use of in vitro 
experiments on a wider range of variables should reduce the amount of in vivo experiments 
needed (Vinardell 2015). Overall, the application of in vitro testing is a key and invaluable 
step in the evaluation of new drug entities for clinical use (Vinken & Blaauboer 2016).  
This studys overall aim is to evaluate the in vitro effects of Gem-Mal, +HNP and the HNPs 
alone against gemcitabine and experimental controls in order to observe their effects. The 
desired clinical effect of the TTLD+HNP formulation is the reduction of cell viability of 
pancreatic cancer cells. Therefore the percentage cell viability will be used as an indicator 
of the effectiveness of these drug and HNP compounds. Cell viability is the term used to 
describe the ability of cells to maintain and grow their population, to basically remain 
viable. The percentage cell viability is the amount of cells that remain viable in an altered 
environment (such as after exposure to a cytotoxic drug) compared to the cell viability from 
a population of cells in optimal growth conditions (Bandele et al. 2012; Weyermann et al. 
2005; Yang et al. 2002). The percentage cell viability changes were determined with the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and trypan blue 
exclusion assay.  
Pancreatic cancer has an absolute 5 year survival rate of 3.7 %. This means that after the 
disease is first diagnosed the patient has a 3.7 % chance of surviving after 5 years (Liu et al. 
2012b; Yuqing Zhang et al. 2013c; Tran et al. 2013b). This particularly deadly type of cancer 
has the worst prognosis of all cancer types (Yuqing Zhang et al. 2013c; Al Shemaili et al. 
2014). It is the 5th most common cause of cancer death in the UK accounting for 2.6 % of 
all cancer cases but 5.2 % of all cancer related deaths (Maraveyas et al. 2012).  
It is administered intravenously over a course of 30 mins slowly to prevent localised toxicity 
at the administration site (Pliarchopoulou & Pectasides 2009). It has a short half-life of 8-
17 mins and a large portion of the dose is metabolised in the liver which leads to high dose 
requirements in order to attain a therapeutic response (Griffith & Jarvis 1996). Some 
patients do not experience a therapeutic effect after gemcitabine administration which has 
led to its reported effectiveness in only 23.8 % of all who receive it (Burris et al. 1997; 
Hoskins et al. 2010). The side effects associated with gemcitabine administration are 
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numerous and often serious especially with its hepatoxicity and renal toxicity effects. These 
side effects often prevent pancreatic cancer patients from continuing their chemotherapy. 
Hybrid nanoparticles (HNPs) can be utilised for improving the chemotherapeutic treatment 
of pancreatic cancer. They can aid in the faster uptake and intracellular accumulation of 
their drug cargo and facilitate their heat triggered release in a controlled manner by 
exploiting the surface plasmon resonance properties from the gold coating of the HNPs. 
They can also be used to visually map the presence of drug-HNP formulations due to their 
iron oxide cores acting as MRI contrasting agents.   
4.0.1. MTT assay 
The MTT assay utilises colourimetry to indicate the metabolic activity of cells after exposure 
to an introduced substance. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) is a yellow soluble dye that is enzymatically metabolised (reduced) into insoluble 
purple formazan crystals intracellularly. This is carried out by mitochondrial reductase 
within the mitochondria and within endosomes with other reducing enzymes like NADH 
reductase (Bernas & Dobrucki 2002; Lü et al. 2012). This means that after MTT is added, 
the cells have to be left to incubate for a few hours before analysis can occur (Riss et al. 
2004). The addition of DMSO will dissolve these formazan crystals producing a purple 
solution. The intensity of this solution is dependent on the amount of formazan present 
and is therefore indicative of the metabolic activity of the cells. Dead cells cannot 
metabolize MTT so the MTT assay can be used to discern the population of alive cells only 
(Huyck et al. 2012). The MTT assay is run with the use of controls that form the benchmark 
intensity where experimental variables can be based off. The MTT assay is a standard assay 
which is used for almost all cell viability studies as a starting point. Colourimetry is an 
analytical technique used to determine the concentration of a coloured substance within a 
solution (Riss et al. 2004). For example, the MTT assay of gemcitabine inoculated BxPC-3 
cells shown in Figure 165. Note the two control columns on the left have the deepest shade 
of purple and all other well intensities would be compared against them as an indicator of 
percentage cell viability with the assumption that the controls have 100 percentage cell 
viability.  
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Figure 165: Photo of a 96-well plate after MTT incubation and DMSO addition with the first two columns being the 
positive control. 
The plate in Figure 165 would be read on a plate reader where the absorbance would be 
determined for each well. 
4.0.2. Trypan blue exclusion and cell counting 
The trypan blue exclusion assay is a cell counting technique that can calculate the 
population of living and dead cells within a sample. It is based on the premise that trypan 
blue cannot enter living cells due to their structural integrity but it may enter cells which 
have already or are undergoing apoptosis/necrosis (Strober 2001). Once staining has 
occurred, the number of cells within a sample is determined. The dye free cells are 
considered viable and the dead cells will have a blue appearance from the trypan blue 
staining (Strober 2001). Basic cell counting techniques involve placing a diluted sample of 
the cells onto a specialised microscope slide called a haemocytometer which were 
historically used for blood cell counts but can be used for other cell types (Brito et al. 2016). 
These have a grid pattern where each section is a specific area and therefore volume. The 
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average number of cells within each grid is related to the overall cell population of the cell 
stock once dilution factors are incorporated into calculations (Brito et al. 2016). Modern 
automated haemocytometers can use microscopic images of a region from a microscope 
slide to determine the cell population using recognition software that automatically detects 
living and dead cells within a sample region (Grishagin 2015; Han et al. n.d.). 
4.0.3. Drug uptake and centrifugation 
The drug uptake rate of gemcitabine, Gem-Mal and the TTLD+HNP formulation is important 
to determine the effectiveness of the HNPs as a drug delivery vehicle (Fang et al. 2015). 
The cytotoxic activity of gemcitabine and Gem-Mal occurs intracellularly so any initial 
biological assays such as the trypan blue exclusion or MTT may not take into consideration 
whether an equal amount of each substance is present within the cells (Song et al. 2016b). 
For example, gemcitabine may be inherently more cytotoxic than Gem-Mal but have a 
lower uptake rate. In order to analyse the drug uptake rate of these substances, cultures 
of human pancreatic adenocarcinoma BxPC-3 cells will first have to be grown then dosed. 
After enough time has taken place for drug uptake to occur, the extracellular environment 
was purged of gemcitabine, Gem-Mal or TTLD+HNP by washing the wells with PBS. The cells 
are then counted and a volume of suspended cells of known cell population is taken for 
analysis. This will be done with centrifugation which is a technique used for separating the 
components of a mixture with centripetal forces (Zubrick 1997). This causes larger 
components to settle first causing sedimentation of the mixture contents. Only 
components soluble in the supernatant (the surface liquid layer) will be present there. 
Gem-Mal and gemcitabine are water soluble and will be present in the supernatant while 
the destroyed cells which burst due to osmotic pressure, and their organelles will settle at 
the bottom. The supernatant can then be removed and analysed with HPLC to acquire the 
gemcitabine or Gem-Mal concentration.  
4.1. Aims and objectives 
The aim of the in vitro studies is to observe the effects of Gem-Mal, the HNPs alone and 
the TTLD+HNP formulation against controls and gemcitabine on the percentage cell 
viability of BxPC-3 cells. The drug uptake rates of each substance mentioned will be 
190 
 
determined as well in order to ascertain the effectiveness of the HNPs to facilitate the 
uptake of Gem-Mal.  
4.2. Materials and methods 
4.2.1 Materials used 
Material Supplier 
BxPC3 Cells LGC Standards, ATCC (USA) 
RPMI Media Fisher Scientific (UK) 
Gemcitabine Fluorochem (UK) 
Cell Culture Flask Fisher Scientific (UK) 
96-Well Plates Fisher Scientific (UK) 
12-Well Plates Fisher Scientific (UK) 
6- Well Plates Fisher Scientific (UK) 
Dulbecco’s Phosphate Buffered Saline Sigma Aldrich (UK) 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
 
Sigma Aldrich (UK) 
 
Dimethylsulfoxide Fisher Scientific (UK) 
Trypan Blue Stain 0.4 %  Life Technologies (UK) 
Trypsin-EDTA Life Technologies (UK) 
Eppendorf Tubes Fisher Scientific (UK) 
Cell Counting Slides Life Technologies (UK) 
Streptomycin Penicillin  Life Technologies (UK) 
Foetal Bovine Serum Life Technologies (UK) 
Glutaraldehyde Sigma Aldrich (UK) 
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4.2.2. Methods 
4.2.2.1. Preparation of Bx-PC3 cell cultures 
All in vitro experiments and results discussed in this study were carried out using the BxPC-
3 cells. Well plate cell cultures were produced by seeding BxPC-3 cells in their exponential 
growth phase and allowing them to incubate overnight at 37 °C within a 5 % CO2 
atmosphere in RPMI-1640 media supplemented with a 1 % streptomycin penicillin and 5 % 
foetal bovine serum (Fang et al. 2015).  
4.2.2.2. Preparation of excipient solutions and well plate dosing 
Throughout the in vitro studies, eight different concentrations of substances were used to 
monitor their effects on BxPC-3 cell populations over time. Preparation of these 
concentrations is shown in Table 11. Each Aliquot was taken from 20 mg mL-1 stock 
solutions of either gemcitabine, Gem-Mal, TTLD+HNP or HNPs alone. The amount of Gem-
Mal used in these solutions was calculated based on the mass of gemcitabine within Gem-
Mal. With Gem-Mal being roughly twice the mass of gemcitabine, then a stated 0.1 mg mL-
1 of Gem-Mal would actually be 0.2 mg mL-1 of Gem-Mal. This ensures that their cytotoxicity 
comparisons are based on gemcitabine. The TTLD+HNP stock solution was calculated based 
on the gemcitabine content of TTLD (5 mg per 1 mg HNPs) and the HNP stock solution was 
based on the iron content on the HNP’s derived by ICP-OES. 
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Table 11: Preparation of Excipient Solutions for BxPC-3 dosing. 
Concentration 
(mg mL-1) 
Stock Aliquot 
(mL) 
Total Volume 
(mL) 
0.1 22.5 4.5 
0.05 11.5 4.5 
0.025 5.6 4.5 
0.01 2.25 4.5 
0.005 1.125 4.5 
0.001* 90 4.5 
0.0001* 9 4.5 
0.00001* 1 4.5 
* Aliquot was taken from 0.05 mg mL-1 solution. 
4.2.3. MTT assay procedure 
A 96-well plate was seeded with 15,000 of BxPC3 cells/well which were previously 
suspended in media. These were incubated inside an ESCO CelCulture CO2 Incubator for 24 
h at 37 °C in a 5 % CO2 environment to allow the suspended BxPC3 cells to attach to the 
well surfaces. The media was removed and the well plates were dosed in a format 
illustrated in Figure 166.  
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Figure 166: Diagram of the 96-well plate assembly for the MTT assay of gemcitabine dosed BxPC-3 cells setup. 
The 96-well plate was incubated for 24 h at 5 % CO2. Following this, the media and PBS was 
removed and replaced with a 175 μL solution of 10 % MTT in media. The plate is then 
incubated for 4 h to allow the uptake of MTT into the BxPC3 cells. Afterwards, the media 
was removed and the wells were washed three times with PBS to ensure no gemcitabine 
remained. After this wash step, 175 μL of DMSO was added causing the well plate wells to 
rapidly change colour to variable shades of purple due to the dissolution of the purple 
formazan crystals  (Gaudin et al. 2016). The 96-well plate was then analysed by a Tecan 
Infinite M200 Pro Microplate Reader at 570 nm and the percentage cell viability was 
calculated as an intensity percentage of the control wells values. This method was repeated 
two more times on two other 96-well plates to form a triplicate set of results. Two other 
triplicate sets of experiments were carried out at the 48 h and 72 h time point after 
gemcitabine addition. This led to a total of 9 individual 96-well plates for the MTT 
gemcitabine study. Another two studies using the same procedure as the MTT gemcitabine 
study were carried out for Gem-Mal and TTLD+HNP.  
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4.2.3.1. Trypan blue exclusion assay procedure 
The trypan blue exclusion method was used to monitor the change in population over time 
of BxPC3 cells after dosing with gemcitabine, Gem-Mal, TTLD+HNP and the HNP’s alone and 
to determine each substances IC50. The trypan blue procedure for gemcitabine was carried 
out by first seeding a 12-well plate with 0.5 mL of 25,000 cells/well BxPC3 cells which were 
previously suspended in media. The plate was incubated for 24 h at 37 °C in a 5 % CO2 
atmosphere to allow the cells to adhere to the well plate surfaces. The media was removed 
and the BxPC-3 cells dosed with gemcitabine in the same format as shown in Figure 167. 
The 12-well plate was incubated for 24 h before the well plates were washed three times 
with PBS to remove trace gemcitabine. Following this, 75 μL of trypsin and the cells were 
briefly incubated before they were suspended in 0.5 mL of media (Banerjee et al. 2013). 
 
Figure 167: Diagram of the 12-well plate assembly for the trypan blue exclusion assay of gemcitabine dosed BxPC-3 cells 
setup. 
The analysis of each well plate of suspended BxPC3 cells occurred as follows: Into a fresh 
eppendorf tube was added 75 μL of a 0.4 % trypan blue solution, followed a 75 μL aliquot 
of a cell suspension. The 150 μL dyed suspension was briefly shaken and a 10 μL aliquot 
was removed from the eppendorf tube and pipetted into a Countess Invitrogen cell 
counting chamber slide. The cells were counted using a Countess Invitrogen Automated 
Cell Counter and the live cell counts were compared to those of the control well plate cell 
populations to produce a percentage cell viability value for each sample concentration. This 
was repeated to form a set of 12-well plate triplicates for gemcitabine. 
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4.2.3.2. Intracellular drug uptake  
In order to determine the rate of drug uptake over time of gemcitabine, Gem-Mal, 
TTLD+HNP and HNPs alone, BxPC3 cells which had been previously seeded and incubated 
at 37 °C in a 5 % CO2 atmosphere for 24 h. They were then dosed with 3 mL of a 0.05 mg 
mL-1 solution of gemcitabine, Gem-Mal, TTLD+HNP or HNPs alone in media in 6-well plates 
(50,000 cells/well) where each well was dosed with only one of the mentioned four 
substances with a 5th well used as the control. The 6-well plate setup is illustrated below in 
Figure 168.  
 
Figure 168: Diagram of the 6-well plate assembly for the drug uptake study for gemcitabine, Gem-Mal, TTLD+HNP and 
HNP only dosed BxPC-3 cells setup. 
The BxPC-3 cells were incubated for 1 h to allow the uptake of the various substances to 
occur. Following this, the cell media was removed and the wells were washed three times 
with PBS to ensure the removal of trace amounts of the substances. The cells were 
suspended with 185 µL of trypsin before 815 µL of the media was added. The cells were 
then counted with a trypan blue assay to determine the amount of live cells per mL. An 
aliquot of each well plate equivalent to 100000 cells was acquired and placed into an 
Eppendorf tube. Deionised water was then added until the total volume of each tube was 
1 mL. The presence of deionised water causes rupture of the cell membrane due to an 
osmotic imbalance caused by the hypotonic environment which releases the contents of 
the cells into the surrounding solvent. Centrifugation of this solution in a Hermule Z-323 
centrifuge at 500 rpm for 5 min, drives the cell fragments to the bottom of the Eppendorf 
tube. The supernatant was removed and analysed via HPLC with a Pinnacle DB C18 reverse 
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phase column at 268 nm in a Perkin Elmer Flexar LC Autosampler with a flow rate of 1 mL 
min-1 (1:1 v/v water:acetonitrile) where a sample injection volume of 10 μL was used. The 
observed HPLC intensities were converted to concentrations with the calibration curve 
"𝑦 =  22702849.34𝑥" where y is the intensity and x is the concentration in mg mL-1. Each 
resulted calculated concentration was divided by 100000 to acquire the amount of 
gemcitabine per cell. This procedure was repeated two more times to generate a triplicate 
set of results for the uptake of gemcitabine in the unbound form, as unbound Gem-Mal, as 
released Gem-Mal and from the HNP’s alone without any surface attachments after 1 h. 
This procedure was repeated again in triplicate at the 4 h and 24 h mark.  
4.2.3.3. Effect of heat on cell viability  
In a clinical setting, the TTLD+HNP formulation would release its Gem-Mal cargo after 
exposure to laser irradiation resulting in a localised elevated temperature. Previously we 
have shown that this release occurs at 37 °C and more significantly at the desired 44 °C 
temperature. Therefore a trypan blue exclusion was carried out on a previously seeded 12-
well plate of BxPC-3 cells, where 8 different concentrations of gemcitabine, Gem-Mal, 
TTLD+HNP and the HNPs alone were added. This was repeated five times to produce 6 
individual 12-well plates. The diagram in Figure 169 illustrates the well plate setup for this 
study. 
 
Figure 169: Diagram of the 12-well plate assembly for the increased heat exposure study for gemcitabine dosed BxPC-3 
cells setup. 
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The 6 individual 12-well plates were incubated for 48 h to ensure that an adequate uptake 
of gemcitabine, Gem-Mal and TTLD+HNP occurred so that the IC50 of BxPC-3 (determined 
by trypan blue exclusion) would be reached. Half of the well plates were removed after 24 
h and placed into a preheated Memmert IN-30 incubator and heated at 44 °C for 0.5 h to 
simulate the thermal rise generated by the SPR of laser irradiated HNP gold coatings before 
returning back into the 37 °C, 50 % CO2 incubator. The other three plates were not removed 
throughout their 48 h incubation. The IC50 was determined for all 6 plates and the heat 
activated IC50 results were compared to the non-activated plates to note the effect on 
percentage cell viability using trypan blue exclusion.  
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4.3. Results  
4.3.1. Cell viability 
The effects of gemcitabine, Gem-Mal, TTLD+HNP and the HNP alone were observed by 
dosing BxPC-3 cells with known concentrations of these substances over a 72 h period with 
analysis taking place at the 24 h 48 h and 72 h time points. Gem-Mal is comprised of 
gemcitabine attached to a maleimide via an amide linker. 
4.3.1.1. MTT assay for cell viability 
The graph ahead in Figure 172 shows the relationship between gemcitabine concentration 
and time on the percentage cell viability of BxPC-3 cells. The graphs in Figure 170 and 171 
use the same experimental parameters for Gem-Mal and TTLD+HNP respectively.  
 
Figure 170: Graph depicting the effect of Gem-Mal concentration on BxPC-3 cells at various concentrations at 24, 48 and 
72h time points with the MTT assay (n=3) (± 5.5 %). Data points labelled with * and  show statistically significant 
effects on % cell viability at 48 h and 72 h compared to the previous time points 24 h and 48 h respectively (P < 0.05). 
Only Gem-Mal achieves an IC50 using the MTT assay within 24 h of incubation with a 
concentration of 0.038 mg mL-1. Gem-Mal displays increasing cytotoxicity over time as the 
percentage cell viability decreases from over the 24 h, 48 h and 72 h time points at all 
0%
20%
40%
60%
80%
100%
120%
140%
0 0.02 0.04 0.06 0.08 0.1 0.12
%
  C
el
l V
ia
b
ili
ty
Gem-Mal Concentration (mg mL-1) 24 hr 48 hr 72 hr
* * 
* * 
* 

199 
 
concentrations indicating its cytotoxic properties, even when introduced extracellularly in 
an unbound form and taken up. (P < 0.05). The graph lines in Figure 170 show that Gem-
Mal’s detrimental effect on percentage cell viability is also the highest at the 72 h time 
point compared to gemcitabine and the TTLD+HNP formulation. At a concentration of 0.1 
mg mL-1 the percentage cell viability has fallen to the lowest point in all experimental 
conditions of 19 %. Therefore Gem-Mal displays the most cytotoxicity at the 24 h and 72 h 
time points (P < 0.05).  
The TTLD+HNP formulation does not achieve an IC50 until its analysis at the 72 h time point 
which occurs at a concentration of 0.0005 mg mL-1 shown in Figure 171.  
 
 
Figure 171: Graph depicting the effect of TTLD+HNP concentration on BxPC-3 cells at various concentrations at 24, 48 
and 72h time points with the MTT assay (n=3) (± 7.8 %). Data points labelled with * and  show statistically significant 
effects on % cell viability at 48 h and 72 h compared to the previous time points 24 h and 48 h respectively (P < 0.05). 
At the highest concentration the cell viability decreases from 70 % at 24 h to 59 % and 31 
% for the 48 h and 72 h time points respectively (P < 0.05). This shows that increasing the 
exposure time to TTLD+HNP decreases the cell viability. After 72 h there is no decrease in 
percentage cell viability for TTLD+HNP compared to the 24 h mark at 0.01 µg mL-1. In fact 
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the percentage cell viability has increased from 96 % at 24 h, which might indicate that 
there is no pharmaceutical effect of the TTLD+HNP at 0.01 µg mL-1. This is shown at the 48 
h mark as well (P < 0.05). The 4 % reduction in cell viability from the 24 h to 48/72 h might 
be due to experimental errors and not a factor of TTLD+HNP exposure.  
At the lowest concentration of 0.01 µg mL-1 for TTLD+HNP, there is little discernible effect 
on percentage cell viability. The percentage cell viability is 99 % on average at the 48 h in 
Figure 171, which indicates that the activity of TTLD+HNP is so low that it has marginal 
effects on cell viability if any at all.  One theory for this, is that the formulation cannot 
produce an effect until it has been taken up in sufficient amounts and also released from 
the HNP surface. After the cells were exposed to TTLD+HNP the percentage cell viability 
decreased from 99 % at 0.01 µg mL-1to 31 % at 0.1 mg mL-1. However much of this reduction 
in percentage cell viability occurs between 0.01 µg mL-1 to 0.001 mg mL-1 where it falls to 
41 % (P < 0.05). Between 0.001 mg mL-1 to 0.01 mg mL-1 there is a small decrease in 
percentage cell viability from 41 % to 34 % as well (P < 0.05). This trend of a sharp decrease 
in percentage cell viability between 0.01 µg mL-1 and 0.001 mg mL-1 followed by a gentle 
decrease is also observed at the 24 h and 48 h time points. At all three time points there is 
a statistical decrease in percentage cell viability from 0.001 mg mL-1 to 0.01 µg mL-1 (P < 
0.05). 
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Unlike the TTLD+HNP formulation, gemcitabine has a noticeable effect on cell viability, 
even at a concentration of 0.00001 mg mL-1 after 24 h, which has dropped to 81 % in Figure 
172.  
 
Figure 172: Graph depicting the effect of gemcitabine concentration on BxPC-3 cells at various concentrations at 24, 48 
and 72 h time points with the MTT assay (n=3), (± 3.7 %). Data points labelled with * and  show statistically significant 
effects on % cell viability at 48 h and 72 h compared to the previous time points 24 h and 48 h respectively (P < 0.05). 
This drop in cell viability increases as the concentration does, where it falls from 81 % to 
64 % between gemcitabine concentrations of 0.00001 mg mL-1 to 0.1 mg mL-1, an overall 
decrease of 17 % (P < 0.05). TTLD+HNP ranges from 96 % cell viability to 70 %, a 
difference of 26 % over this concentration range at 24 h (P < 0.05). At the 72 h time point 
gemcitabine at 0.00001 mg mL-1 reduces the cell viability to 46 % and at 0.1 mg mL-1 the 
percentage cell viability is at 23 % (P < 0.05). Even at the lowest concentration, 
accumulation of gemcitabine within the cells is enough to cause the desired 
pharmaceutical activity which only improves as the concentration and exposure time 
increases (P < 0.05). Gemcitabine has an IC50 of 0.0009 mg mL-1 after 48 h and <0.00001 
mg mL-1 after 72 h. 
The overall trend between gemcitabine and TTLD+HNP is that, lower concentrations of 
TTLD+HNP decreases the cell viability less than gemcitabine does. This continues to higher 
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concentrations where gemcitabine has a lower cell viability to TTLD+HNP at all 
concentrations. Gemcitabine’s path will be a combination of drug uptake/accumulation 
into the cell versus the drug’s expulsion/metabolism out of the cell. Overall gemcitabine 
would accumulate within the cell, even at very low concentrations of 0.00001 mg mL-1 
decreasing percentage cell viability. TTLD+HNP has to first accumulate within the cell and 
then release its cargo. Previous results shown earlier in chapter 3 show that the Gem-Mal 
is released from the HNP surface more rapidly at 44 °C with a much retarded release  at 37 
°C. Therefore it’s likely that even after accumulation of TTLD+HNP within the cells the 
pharmaceutical component of the formulation does not produce an effect until it is 
released from the HNP inside the cell. This release stage will stagger the activity of the 
TTLD+HNP formulation within the cell at low concentrations. As the concentration 
increases, this inhibition effect decreases as the cell viability begins to resemble those of 
gemcitabine.  This suggests that TTLD+HNP is accumulating faster in the cells than 
gemcitabine, followed by a slow release within the cell. This might explain the sharp 
decrease in percentage cell viability of 40 % from 0.0001 mg mL-1 to 0.001 mg mL-1 for 
TTLD+HNP compared to a reduction of only 6 % for gemcitabine. The requirement of Gem-
Mal to be released from the HNP after uptake appears to reduce its effect on cell viability.  
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4.3.1.2. Trypan blue exclusion for cell viability 
The graphs in Figures 173, 174, 175 and 176 shows the relationship between the stated 
drug compound or HNP concentration and time on the cell viability of BxPC-3 cells. The 
trend seems to be that increased levels of gemcitabine, Gem-Mal, TTLD+HNP and the HNPs 
alone all reduce the cell viability of BX-PC3 cells over time. There is a clear difference in all 
cases in cell viability after 24 h, 48 h and 72 h of exposure to gemcitabine (P < 0.05). The 
earliest recorded gemcitabine IC50 is reached at the 48 h time point with a gemcitabine 
concentration of 0.0175 mg mL-1. At the 72 h time point the IC50 occurs at a gemcitabine 
concentration of 0.008 mg mL-1. Gem-Mal has an IC50 of 0.06 mg mL-1 at the 48 h time point 
and 0.012 mg mL-1 at the 72 h time point. The TTLD+HNP formulation has an IC50 0.025 mg 
mL-1 after 48 h and 0.004 mg mL-1 after 72 h. The HNPs alone did not reduce the cell viability 
enough to produce an IC50 after 72 h indicating their biocompatibility over concentration 
ranges tested.  
 
Figure 173: Graph depicting the effect of gemcitabine concentration on BxPC-3 cells at various concentrations at 24, 48 
and 72h time points with the trypan blue assay (n=3, ±0 %, 5.9 % and 6.6 % respectively). Data points labelled with * 
and  show statistically significant effects on % cell viability at 48 h and 72 h compared to the previous time points 24 h 
and 48 h respectively (P < 0.05). 
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Figure 174: Graph depicting the effect of Gem-Mal concentration on BxPC-3 cells at various concentrations at 24, 48 and 
72h time points with the trypan blue assay (n=3, ± 0 %, 5.8 % and 3 % respectively). Data points labelled with * and  
show statistically significant effects on % cell viability at 48 h and 72 h compared to the previous time points 24 h and 
48 h respectively (P < 0.05). 
Gemcitabine and Gem-Mal both have a strong effect on cell viability in both a time and 
concentration dependant manner. Gemcitabine has a lower IC50 than Gem-Mal after 48 h 
with a difference of 0.0425 mg mL-1. Gemcitabine’s IC50 falls to 0.008 mg mL-1 after 72 h 
while Gem-Mal’s decreases to 0.02 mg mL-1.  Overall this shows that gemcitabine is more 
cytotoxic than Gem-Mal. This may be because Gem-Mal’s intracellular cytotoxicity is 
lower than gemcitabine or that its uptake is slower which reduces its accumulation rate. 
Drug uptake experiments were carried out later on in this study that investigates this 
further. 
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Figure 175: Graph depicting the effect of TTLD+HNP concentration on BxPC-3 cells at various concentrations at 24, 48 
and 72h time points with the trypan blue assay (n=3, ±6.6 %, 5.4 % and 6.6 % respectively). Data points labelled with * 
and  show statistically significant effects on % cell viability at 48 h and 72 h compared to the previous time points 24 h 
and 48 h respectively (P < 0.05). 
The TTLD+HNP formulation has a lower IC50 of 0.025 mg mL-1 at 48 h compared to just the 
unbound Gem-Mal. This value is still 1.6 fold lower than gemcitabine’s IC50 though, which 
remains the most cytotoxic substance at 48 h. This may be due to the fact that the 
TTLD+HNP is taken up faster than the unbound gemcitabine which increases its intracellular 
concentration at the 48 h time point, but the bound Gem-Mal is unable to have a cytotoxic 
effect until the retro Diels Alder takes place. The need for a retro Diels Alder step may have 
acted as a bottlenecking event intracellularly leading to a lower IC50. This might explain why 
the IC50 of TTLD+HNP is lower at 0.004 mg mL-1 compared to gemcitabines 0.008 mg mL-1. 
If the uptake of the TTLD+HNP’s is one way then the overall concentration of the 
intracellular TTLD+HNP increases over time. This may lead to similar activities to unbound 
gemcitabine the longer the cells take up TTLD+HNP. These statements will be confirmed or 
repealed following the drug uptake experiments. 
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Figure 176: Graph depicting the effect of HNP concentration on BxPC-3 cells at various concentrations at 24, 48 and 72h 
time points with the trypan blue assay (n=3, ±2.6 %, 4.4 % and 3.6 % respectively). Data points labelled with * and  
show statistically significant effects on % cell viability at 48 h and 72 h compared to the previous time points 24 h and 
48 h respectively (P < 0.05). 
The cells appear to tolerate the presence of the HNPs even at the highest experimental 
concentration of 0.1 mg mL-1 where the percentage cell viability falls from 90 % to 77 % 
after 24 h and 72 h of incubation. At some lowered measured concentrations the cell 
viability is slightly higher at the 72 h time point compared to the 48 h time point. For 
example at 0.025 mg mL-1 the cell viability is 88 % after 72 h but 86 % for the same 
concentration at the 48 h time point. Each time point result is acquired from a triplicate set 
of individual well plate and hence experimental errors are likely the cause for the large 
standard deviations. The differences are large enough for the calculated error bars to 
overlap both results. Therefore the effects of the HNPs on percentage cell viability seems 
to peak at 48 h and no change in percentage cell viability occurs beyond that for 
concentrations of the HNPs between 0.1 mg mL-1 and 0.01 mg mL-1 (P < 0.05). Only at 
concentrations between 0.01 mg mL-1 and 0.005 mg mL-1 is there a statistical difference in 
cell viability between the 48 h and 72 h time points (P < 0.05). 
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4.3.2. Drug uptake results 
In order to get a clearer picture of the activity of gemcitabine, Gem-Mal, TTLD+HNP have 
on cell viability, their intracellular concentrations were determined at set time points using 
reverse phase HPLC. This is because the cells may have more than one trafficking 
mechanisms for the internalisation and hence this effect the rate of uptake and hence 
ability to exhibit therapeutic effect. 
4.3.2.1. HPLC determination for the cell uptake of excipients  
The bar chart in Figure 177 shows the intracellular amount of each of the excipients per 
cell. 
Figure 177: Bar chart displaying the average amount of gemcitabine inside the BxPC-3 cells after exposure to free drug 
(n=3) (± 4.27 %) compared to Gem-Mal (n=3), TTLD+HNPs (n=3) and HNPs (n=3) for 1 h, 4 h and 24 h exposure time. 
Data points labelled with *,  and  show statistically significant effects on % cell viability compared to the control 
for the 1 h, 4 h and 24 h time points respectively (P < 0.05).
Gemcitabine and Gem-Mal have very similar intracellular levels at all time points which 
suggests that Gem-Mal enters the cell via similar mechanisms. It is likely that both the free 
drug and prodrug enter via the tight junction in the cell membrane which can be a time 
consuming process, as well as being actively transported across the cell membrane with 
SLC28 and SLC29 nucleoside transporters (Mini et al. 2006; Rudin et al. 2011). The amounts 
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of detected drug after exposure to the TTLD+HNP formulation is significantly higher than 
at all time points when compared to gemcitabine and unbound Gem-Mal (P < 0.05). Hence 
this would indicate that the cellular trafficking mechanism of the formulation is different 
compared with the drug and prodrug. Numerous studies have indicated that 
nanoparticulate vehicles enter cells via endocytosis. This is often relatively rapid and results 
in much higher intracellular concentrations. As such, it is logical to postulate that 
endocytosis is the mechanism for the uptake of TTLC+HNP. 
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4.3.3. Effect of heat on cell viability 
As previously discussed, the HNP-drug formulation requires heat activation before drug 
release is achieved. Our studies suggested that at 44 °C drug release is optimal. Hence we 
designed a study that allowed for this activation without adverse effects on the cells. After 
a 24 h incubation at 37 °C in a 5 % CO2 atmosphere BxPC-3 cells which had been exposed 
to gemcitabine, Gem-Mal, TTLD+HNPs and the HNPs alone were placed in an incubator set 
to 44 °C for 0.5 h before returning back into the 37 °C 5 % CO2 environment. The graphs in 
Figures 178, 179, 180 and 181 show the effects this 0.5 h of heating had on the percentage 
cell viability for gemcitabine, Gem-Mal, TTLD+HNP and HNPs respectively. The results 
garnered from the percentage cell viability of the BxPC-3 cells incubated in a 37 °C 5 % CO2 
environment and for 0.5 h at 44 °C have been named non-activated and heat activated 
respectively.  
     
Figure 178: Graph of the change in percentage cell viability of gemcitabine dosed BxPC-3 cells with and without a 0.5 h 
incubation at 44 °C (n=3) (± 3.7 %). No statistical difference observed (P < 0.05). 
The heat activated incubated cells that were dosed with gemcitabine, have a lower cell 
viability than the non-activated incubated cells, however the miniscule differences are of 
no statistical difference. The largest difference occurs at the lowest used concentration of 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
0 0.02 0.04 0.06 0.08 0.1 0.12
%
 C
el
l V
ia
b
ili
ty
Gemcitabine Concentration (mg mL-1) Non Activated Heat Activated
210 
 
0.0001 mg mL-1. This is surprising as it suggests that gemcitabine concentration is not the 
major factor in the differences in cell viability. This is confirmed with the error bars 
overlapping the differences between the cell viabilities suggesting that experimental errors 
are likely the cause of these differences. 
There appears to be a slight difference between the heat activated and non-activated cell 
viabilities. In the cases of the Gem-Mal and the HNP only studies, there is no statistical 
difference between the two variables meaning that the slight differences are due to 
experimental errors (P < 0.05).  
 
Figure 179: Graph of the change in percentage cell viability of Gem-Mal dosed BxPC-3 cells with and without a 0.5 h 
incubation at 44 °C (n=3) (± 3.6 %). No statistical difference observed (P < 0.05). 
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Figure 180: Graph of the change in percentage cell viability of HNP dosed BxPC-3 cells with and without a 0.5 h 
incubation at 44 °C (n=3) (± 5.9 %). No statistical difference observed (P < 0.05). 
The only situation where there is a real difference between the heat activated and non-
activated were the cells incubated is with the TTLD+HNP formulation shown in Figure 181. 
This was expected as the rate of retro Diels Alder was shown to increase at increased 
temperatures. The difference in cell viability between the heat activated and non-activated 
variables increases as the TTLD+HNP concentration increases.  
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Figure 181: Graph of the change in percentage cell viability of TTLD+HNP dosed BxPC-3 cells with and without a 0.5 h 
incubation at 44 °C (n=3) (± 5.4 %). Data points labelled with * show statistically significant effects on % cell viability 
after heat activation compared to non-activated samples (P < 0.05). 
The heat activated samples display a 2.4 fold decrease in cell viability compared to the non-
activated samples based on their IC50 values of 0.0105 mg mL-1 and 0.025 mg mL-1 
respectively. This indicates that an increase in temperature improves the activity of 
TTLD+HNP which is due to the intracellular release of Gem-Mal via the thermally triggered 
retro Diels Alder reaction.  
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4.4. Discussion 
The IC50 of gemcitabine, Gem-Mal and the TTLD+HNP formulation differ in the trypan blue 
exclusion assay results when compared to the MTT assay results. Overall the IC50 values are 
lower when calculated via the MTT assay compared to the trypan blue exclusion assay. The 
main reason for this is that the MTT assay merely estimates the number of living cells based 
on their ability to metabolise MTT into formazan crystals and compares this activity to 
controls. The trypan blue exclusion assay provides the specific number of living cells in a 
sample allowing us to compare the population of living cells detected with controls. The 
MTT assay could indicate that gemcitabine, Gem-Mal and TTLD+HNP reduce percentage 
cell viability more than actual amounts, if those cells are in a state of reduced metabolism. 
These cells may still be alive but performing in suboptimal metabolism conditions due to 
the exposure of the introduced cytotoxic agents. The trypan blue exclusion assay will 
display a positive result for living cells, even if their metabolic processes have been reduced. 
Because of the advantage the trypan blue exclusion assay has over the MTT assay, the 
trypan blue exclusion assay derived IC50 results will be considered the true IC50 results for 
the rest of this study. 
Overall the in vitro evaluation of Gem-Mal and the TTLD+HNP formulation has shown that 
Gem-Mal has a cytotoxic effect on BxPC-3 cells and that modification of the gemcitabine 
molecule to include the linker has not had a significant impact on its overall toxicity. The 
IC50 of Gem-Mal after 48 h is 0.07 mg mL-1 which 4.6 fold higher than gemcitabines IC50 of 
0.0175 mg mL-1. Due to Gem-Mals lower cytotoxicity, its potential to cause unwanted side 
effects is also lower as well until heat activation of the HNPs causes a significant release of 
the drug. It has already been shown in section 3.3.3.2 of this study that the TTLD+HNP 
formulation will release a much smaller portion of its Gem-Mal at 37 °C than at 44 °C. 
Because the uptake of the TTLD+HNP formulation is not instantaneous, part of this release 
at 37 °C will occur extracellularly. However due to the 11 fold uptake rate of the TTLD+HNP 
formulation, the majority of the formulation will be inside the cells releasing their drug 
cargo intracellularly. It is therefore advantageous that Gem-Mal (released from the 
TTLD+HNP formulation) has a lower cytotoxicity than gemcitabine until heat activation. 
This allows the TTLD+HNP formulation to function as a theranostic agent which are 
substances that are both diagnostic and therapeutic. The iron oxide cores provide visibility 
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of the TTLD+HNP formulation because they are excellent MRI contrast agents (Wang 2011). 
The HNPs themselves provide a therapeutic effect due to their ability to facilitate the 
release of their thermally labile attached drugs via the gold coatings surface plasmon 
resonance properties. The graph in Figure 182 displays the relationship of concentration of 
gemcitabine, Gem-Mal and the TTLD+HNP formulations in non-activated experimental 
conditions.  
 
Figure 182: Comparative graph of the effect of gemcitabine, Gem-Mal and the TTLD+HNP formulation on percentage 
cell viability in non-activated experimental conditions (n=3, ±3.7 %, 3.6 % and 5.4 % respectively). 
The graph above in Figure 182 is a graph of gemcitabine, Gem-Mal and the TTLD+HNP 
formulation effect on the 48 h cell viability with the non-activated conditions, in which their 
IC50 values are 0.015 mg mL-1, 0.07 mg mL-1 and 0.025 mg mL-1 respectively. Here we see 
that gemcitabines cytotoxicity is 1.6 fold higher than the TTLD+HNP formulation and 4.6 
fold higher than Gem-Mal. At all concentrations gemcitabine exposure has the highest 
detrimental effect on percentage cell viability of BxPC-3 cells followed by the TTLD+HNP 
formulation and lastly the unbound Gem-Mal. The graph in Figure 183 below displays the 
effect of gemcitabine, Gem-Mal and the TTLD+HNP formulation on the 48 h cell viability 
after heat activation. 
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Figure 183: Comparative graph of the effect of gemcitabine, Gem-Mal and the TTLD+HNP formulation on percentage 
cell viability in heat activated experimental conditions (n=3, ±3.7 %, 3.6 % and 5.4 % respectively). Data points labelled 
with * show statistically significant effects on % cell viability after heat activation of TTLD+HNP compared to non-
activated samples (P < 0.05). 
The IC50 of gemcitabine has remained the same at 0.015 mg mL-1 after heat activation 
indicating that the 0.5 h, 7 °C temperature increase does not affect the cytotoxicity of 
gemcitabine. The TTLD+HNP formulation on the other hand has displayed a 56 % increase 
in cytotoxicity with its IC50 decreasing from 0.025 mg mL-1 in the non-activated experiment 
to 0.011 mg mL-1, a 2.3 fold improvement. These results show us that the TTLD+HNP 
formulation after heat activation is 26 % more cytotoxic than gemcitabine alone, a 1.36 fold 
improvement in cytotoxicity. The IC50 of Gem-Mal has also decreased from 0.07 mg mL-1 in 
the non-activated experiments to 0.068 mg mL-1. This is likely due to experimental errors 
causing such a small decrease. Regardless Gem-Mal remains significantly less cytotoxic 
than gemcitabine and TTLD+HNP with and without heat activation (P < 0.05). Table 12 
provides a clearer comparison of each substances IC50 with and without heat activation. 
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Table 12: IC50 values of Gemcitabine, Gem-Mal and the TTLD+HNP formulation with and 
without heat activation 
 Gemcitabine TTLD+HNP Gem-Mal 
Non Activated IC50 
(mg mL-1) 
0.015 0.025 0.07 
Heat Activated IC50 
(mg mL-1) 
0.015 0.011 0.068 
Activation Effect on 
cytotoxicity 
Nil + 56 % - 3 % 
 
All of these profound revelations greatly enhances the TTLD+HNP formulation as a 
potential first line replacement of gemcitabine for the treatment of pancreatic cancer.  
Current use of gemcitabine for the treatment of pancreatic cancer poses many problems. 
Gemcitabine has a short half-life of 8-17 min after intravenous administration where the 
majority of the dose does not penetrate the intended pancreatic cancer cell target due to 
its hydrophilic nature (Griffith & Jarvis 1996; Immordino et al. 2004). This leads to a high 
dose requirement in order to achieve a therapeutic effect.  
One of the main reasons why gemcitabine has the reported effectiveness of 23.8 % is due 
to the side effect caused by the nonspecific uptake of gemcitabine into healthy tissues. The 
majority of pancreatic cancer sufferers are elderly who cannot tolerate the side effects 
associated with gemcitabine use (Takeuchi et al. 2004). These side effects can include renal 
toxicity and hepatoxicity. The high dose requirement of gemcitabine prevents many 
sufferers of pancreatic cancer from receiving it as part of a life extension treatment or as a 
neoadjuvant chemotherapeutic treatment prior to the potentially lifesaving surgery to 
remove the rest of the tumours.  
One thing to note, is that prior to the use of gemcitabine the first line drug for treating 
pancreatic cancer was 5-fluorouracil (5-Fu). Gemcitabine replaced 5-Fu because it 
displayed fewer and less serious side effects as well as a greater therapeutic effect (Burris 
et al. 1997). Based on the rapid uptake and lower cytotoxicity of the TTLD+HNP 
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formulation, its side effects should be reduced in vivo. Its improved in vitro cytotoxicity 
after heat activation surpasses that of gemcitabine. Together, these results demonstrate 
the potential of the TTLD+HNP formulation as a worthy replacement to gemcitabine as a 
first line treatment of pancreatic cancer. 
The TTLD+HNP formulation has displayed a superior cytotoxicity to the currently used 
gemcitabine and a faster uptake which should prevent the systemic side effects present 
with gemcitabine. This would reduce the dose needed to achieve the same effectiveness 
as gemcitabine, thereby allowing more pancreatic cancer sufferers the opportunity to 
receive treatment improving the overall survival rates and reducing patient discomfort. 
Gem-Mal, the compound that is released from the TTLD+HNP formulation 4.6 times less 
cytotoxic that gemcitabine. This means that any release that might occur before its rapid 
cellular uptake will have a greatly reduced effect on the patients wellbeing.  The TTLD+HNPs 
prior to activation are 1.6 times less cytotoxic than gemcitabine. This allows for higher 
doses of TTLD+HNP to be administered before a maximum therapeutic dose is reached, 
which further improves the cytotoxicity of the activated TTLD+HNP formulation at the 
tumour site.  
The next logical step in the continuation of this research study would be to acquire 
microscopic images of the cells that have been exposed to and incubated with 
gemcitabine, Gem-Mal, TTLD+HNP and the HNPs alone and compare the cell morphology 
with those that have been heat activated at 44 °C. One method of carrying this out would 
be with the use of atomic force microscopy (AFM). This technique works on the basis that 
the AFM has a cantilever which has a probe in the form of a sharp tip. This tip scans the 
sample surface by being dragged which causes the cantilever to raise and dip depending 
on the topography of the surface. This would provide a 3D rendering of the cell shape 
indicating whether the cells are healthy, preparing for cellular apoptosis or are already 
dead (Pishkenari & Meghdari 2011). The drug uptake results have already concluded that 
the HNPs are taken up. This is evident with the 11 fold uptake rate of TTLD+HNP 
compared to gemcitabine alone. TEM imaging would further enhance this knowledge by 
providing images of nanoparticles in an intracellular environment. Lastly, fluorescence 
microscopy could also be employed on cells stained with a dye in order to observe the 
physical effects caused by exposure to gemcitabine, Gem-Mal, TTLD+HNP and the HNPs 
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alone with and without heat activation. A fluorescent molecule could also be attached to 
the HNP surface that would further confirm the uptake of the TTLD+HNP formulation as 
well.   
4.5. Conclusion 
The in vitro effects of Gem-Mal and the TTLD+HNP formulation has been evaluated 
successfully. The 11-fold increase in the uptake of Gem-Mal when attached to the HNPs 
surface is a very favourable discovery that further highlights the significant clinical potential 
this thermally sensitive formulation has for treating pancreatic cancer.  The next steps 
should include the in vivo testing of the TTLD+HNP formulation in order to understand the 
clinical relevance of this novel treatment in whole living organisms especially with the 
possibility of reduced side effects with same dose regimens compared to gemcitabine. 
While the 4 week assessment of the TTLD+HNP displays medium term stability, the long 
stability of the TTLD+HNP formulation in various storage conditions also needs to be 
determined. If these experiments show promise then further successful testing with human 
trials could lead to this formulation replacing gemcitabine as the first line treatment for 
pancreatic cancer.  
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CHAPTER 5: GENERAL DISCUSSION 
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5.0. General Discussion 
The objectives of this study included the successful synthesis of a thermally triggered drug 
delivery system via the use of a thiolated thermally labile linker. Another objective was that 
this novel formulation would display a significant and rapid release of its drug cargo at 
elevated temperatures. The data obtained from this study indicate that these 
characteristics are present in the thiolated thermally labile drug (TTLD) attached via a 
dative covalent bond to hybrid nanoparticles comprised of an iron oxide core and gold coat 
(HNPs) forming the new formulation abbreviated TTLD+HNP. This TTLD+HNP formulation 
would release a maleimide containing gemcitabine analogue called Gem-Mal. The 
synthesis of a thermally triggered drug formulation comprised of, a thermally labile linker 
functionalised with gemcitabine covalently attached to the gold surface of HNPs, has been 
successful. The linker and drug component dubbed TTLD displayed water solubility and the 
ability to break apart under elevated temperatures while retaining its stability at typical 
storage conditions. Within a closed system inside a round bottom flask, TTLD has a 
percentage release of 1 % when heated to 37 °C after 5 min. Within this environment, the 
opportunity for the released Gem-Mal to reattach back onto the HNP via the Diels Alder 
reaction was higher which slowed the net % release over time. Under sink conditions the 
% release of Gem-Mal across a dialysis membrane increased to 14 % after 5 min. This means 
that sink conditions improve the % release of Gem-Mal by 14-fold because the Diels Alder 
coupling reaction does not occur in any meaningful amount. This lack of the Diels Alder 
reaction in sink conditions leads to a higher net breakdown of the linker over time. 
TTLD compounds were loaded onto HNPs at a concentration of 5 mg of TTLD per 1 mg HNP 
(based on iron mass) to form the formulation known as TTLD+HNP. Under aqueous sink 
conditions at pH 7 this TTLD+HNP formulation performed rapid and total drug release of 
Gem-Mal via the retro Diels Alder when exposed to a temperature of 44 °C within 1 h where 
80 % was released within 1 min. This release also occurs at 37 °C to a much lower and 
overall incomplete manner where only 23 % was released after 1 h (13 % after 1 min). This 
is due to the reversible Diels Alder reaction establishing a temperature dependant 
equilibrium. This experiment was repeated at a pH of 7.4 and pH 5.6 within cell media 
producing very similar results to the experimental condition at pH 7 in water. This suggests 
that temperature serves as the majority, if not the sole trigger for drug release. No 
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detectable release occurred at 20 °C and 5 °C over 4 weeks, displaying the TTLD+HNP 
formulations medium term stability. 
During the in vitro experiments, the attachment of TTLD to the HNPs improved the 
cytotoxicity of the formulation. Four substances (gemcitabine, Gem-Mal, TTLD+HNP and 
the HNPs alone) all displayed increasing cytotoxicity as the concentration rose. Out of the 
four investigated substances, only the HNPs alone lacked an IC50 after 24 h, 48 h and 72 h 
where the cell viability fell to just 90 %, 80 % and 77 % respectively at the highest 
experimental concentration of 0.1 mg mL-1. This indicates that the Bx-PC3 cells tolerated 
the HNP presence well with little adverse effect. After 24 h the cell viability of Bx-PC3 cells 
exposed to 0.1 mg mL-1 of Gem-Mal and the TTLD+HNP formulation is 80 % and 70 % 
respectively. 
The therapeutic activity of the heat activated TTLD+HNP formulation has already been 
observed and deemed advantageous over gemcitabine in terms of its lower IC50, faster 
cellular uptake rate and controllable release. This is due to a combination of a faster cellular 
uptake of TTLD via attachment to HNPs and the large burst of released Gem-Mal that 
occurred during heating. As the uptake is time dependant, it’s very likely that the 
concentration of the TTLD+HNP formulation required to illicit the same cytotoxic effect as 
gemcitabine would be lower at the 72 h mark. The IC50 of the TTLD+HNP formulation 
decreased by 56 % when activated, compared to the non-activated formulation improving 
its cytotoxicity to a level 36 % higher than gemcitabine. This is evident from the lower cell 
viability of 48 h 0.1 mg mL-1 TTLD+HNP dosed Bx-PC3 cells exposed to a temperature of 44 
°C for 30 min compared with gemcitabine. Add to this the fact that the TTLD+HNP 
formulation has an 11-fold higher uptake and accumulation rate intracellularly compared 
to gemcitabine alone and it becomes clear. The TTLD+HNP formulation shows immense 
potential as the future first line treatment of pancreatic cancer and a worthy successor to 
gemcitabine.   
The attachment of gemcitabine to the Diels Alder linker was achieved via an amide bond. 
It has been reported that the amide group attached to gemcitabine is enzymatically 
removed with hydrolysis by proteases and peptidases (Wickremsinhe et al. 2013). 
Therefore the cytotoxic activity of Gem-Mal may only occur after the maleimide linker 
component is enzymatically cleaved. Gemcitabine itself is a prodrug but Gem-Mal may be 
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functioning as a secondary prodrug after its initial release from the TTLD+HNP formulation. 
If Gem-Mal needs to be converted to gemcitabine first this might explain why the 
difference in cell viability from the 24 h to 48 h time point is greater for Gem-Mal than with 
gemcitabine but narrows over time. For example, the percentage cell viability at 24 h is 60 
% for gemcitabine and 80 % for Gem-Mal, a difference of 20 %. At the 48 h mark the 
percentage cell viability is 37 % and 43 % for gemcitabine and Gem-Mal respectively which 
is a difference of 6 %. Gemcitabine and Gem-Mal have similar uptake times which means 
their intracellular concentration is nearly equal. This suggests that Gem-Mals activity is 
somehow gated by a time dependant process such as amide cleavage that doesn’t apply to 
gemcitabine and/or Gem-Mal is simply less cytotoxic due to the presence of the amide 
coupled maleimide.  
This study has progressed as far as the in vitro experiments detailed in Chapter 4. The next 
stages of this study will include in vivo testing of the novel TTLD+HNP in order to assess its 
clinical potential. In vitro assays give a good indication of the likely outcome in vivo 
however, they are not truly representative and therefore it is very important to carry out 
in vivo xenograft studies in order to obtain their ability in more realistic conditions. It is 
possible that the TTLD+HNP formulation has a longer half-life within the body leading to a 
higher rate of cellular uptake and subsequent cytotoxicity than observed in the in vitro 
experiments. The diagnostic properties of this formulation also needs to be evaluated, 
where the iron oxide cores of the HNPs are imaged with MRI to map their in vivo 
movement. This is important not just because of the diagnostic imaging opportunities, but 
also to map the extent that the Gem-Mal might be released systemically. Gem-Mal is 
released at 37 °C so side effects may occur if the TTLD+HNP formulation migrates as easily 
as gemcitabine does. Therefore the Gem-Mal released could cause side effects. Within a 
closed system this release is 6.7 % in 1 h and 17 % in vitro (based on sink conditions).  
In vivo the formulation is not likely to be laser irradiated for 1 h. Therefore, further 
investigation taking into account drug release, efficacy and maximum tolerated dose needs 
to be carried out. It is possible that the slow release at 37 °C may allow for a higher dose of 
Gem-Mal compared to gemcitabine. The TTLD+HNP formulation would be administered 
intratumourally which would ultimately improve its half-life over gemcitabine which is 
administered intravenously. This is because the TTLD+HNP formulation would avoid the 
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rapid renal excretion after enzymatic conversion of its gemcitabine component (Eda et al. 
1998). Therefore it may be possible to load a greater dose of Gem-Mal onto HNPs beyond 
the maximum tolerated dose of gemcitabine. This would lead to a higher concentration of 
the TTLD+HNP formulation which leads to a faster accumulation of this formulation within 
the tumour tissue. The possibility of whether a significant increase in the dose of TTLD+HNP 
would not cause severe side effects, can only be determined with in vivo experiments which 
further highlights their importance in future work (Pathania et al. 2014; Megha et al. 2015). 
The excellent stability of the HNPs over a period of 6 months has been reported (C. M. 
Barnett et al. 2013). The TTLD+HNPs primary function is to act as a thermally triggered drug 
delivery system. Therefore this formulations goal is to facilitate drug release at elevated 
temperatures. The thermal stability of the TTLD+HNPs formulation over a 4-week period 
has shown us that no drug release occurs over time at 5 °C and 20 °C.  Some drug 
formulations are freeze dried which is a process where the material is frozen and then the 
surrounding air pressure is reduce to allow the frozen water to evaporate via sublimation 
(Patel et al. 2014). The effects of freeze drying on the integrity of the TTLD+HNP 
formulation has not been determined. Conversely, drug formulations have shelf lives that 
range from several months to years. A 4-week stability study provides some estimation of 
the shelf life, but in order to fully determine the long term stability of the TTLD+HNP 
formulation, an extended shelf life experiment is required. The effects of storage at 5 °C 
and 20 °C as well as the  long term freeze drying of the TTLD+HNP formulation needs to be 
determined in future work.  
The TTLD+HNP drug delivery system could revolutionise the future of drug delivery far 
more than just improving the effectiveness of pancreatic cancer treatment. Other forms of 
cancers may garner advancements in survival and remission rates with the use of this 
formulation as well. The attached gemcitabine compound may be replaced with other drug 
substances tailored to treat other forms of cancer. Chemotherapy medicines are often 
given in combination as they sometimes prove more effective than standalone drug 
formulations. Gem-Mal does not play a part in its release from the TTLD+HNP formulation. 
That is solely dependent on the onset of the retro Diels Alder reaction. Therefore different 
thiolated thermally labile drug linkers could be synthesised and attached simultaneously to 
the HNP surface. The relevant concentrations of the attached drugs could be tuned 
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depending on the concentration of each linker with attached drug. This could lead to a form 
of “click chemistry” where perhaps hundreds of forms of the TTLD+HNP formulation arises 
from different compositions of attached drug linkers, tailored to the patients clinical needs 
and every attached drug linker would be released at the same rate intracellularly upon heat 
activation. Most drug candidates do not reach clinical use from the drug discovery and 
development stages due to various factors such as, poor bioavailability and reduced cell 
permeation. Previously benched drug candidates which showed great promise despite 
their setbacks, may see potential use again in a TTLD+HNP formulation, which could 
address the issues that prevented these drug candidates from being considered worthy of 
human trials and eventually clinical use. Overall it’s not just that the TTLD+HNP formulation 
shows tremendous promise in improving pancreatic cancer treatment, but it’s the 
capability of the TTLD+HNP formulation to change the very face of clinical pharmaceutics 
as a whole. 
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